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A mis padres

“Now, this is not the end. It is not even the beginning of the end. But it is 
perhaps, the end of the beginning” 
Winston Churchill, 
The bright gleam of victory, 1942

“It has always seemed to me extreme presumptuousness on the part of those 
who want to make human ability the measure of what nature can and knows 
how to do, since, when one comes down to it, there is not one effect in 
nature, no matter how small, that even the most speculative minds can fully 
understand.”
Galileo Galilei 
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En los últimos años se ha descrito el importante papel de la proteína quinasa GRK2 como nodo de señalización 
en diferentes tejidos y contextos celulares, y en particular como modulador de diferentes procesos y vías de 
señalización críticas en la ϐisiología cardiovascular. Los niveles de GRK2 se encuentran aumentados, tanto en 
humanos como en modelos experimentales animales,  en procesos patológicos como la hipertensión, insuϐiciencia 
cardíaca o isquemia, mientras que la inhibición genética de GRK2 ha sido descrita como cardioprotectora en 
distintos modelos animales relacionados. Sin embargo, no se conocen con precisión los mecanismos moleculares 
por los que cambios en la expresión de GRK2 producen estos efectos deletéreos o beneϐiciosos. Es de destacar 
que GRK2 no sólo fosforila y desensibiliza diversos receptores acoplados a proteínas G (GPCR) que son críticos 
para la función cardiovascular tales como los receptores β-adrenérgicos o de angiotensina, sino que también 
modula la cascada de señalización de la insulina, muy importante para la ϐisiología cardiaca. Dado que estas 
rutas de señalización se encuentran alteradas en situaciones que son importantes factores de riesgo para el 
desarrollo de la enfermedad cardiovascular, como hipertensión, insulinoresistencia u obesidad, nos propusimos 
profundizar en las interrelaciones funcionales de GRK2 con esas vías de señalización y sus posibles implicaciones 
ϐisiopatológicas. Para ello hemos utilizado ratones hemicigotos para GRK2 (GRK2+/-) como un modelo válido 
para evaluar los efectos de una inhibición sistémica sostenida de GRK2 en el corazón y el tejido vascular en 
diferentes contextos patológicos tales como la hipertensión arterial, la edad y la obesidad/resistencia a insulina 
inducida por dieta rica en grasa.
 
Hemos observado que en ratones adultos (9-10 meses de edad, una condición más concordante con el 
periodo de incidencia de patologías CV en humanos) los animales GRK2+/- presentan mayor sensibilidad a 
algunas señales vasoconstrictoras ante determinados agonistas y son más ampliamente sensibles a diversos 
estímulos vasodilatadores, en parte gracias a una mayor disponibilidad de óxido nítrico incluso a nivel basal. Más 
aún, tras promover un estado de hipertensión primaria inducida por infusión crónica de angiotensina,  los ratones 
con menores niveles de GRK2 preservaron la activación de la cascada de Akt, presentaron mayores niveles de la 
enzima eNOS, y mantuvieron una mayor biodisponibilidad de NO mientras que en sus hermanos silvestres estos 
parámetros disminuían signiϐicativamente. En resumen, en este trabajo demostramos que menores niveles de 
GRK2 favorecen una mayor biodisponibilidad de óxido nítrico por varios mecanismos, así como resistencia al 
desarrollo de hipertensión y del consecuente remodelado vascular. 
Por otro lado, abordamos el papel de GRK2 en el corazón de ratones adultos (9 meses) o alimentados con 
dieta rica en grasa, dos condiciones que promueven el desarrollo de insulino-resistencia.  En ratones adultos 
hemos observado que una menor expresión de GRK2 promueve una mayor sensibilidad cardiaca a la insulina, 
lo que se correlaciona con un perϐil de expresión génica cardioprotector y una leve hipertroϐia que no es de 
naturaleza patológica. Nuestro trabajo describe cómo los niveles de GRK2 aumentan en el tejido cardiaco en 
modelos experimentales bien establecidos de resistencia sistémica a la insulina, tales como animales alimentados 
con dieta alta en grasa o en los ratones obesos ob/ob. Este aumento en los niveles de GRK2 cardíacos se 
correlaciona con la disminución de la sensibilidad cardiaca a la insulina en estas condiciones, en un proceso que 
implica la formación de complejos GRK2/IRS1 que impedirían una correcta propagación intracelular de la señal 
de la insulina. 
Por último, nuestros datos indican que menores niveles de GRK2 protegen al corazón de los efectos 
deletéreos de la obesidad. Los ratones GRK2+/- adultos están protegidos frente a la hipertroϐia patológica de 
corazón que desarrollan los animales silvestres tras 33 semanas de alimentación con dieta rica en grasa, y son 
resistentes a la acumulación excesiva de lípidos en tejido cardiaco, característica propia de la lipotoxicidad que se 
produce como consecuencia de la obesidad.
Nuestros hallazgos indican que  estímulos patológicos de diferente etiología, tales como elevados niveles de 
catecolaminas o angiotensina, o el alto contenido en grasa de la dieta, convergen en incrementar la expresión de 
GRK2 en corazón y en el tejido vascular. Dado el papel de esta proteína como nodo un estratégico en las redes de 
señalización celular tanto de GPCRs como de la insulina, este aumento de sus niveles/actividad desempeñaría un 
papel central en la  progresión hacia la adaptación patológica, el remodelado cardiaco y vascular y la disfunción. 
GRK2 emerge así como un relevante nexo de unión entre la funcionalidad cardiovascular y el metabolismo, 
especialmente interesante en el contexto de la enfermedad cardiovascular derivada de hábitos de vida poco 
saludables, y, precisamente por su función nodal como sensor de múltiples patologías y como transmisor de esos 
efectos deletéreos, se desvela como una prometedora diana terapéutica.
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 Increasing evidence points to an important role for G protein-coupled receptor kinase 2 (GRK2) as a key 
signaling node in different tissues and cell contexts, and, in particular, as a modulator of critical processes and 
signaling pathways in cardiovascular physiology. GRK2 levels are increased both in humans and animal models 
under different pathological conditions such as hypertension, heart failure or ischemia, while the genetic 
inhibition of GRK2 has been described to be cardioprotective in different animal models of these diseases. 
However, the molecular mechanisms by which altering GRK2 expression promotes both the deleterious and 
beneϐicial effects are not completely understood. Importantly, GRK2 not only phosphorylates and desensitizes 
G protein coupled receptors (GPCRs) that are critical for cardiovascular function such as the β-adrenergic 
receptors or angiotensin, but also modulates other pathways relevant for cardiac physiology, such as the insulin 
cascade. Since these signaling pathways are often altered in pathological processes such as hypertension, insulin 
resistance and obesity, known risk factors in the development of cardiovascular disease, we aimed to investigate 
in detail the functional relationships between GRK2 and the aforementioned signaling pathways with focus on 
their potential physio-pathological implications. To this end we have used hemizygous GRK2 (GRK2+/-) mice 
as a suitable model to assess the effects of sustained systemic inhibition of GRK2 in the heart and vascular 
tissue under different pathological contexts such as hypertension, age and high fat diet- induced obesity/insulin 
resistance.
 
We observe that middle-aged adult mice (9-10 months old, a model that would better mimic the conditions 
in which CV events are ϐirst detected in humans) with lower levels of GRK2 (GRK2+/-) show increased sensitivity 
to certain vasoconstrictor signals, and are more generally sensitive to various vasodilator stimuli at least in 
part  by means of an increased availability of nitric oxide (NO). Moreover, when primary hypertension was 
induced in these animals upon chronic angiotensin infusion, GRK2+/- mice displayed a preserved activation 
of the Akt cascade, higher levels of the eNOS enzyme, and preserved NO bioavailability whereas in their wild 
type littermates these parameters  were signiϐicantly decreased. Furthermore, we ϐind that lower levels of GRK2 
promote increased NO bioavailability by different mechanisms, and resistance against the development of 
hypertension and subsequent vascular remodeling.
On the other hand, we addressed the role of GRK2 in the heart of adult (9 month) mice or of mice fed with 
high-fat diet, two conditions known to promote insulin resistance. In adult mice, we have unveiled that a lower 
GRK2 dosage promotes enhanced insulin sensitivity what correlates with a cardioprotective gene expression 
proϐile and a mild hypertrophy that is not of a pathological nature. Interestingly, cardiac GRK2 levels increased 
in well-established experimental models of systemic insulin resistance, such as after high-fat diet feeding or in 
the obese ob/ob mouse strain. Such increased cardiac GRK2 levels correlate with the impaired cardiac insulin 
sensitivity observed in these conditions, which seems to involve enhanced formation of GRK2/IRS1 complexes 
that prevent the proper intracellular propagation of the insulin signal.
Finally, our data indicate that lower levels of GRK2 safeguard the mouse heart from the deleterious effects 
of obesity. Adult GRK2+/- mice are protected against the pathological cardiac hypertrophy that develops in wild 
type littermates after 33 weeks of high-fat diet feeding, by preventing an excessive lipid accumulation inside the 
heart, a feature of lipotoxicity produced as a consequence of obesity.
Our ϐindings indicate that pathological stimuli of different etiology, such as increased levels of 
catecholamines/angiotensin, or high dietary fat, would converge on promoting enhanced GRK2 expression in 
cardiac and vascular tissues. Given the role of this protein as a central node of both GPCRs and insulin signaling 
cascades, such increased GRK2 levels/functionality would play a key role in allowing progression to pathological 
maladaptation, cardiac and vascular remodeling and dysfunction. GRK2 thus emerges as a relevant link between 
cardiovascular function and metabolism, particularly interesting in the context of cardiovascular disease related 
to unhealthy lifestyle habits, and, given its role as a sensor of multiple pathological insults and as a transmitter of 
deleterious effects, as a promising therapeutic target.
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1. THE CARDIOVASCULAR SYSTEM AND CARDIOVASCULAR DISEASE 
CONTINUUM
The cardiovascular or circulatory system is composed of the heart, blood vessels, and 
the blood. It is responsible for transporting oxygen, nutrients, hormones, and cellular 
waste products throughout the body to maintain homeostasis. The cardiovascular 
system (CVS) is essential to survival as all parts of the body require oxygen-rich blood 
in order to thrive. In fact, heart failure or congestive heart failure, the condition in which 
the heart cannot supply the body´s tissues with enough blood and the end-stage of most 
cardiovascular diseases (CVD), remains the major cause of death worldwide [1].
1.1. THE HEART
The primary driving force behind a healthy circulatory system is the body’s hardest-
working organ, the heart. Heart beats about once every second what means over 2.5 
billion times in an average life span. The structure of cardiac muscle cells enables a quick 
propagation of electrical signals and mechanical contractions that pump blood forward. 
The only time the heart gets a rest is between beats [2].
The heart itself is an organ of extreme structural and functional complexity. The heart´s 
wall is composed of tightly packed cardiomyocytes and ϐibroblasts, with dense supporting 
vasculature and collagen-based extracellular matrix. Because of the high density and high 
metabolic demand of the cells, myocardium consumes large amounts of oxygen and has 
very low tolerance to hypoxia [3]. Cardiomyocytes are a highly differentiated cell type 
with very limited replicative potential after birth, thereafter subsequent growth of the 
heart is achieved predominantly by hypertrophy of individual cardiomyocytes. Following 
signiϐicant injury, the heart undergoes induced compensation and gradually deteriorates 
towards heart failure. Current therapy slows but does not arrest the resultant adverse 
remodeling and this is the reason why the best treatment for CVDs is prevention [4].
1.2. VASCULATURE
Blood pumped by the heart reaches every cell of the body through the massive network 
conformed by arteries, veins, and capillaries. Inside the CVS, the network of coronary 
arteries, cardiac veins and capillaries that irrigate the heart is of special interest because 
its correct function is critical to maintain a working heart and an appropriate vascular 
tone [5]. The largest blood vessels, such as the aorta (which is a conductance artery), have 
a thick, tough wall of connective tissue and many layers of smooth muscle cells. The wall 
is lined by a thin single sheet of endothelial cells called the endothelium, separated from 
the surrounding outer layers by a basal lamina. The amounts of connective tissue and 
smooth muscle in the vessel wall vary according to the vessel’s diameter and function. In 
the thinnest branches of the vascular tree the walls consist of nothing but endothelial cells 
and a basal lamina, together with a few scattered pericytes. As the diameter of the artery 
narrows, as for example in mesenteric resistance arteries (MRA), the contraction and 
relaxation of the muscle changes vessel diameter, which alters resistance to blood ϐlow to 
adapt to blood pressure ϐluctuations. Therefore they are referred as resistance arteries or 
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arterioles. In this process endothelial cells sense the shear stress due to ϐlow of blood; 
by signaling this information to the surrounding connective tissue and smooth muscle 
cells, they enable the blood vessel to adapt its diameter and wall thickness to suit the 
blood ϐlow. Endothelial cells also mediate rapid responses to neural signals for blood 
vessel dilation, by releasing the gas nitric oxide (NO) to make smooth muscle relax in 
the vessel wall. These processes are crucial for the regulation of blood pressure [6].
1.3. THE CARDIOVASCULAR DISEASE CONTINUUM
The cardiovascular disease continuum (CVDC) was ϐirst conceived by Dzau and 
Braunwald in 1991 and is a sequence of events precipitated by several risk factors 
which, if left untreated, inexorably culminate in end stage heart failure (HF) and death 
[7]. Despite recent improvements in therapy and clinical care, HF remains the leading 
cause of death in developed countries and it has been estimated that by 2030 more 
than 23 million people will die annually from CVD [1].
The major events of CVDC (atherosclerosis, coronary artery disease, myocardial 
infarction (MI), left ventricular hypertrophy and left ventricular dilation) usually begin 
as remodeling processes of the myocardium and vasculature to a range of potentially 
noxious hemodynamic, metabolic, and inϐlammatory stimuli in order to compensate 
or adapt to alterations in the CVS; but, when they persist, they progress to structural 
changes that become self-perpetuating and pathogenic (Figure 1) [8]. Treatment 
intervention at any stage during its course will either arrest or delay its progress but 
would never make it reversible, so the main focus remains on the prevention.
Figure 1: The Cardiovascular Disease Continuum (CVDC) is a pathological sequence of events that become 
progressively more severe and whose end-stage is heart failure and death. The CVDC links various risk factors that, 
with the exception of smoking, constitute the metabolic syndrome. By treating pathological processes that occur 
early on in the CVDC, like hypertension, insulin resistance or obesity it may be possible to prevent or slow the 
development of heart disease and to prolong life. LVH, left ventricle hypertrophy; CAD, Coronary artery disease.
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 2. CARDIOVASCULAR RISK FACTORS
The major risk factors of CVD are dyslipidemia, hypertension, insulin resistance (IR), 
obesity and smoking [9]. With the exception of smoking, all other risk factors of CVD 
constitute what we nowadays deϐine as Metabolic Syndrome (MetS). MetS, also known as 
Syndrome X, is dramatically increasing in the wake of urbanization, surplus energy intake, 
increasing obesity, and sedentary life habits. The International Diabetes Federation 
estimates that one-quarter of the world´s adult population has the MetS [10]. It is deϐined 
by a constellation of interconnected physiological, biochemical, clinical, and metabolic 
factors that directly increases the risk of CVD, type 2 diabetes mellitus (T2DM), and cause 
mortality [11]. Further, MetS increases the risk of stroke, leads to a 3 to 4-fold increase in 
the risk of MI, and to a 2-fold increase in the risk of dying from such an event [12]. The 
physiological and biochemical effects brought about by MetS include abnormal adipose 
tissue functions, hepatic steatosis, heart diseases, systemic inϐlammation and chronic 
diabetes complications [13]. Therefore IR, visceral adiposity, atherogenic dyslipidemia, 
endothelial dysfunction, genetic susceptibility, elevated blood pressure, hypercoagulable 
state, and chronic stress are the several factors which constitute the syndrome [14].
2.1. OBESITY
Overweight and obesity are deϐined as abnormal or excessive fat accumulation 
that represents a risk to health [15]. The “obesity epidemic” is principally driven by 
an increased consumption of cheap, calorie-dense food and reduced physical activity. 
Adipose tissue can respond rapidly and dynamically to alterations in nutrient excess 
through adipocyte´s hypertrophy and hyperplasia [16]. Obesity does not only result in the 
storage of excessive fat by adipocytes, but rather it also constitutes a metabolic and low 
intensity inϐlammatory disorder where adipose tissue works as a hormone-generating 
tissue, secreting various peptides and second messengers, as well as inϐlammatory 
cytokines.
 Many of these compounds (Angiotensin II (Ang II), plasminogen activator inhibitor-1, 
TNF-α, interleukin-6 (IL-6), C-reactive protein (CRP) and ϐibrinogen)  are important 
markers in human CVDC, and correlate with the degree of obesity [17]. An imbalance 
between inϐlammatory responses associated with obesity can result in endothelial 
dysfunction as an initiating event in atherosclerosis [18]. Besides, the development of 
obesity triggers different adaptations in the morphology of cardiac structure and function. 
The connection between heart failure and obesity implicates complex pathophysiological 
mechanisms: an increase in total blood volume, and thus increased cardiac output, 
left ventricular hypertrophy, left ventricular systolic and diastolic dysfunction and fat 
accumulation. The latter was found to be in positive correlation with the degree of obesity 
since the myocardium gradually accumulates fat between muscle ϐibers what leads to 
myocyte degeneration and alterations of electrical conduction [19-21].
More important in the pathogenesis of obesity is that excessive body weight, besides 
constituting an independent risk factor for CVD, also contributes to other risk factors 
such as type 2 diabetes mellitus (T2DM), hypertension and dyslipidemia, which further 
increase the prevalence and severity of CVD [22].
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2.2. INSULIN RESISTANCE
Insulin-resistant individuals show an abnormal response to a glucose challenge, 
an elevated fasting glucose levels and/or overt hyperglycemia, or a reduction in insulin 
action after intravenous administration of insulin with decreased insulin-mediated 
glucose clearance and/or a lesser ability to suppress endogenous glucose production. An 
inability of the pancreatic β cells to produce sufϐicient insulin to correct the deteriorating 
IR in peripheral tissues leads to hyperglycemia and overt T2DM [27].
Type 2 diabetes (formerly called non-insulin-dependent or adult-onset diabetes) is 
caused by the body’s ineffective use of insulin and often results from excess body weight 
BOX 1: ANIMAL MODELS OF OBESITY
Animal models with generalized obesity are frequently classifi ed in two groups: 
genetically-engineered animals with mutations that result in obesity, and genetically intact 
animals exposed to obesogenic environments such as being maintained on high-fat diets. 
In evaluating results from animal models of obesity it is important to bear in mind that, as 
so happens in humans, obesity in certain animal models is associated with coincident 
morbidities such as impaired glucose tolerance, diabetes and hypertension. 
Commonly used genetically-induced obese animal models are those who develop 
obesity because of mutations in the leptin receptor or leptin gene. One such example 
is the ob/ob mice, which are defi cient for the leptin gene. On the C57BL6/J background 
they develop obesity, hyperinsulinemia, and impaired glucose tolerance shortly after 
weaning, and develop overt diabetes between 10 and 15 weeks of age [23] while mice 
with mutations in the leptin receptor (db/db) develop diabetes as early as at 5 weeks of 
age [24]. It is important in these animal models (ob/ob, db/db, Zucker diabetic fatty rats) to 
take into consideration the age at which the studies are performed, given the potentially 
confusing effects of hyperglycemia on the observed phenotypes. Moreover, it is important 
to determine which changes in these models are a consequence of obesity versus the 
effects that are secondary to loss of the leptin-mediated system.  
Most instances of human obesity are nonetheless considered to be multifactorial, 
resulting from the integrated activity of numerous conditions and/or genes responsible 
only for a small risk factor on its own, so diet-induced obesity animals are believed to 
better mimic the state of common obesity in humans than most of the genetically-modifi ed 
models and may be the best choice for testing prospective therapeutics [25]. Nevertheless, 
the pathological characteristics of animal models whose phenotype depend on the diet 
are also dependent on different facts such as differences in dietary lipid composition 
(saturated versus unsaturated fats), whether or not the high fat diets are isocaloric or 
promote obesity, and the period along which the animals are fed with the specifi c diet. 
Thus, C57BL6 mice fed with a high fat diet (HFD) of 55% calories from fat for 20 weeks 
develop cardiac dysfunction associated with mild hyperglycemia, hyperleptinemia and 
reduced adiponectin levels [26], although in vivo changes in cardiac function in mouse 
models with lesser degrees of obesity are more subtle. In sum, it is important to know the 
characteristics of each experimental animal model in order to choose the most appropriate 
one for each study, to analyze the results obtained and to compare them with other studies.
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and physical inactivity [28]. Diabetes mellitus, especially type 2, accounts for > 97% of 
adult diabetic population and its prevalence has increased globally. Nowadays 382 million 
people are diabetic and by 2030 the number is expected to rise to 552 million reaching 
the 7th position in the list of leading causes of death [29].
Overt T2DM and its main feature, IR, are serious CVD risk factors and are considered a 
“cardiovascular risk equivalent”, thus conferring diabetic patients the same risk for future 
cardiovascular complications as those who have already suffered a prior MI [30]. IR is 
responsible for diverse cardiovascular complications such as increased atherosclerosis in 
large arteries and increase coronary atherosclerosis promoting coronary artery disease. 
Besides, it can also affect cardiac structure and function in the absence of changes in blood 
pressure and coronary artery disease, a condition called diabetic cardiomyopathy [31]. 
Together, these events, acting through a variety of mediators such as altered intracellular 
calcium, increased reactive oxygen species (ROS), activation of the Renin-Angiotensin 
System (RAS), altered substrate metabolism, mitochondrial dysfunction, ceramides, 
hexosamines, advanced glycation end products, and more, contribute to the pathogenesis 
of the disorder [31, 32].
From all the above, CVD is the most common cause of death in people with IR the 
underlying reason being the coexistence of other well-known risk factors such as 
hypertension, dyslipidemia and obesity in these patients.
BOX 2: ANIMAL MODELS OF INSULIN RESISTANCE
Typical animal models of T2DM (db/db mice, ob/ob mice or Zucker fatty rats) reproduce 
the functional and structural alterations observed in patients with diabetic cardiomyopathy 
such as diastolic and systolic dysfunction and left ventricular hypertrophy (LVH) [31] 
however it is important to bear in mind that, as T2DM develops at varying tempos in these 
models, studies performed in animals before the onset of diabetes may refl ect changes 
that are promoted by the underlying obesity and IR while studies performed after overt 
T2DM may refl ect the added effects of hyperglycemia.  
Apart from the typical animal models for the study of IR, that also constitute models of 
obesity and overt T2DM, engineered animal models with tissue-specifi c deletion of the 
insulin receptor enable us to investigate the specifi c role of impaired insulin signaling in the 
apparent absence of the confounding effects of systemic metabolic perturbations. Some 
examples of this category are CIRKO (Cardiomyocyte-specifi c Insulin Receptor Knock 
Out) mice [33] and VENIRKO (Vascular Endothelial cell Insulin receptor Knock Out) [34] 
mice. They are a potent tool to study the mechanistic features of insulin signaling in these 
specifi c cellular contexts but they do not fully mimic physiological IR since a total absence 
of the receptor is achieved instead of alterations in the fi nely-tuned regulation of the insulin 
signaling pathway observed under IR conditions. On the other hand, they do not reproduce 
overt IR since insulin signaling deletion is not taking place systemically; therefore they 
lack systemic alterations in metabolism such as hyperglycemia and hyperlipidemia, which 
represent highly deleterious features for CVS.
Introduction
44
2.3. HYPERTENSION
High blood pressure or hypertension is one of the most common chronic diseases in 
the human population, affecting one in three adults worldwide in 2013 [35]. Hypertension 
has a substantial impact on public health because of its complications including kidney 
disease, stroke and HF (as end-stage of cardiac remodeling, LVH and ventricular 
dysfunction) which are major sources of morbidity and mortality. 
Determinants of blood pressure are approximated by Ohm´s law modiϐied for ϐluid 
dynamics (pressure = ϐlow x resistance). Blood ϐlow depends on cardiac output and blood 
volume, whereas resistance is determined by the contractile state of small arteries and 
arterioles throughout the body. Despite the physiological complexity of hypertension, 
only a few key pathways have a major inϐluence on the control of blood pressure: sodium 
excretion by the kidney, activity of the central nervous system (SNS), and contractile 
processes in the vasculature [36]. The latter regulates the radius of blood vessels, thus 
modulating peripheral resistance and is controlled by a delicate balance of vasoconstrictor 
and vasodilator inputs explained below in more detail.
An important modulator of hemodynamic homeostasis is the RAS. Upon a decrease 
in blood ϐlow, kidney´s juxtaglomerular cells activate their pro-renin and secrete renin 
directly into circulation. Renin then carries out the enzymatic conversion of liver-
secreted angiotensinogen to Angiotensin I and subsequently Angiotensin I is converted 
to Ang II by the angiotensin-converting enzyme found in the lungs. Ang II is a potent 
vasoactive peptide that causes sympathetic activation, tubular water retention, arteriolar 
vasoconstriction and it also promotes the release of aldosterone, an hormone which fuels 
renal sodium reabsorption and an increase in blood pressure. Moreover the RAS can also 
be activated by a low concentration of salt in the kidney or by sympathetic activation [37].
An association between hypertension and inϐlammation has been clearly 
demonstrated; however, it is presently unclear whether inϐlammation is predominately 
a cause or an effect of hypertension [38]. Essential hypertension is frequently associated 
with several metabolic abnormalities, among which obesity and IR are the most common 
[39].
BOX 3: ANIMAL MODELS OF HYPERTENSION
In order to understand the pathogenesis and to study the treatment and prevention 
of hypertension several widely used genetic models have been generated, principally in 
rats, through selective breeding for the traits of increased blood pressure, salt sensitivity 
or both. There are also alternative animal models in which hypertension is induced by 
pharmacological and transgenic modulation of key neurohormonal regulators of blood 
pressure [36]. They share many features in common with human hypertension, as most 
of them have been developed based on the etiological factors that are responsible for 
human hypertension (such as excessive salt intake, hyperactivity of RAS, or defi ned 
genetic factors), however, these models do not fully recapitulate all the features of human 
hypertension. Therefore, a thorough understanding of the animal models and a rigorous 
analysis is required before extrapolating the fi ndings in animals to humans. 
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2.4 . ENDOTHELIAL DYSFUNCTION
Another important feature of MetS that is a risk factor for CVD and is intimately 
related to hypertension and IR is endothelial dysfunction. It is one potential mechanism 
by which inϐlammation may promote hypertension and it is characterized by an impaired 
endothelium-dependent vasodilation, a reduced arterial compliance and an accelerated 
process of atherosclerosis [43]. Various factors like oxidative stress, hyperglycemia, 
advanced glycation products, free fatty acids (FFAs), inϐlammatory cytokines or adipokines 
cause an inability of endothelium to serve its normal physiological and protective 
mechanisms, but the key regulator in endothelial homeostasis is NO bioavailability, and 
IR is implicated in this process.
It is well known that IR and compensatory hyperinsulinemia, besides activating 
the mechanisms mentioned above, also have a toxic effect in the vasculature, mainly at 
the endothelial level. This takes place partly because IR impairs the production of NO, 
favors the production of endothelin-1 (ET-1) and the vasoconstrictive and mitogenic 
responses on the vascular wall [44]. Interestingly, insulin signaling pathways in vascular 
endothelium leading to the activation of endothelial NO synthase (eNOS) are completely 
independent and distinct from classical calcium-dependent mechanism used by G 
protein-coupled receptors, such as the muscarinic acetylcholine (ACh) receptors. 
Insulin exhibits a dual and opposing action on blood vessels: NO-mediated 
vasodilation (via PI3K/Akt/eNOS axis) and ET-1-triggered vasoconstriction (via MAPK), 
so insulin induces endothelin-mediated vasoconstriction only when PI3K is inhibited as so 
happens in T2DM [45]. Furthermore, ET-1 promotes IR (by reducing blood supply to the 
skeletal muscle), increases oxidative stress and reduces the bioavailability of NO fueling 
a detrimental vicious circle that promotes a proatherogenic state [46]. These events take 
place also in genetic animal models of MetS (Zucker Obese, Spontaneously Hypertensive 
Obese and JCR-LA-cp corpulent rats) and in diet-induced obese animal models, not only 
in macrovascular but specially in microvascular resistance vessels [47].
Ang II is the fi nal effector of the RAS, plays a major role in the physiological control of 
vasomotor tone and the vessel structure, and is an important contributor to blood pressure 
increase, vascular infl ammation and fi brosis in pathological conditions such as hypertension 
[40]. Ang II-induced hypertension has therefore become a widely used experimental model 
of hypertension in rodents by its continuous administration through osmotic minipumps. 
It is usually delivered subcutaneously and, in the fi rst days of the experimental model, 
hypertension predominantly results from the vasoconstrictor effects of the peptide, involving 
smooth muscle cell contraction and cytoeskeletal remodeling. In addition Ang II induces 
oxidative stress, which further aggravates the hypertensive phenotype and causes the 
release of aldosterone leading to salt and water retention resulting in increased blood 
volume and tension [41]. Experimental models based on Ang II infusions are reported 
to replicate human pathologies such as postmenopausal hypertension, preeclampsia, 
vascular remodeling, vascular aging, and neovascularization [42].
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3. CARDIAC AND VASCULAR REMODELING
Pump failure leading to congestive heart failure (CHF) is the common endpoint 
of the spectrum of progressive CVDs of the CVDC. Many compensatory mechanisms 
-such as myocardial hypertrophy and dilation, as well as neurohormonal, cytokine, and 
endothelial activation- precede cardiac failure; however, such myocardial (and extra-
cardiac) adaptations eventually progress to a maladaptive response, and ultimately lead 
to decompensation and CHF. Maladaptation manifests as hemodynamic abnormalities, 
neurohormonal imbalance, cytokine overexpression, and endothelial dysfunction.
3.1 . VASCULAR REMODELING
There is a high plasticity in vessels to accommodate changing conditions of mechanical 
load. The contractile state of vascular smooth muscle cells (VSMC) regulates the radius of 
blood vessels, thus modulating peripheral resistance. 
Vascular remodeling refers to alterations in the structure and arrangement in blood 
vessels through cell growth, cell death, cell migration and production or degradation 
of the extracellular cell matrix (ECM), contributing to elevated vascular resistance in 
response to hypertension. 
Of special interest is vascular remodeling in resistance arteries, involved in systemic 
vascular resistance and therefore in the regulation of arterial blood pressure as well as 
blood ϐlow within tissues. These vessels are highly innervated by autonomous nerves 
(particularly sympathetic adrenergic), and respond to changes in nerve activity and 
circulating hormones by constricting or dilating. 
• Types of remodeling
Depending on whether lumen diameter decreased or increased, remodeling could be 
“inward” or “outward”.  In resistance vessels lumen is reduced and inward remodeling 
occurs in primary hypertension –with RAS activation- [48] that is, of an eutrophic nature 
(no net change in the amount of tissue and constant cross-sectional area). However, the 
growth is hypertrophic (with net growth and increased cross-sectional area) in salt-
dependent hypertension, T2DM and all conditions in which the endothelin system is 
activated. Besides, in small arteries of hypertensive rats hyperplasia of VSMC was found, 
whereas VSMC hypertrophy has been reported in the aorta [49].
•  Signaling pathways implicated in vascular remodeling
Rises in blood pressure directly affect remodeling of blood vessels by increasing wall 
stress and stimulation of mechanoreceptors [50]. Remodeling is importantly affected 
by Ang II as it inϐluences vascular structure in hypertension (Figure 2). It binds to the 
AT1 receptor (AT1R), leading to the transactivation of receptor tyrosine kinases, such 
as epidermal growth factor receptor (EGFR), platelet-derived growth factor receptor 
(PDGFR) and insulin-like growth factor-1 receptor (IGF-1R), and nonreceptor tyrosine 
kinases, such as c-Src [51]. In addition, Ang II:AT1R binding induces activation of NADPH 
oxidase resulting in intracellular generation of ROS, which inϐluence redox-sensitive 
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signaling molecules, such as mitogen-activated protein kinases (p38, JNK, ERK1/2 and 
ERK5), transcription factors -NF-κB, AP-1 and HIF-1- and matrix metalloproteinases 
(MMP) [52]. Ang II may also downregulate peroxisome proliferator-activated receptors 
(PPARs), which have anti-inϐlammatory effects, thus enhancing vascular inϐlammation 
[53]. Then, under pathological conditions, altered Ang II signaling leads to altered 
growth, ϐibrosis, and inϐlammation, which altogether contribute to structural remodeling 
in hypertension [40].
Figure 2: Mechanisms governing hypertension and vascular remodeling. In the presence of genetic 
predisposition and unfavorable environmental conditions (eg, excess salt or inappropriate diet), the brain through 
activation of the sympathetic nervous system will induce small rises in blood pressure. Blood pressure elevation 
directly affects remodeling of blood vessels by increasing media stress and stimulation of mechanoreceptors. It may 
also stimulate oxidative stress in the vascular wall by enhancing NADPH oxidase activity. Remodeling of the wall is 
importantly affected by angiotensin II (Ang II), which stimulates calcium release leading to vasoconstriction. Ang 
II–induced vasoconstriction also acts via Rho kinase (ROCK), which increases myosin light chain (MLC) sensitivity 
to calcium. Besides, Ang II signaling assembles in several MAPKs signaling pathways which regulate cell growth, 
apoptosis, inϐlammation and migration. Growth, inϐlammation, and repair processes interact with vasoconstriction 
promoting hypertension which promotes vascular remodeling. EGFR indicates epidermal growth factor receptor; 
ERK, extracellular regulated kinase; JNK, c-Jun N-terminal kinase; MAPK, mitogen activated protein kinase; MK2, 
MAPK activated protein kinase-2; MLCK, MLC kinase; MMP, matrix metalloprotease; TGF-β, transforming growth 
factor-β; TIMP, tissue inhibitor of MMP. Shadowed in green are the molecular mechanisms that lead to hypertension 
(Adapted from Schiffrin E.L. 2012).
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Endothelin and aldosterone acting in an endocrine and paracrine fashion may also 
induce deposition of collagen and ϐibronectin with increased collagen:elastin ratio in 
small vessels thus promoting an enhanced stiffness of the vasculature [54, 55].
3.2. CARDIAC REMODELING
3.2.1. Cardiac hypertrophy
The heart has a unique ability to adapt to acute as well as chronic changes in the 
hemodynamic state in order to maintain optimal circulation. Thus, the process of 
cardiac hypertrophy is an adaptive phenomena initiated in response to an increased 
hemodynamic overload.
Cardiac remodeling is deϐined as alterations in size, geometry, shape, composition 
and function of the heart resulting from cardiac load or injury. Left ventricular (LV) 
remodeling is frequently seen in hypertensive subjects and has been considered an 
adaptive response to hemodynamic overload imposed by systemic hypertension. This 
compensatory response is assumed to be explained by the Laplace´s law, T =P x r/2h, 
where tension or stress in the LV wall (T) is directly related to LV pressure (P) and radius 
(r) and is inversely related to LV wall thickness (h). Therefore, sustained elevated blood 
pressure leads to increases in LV wall stress [56]. 
• Types of remodeling
 In response to increased LV wall stress, LV wall thickens and LV mass increases, thus 
resulting in normalization of wall stress and the development of a structural pattern 
known as concentric hypertrophy (see Figure 3). Alternatively, increases in blood volume 
would lead to an increase in the chamber radius, resulting in eccentric hypertrophy 
[57]. Apart from this etiologic/morphometric classiϐication, cardiac hypertrophy can 
be further categorized as “compensated” or “decompensated” based on LV chamber 
ejection performance and the presumed stage of the deteriorating condition, but these 
terms are often used to describe the presence or absence of cardiac failure, regardless 
of whether cardiomyocyte function is normal or abnormal. Cardiac hypertrophy could 
also be classiϐied as “physiological” or “pathological”. The former refers to a temporary 
increase in the size of the organ due to a physiological demand such as during normal 
postnatal maturation or, in adults, during pregnancy in females, or with chronic exercise 
training. In these cases, cardiomyocytes grow longitudinally and no changes in expression 
of fetal genes or collagen are detected [58]. This type of hypertrophy is reversible and it 
is also called “adaptive”. However, under prolonged pathological stress, such unremitting 
hypertension [57] and therefore increase pressure overload instead of volume overload, 
T2DM [59] or obesity [60], cardiac hypertrophy is accompanied by interstitial ϐibrosis, 
contractile dysfunction, altered gene expression pattern with re-expression of fetal 
genes, changes in energy metabolism with diminished fatty acid oxidation and abnormal 
electrophysiological properties which eventually lead to decreased systolic and diastolic 
function and overt decompensated heart failure [61]. This kind of LV hypertrophy is 
considered of a pathological nature and in fact constitutes as an independent risk factor 
for cardiovascular morbidity and mortality [62].
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Cardiac remodeling could evolve to diastolic and systolic dysfunction. 
Echocardiographic measurements are very useful to evaluate cardiac functionality 
and characterize cardiac hypertrophy. Also, fractional shortening and ejection fraction 
are two prototypical measures of cardiac function. The ϐirst is a simple measure of the 
pump function of the heart as the ratio between the diameter of the left ventricle when 
it is relaxed and its diameter when it has contracted. The ejection fraction indicates 
the fraction of blood in the ventricles pumped out with each heartbeat expressed in 
percentual terms. Heart failure risk varies with LV geometric pattern, with eccentric and 
concentric hypertrophy predisposing to HF with reduced and preserved ejection fraction, 
respectively. 
Whereas in hypertension- and obesity-mediated LV hypertrophy the most frequent 
geometric pattern is eccentric hypertrophy, either concentric or eccentric remodeling 
was reported in diabetic patients. Nevertheless, the coexistence of hypertension with 
either T2DM or obesity increases the proportion of concentric hypertrophy in patients 
[57, 60]. Interestingly, although under pathological conditions subjects with concentric 
hypertrophy are predisposed to the highest cardiovascular risk [63], physiological 
concentric hypertrophy can also be developed under resistance training [64].
• Signaling pathways implicated in cardiac hypertrophy
The hypertrophic growth of the myocardium is typically initiated by signal 
transduction pathways in response to either neuroendocrine factors or an ill-deϐined 
mechanical stretch or wall tension-sensing apparatus [65]. 
Physiological hypertrophy is initiated by ϐinite signals, which include growth 
hormones (such as thyroid hormone, insulin, insulin-like growth factor 1 (IGF-1) and 
Figure 3: Types of cardiac 
hypertrophy could be 
classiϐied from a morphological 
point of view in eccentric or 
concentric if the radius of 
the ventricles is increased 
or diminished respectively, 
or from a functional point of 
view, taking into account the 
ϐinal outcome in heart function 
and morphometry: whether 
contractility is affected or 
not, or if the remodeling is 
permanent or reversible.
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vascular endothelial growth factor (VEGF), and mechanical forces that converge on a 
limited number of intracellular signaling pathways (such as PI3K, Akt, AMPK and mTOR). 
These pathways or effectors have been shown to antagonize cell death in the heart or 
to stimulate myocyte renewal, suggesting that physiological growth stimulation through 
such pathways can be cardioprotective despite causing mild heart enlargement [66]. 
On the other hand, pathological hypertrophy is promoted by higher levels of neuro-
endocrine hormones such as ET- 1 and Ang II secreted under biomechanical stress. 
Signaling pathways in pathological hypertrophy converge in the Gα
q
/PLC/Ca2+/PKC and 
calcineurin/NFAT axis. Other examples of mediators of pathological cardiac hypertrophy 
are the p38 and JNK branches of the MAPK cascade, which phosphorylate and activate 
the GATA4 transcription factor. Catecholamines can also signal to adenylyl cyclase (AC) 
to induce activation of protein kinase A (PKA), which then phosphorylates an array of 
intracellular targets, leading to increased calcium release and enhanced contractility, the 
net effect being cardiomyopathy as a result of increased myocyte  apoptosis and necrosis 
[65].
Figure 4: Signaling pathways implicated in pathological and physiological heart hypertrophy. In the ϐirst 
case disorders such as systemic hypertension, myocardial infarction or metabolic cardiomyopaty, among others, 
are responsible for the activation of Gα
s
- and Gα
q/11
-coupled receptors such as β-adrenergic or angiotensin 
receptos (AT1R). Calcium–calcineurin–NFAT pathway downstream Gα
q/11
/AC/PKA and Gα
s
/PLC are related to 
cardiomyocytes growth and the pathological hypertrophy of the heart. On the other hand the p38 and JNK branches 
of the MAPK cascade phosphorylate and activate the GATA4 transcription factor. Both NFAT and GATA4 transactivate 
the transcription of hypertrophic target genes that are typically maladaptive. The net effect of this appears to 
be cardiomyopathic, as it results in increased myocyte apoptosis and necrosis. On the other hand, physiological 
hypertrophy is initiated by intermittent signals of triiodothyronine (T3), vascular endothelial growth factor (VEGF), 
insulin and insulin-like growth factor 1 (IGF1). Downstream their receptors we can ϐind common signalling branches 
controlled by PI3K, Akt and mTOR complex 1 (mTORC1), whereas AMP-activated protein kinase (AMPK) governs 
metabolic adaptive reprogramming. These signalling pathways regulate the transcription of adaptive genes, protein 
synthesis, metabolism and energy production through a set of transcription factors such as FOXO, PGC1 or C/EBPβ 
among others. AC indicates adenylyl cyclase; PKA, protein kinase A; PLC, phospholipase C.
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3.2.2. Metabolic remodeling of the heart
The heart is a constitutive energy-demanding organ. It must contract incessantly, thus 
the requirement for energy to fuel optimal function is immense. Daily turnover of cardiac 
ATP is calculated to range between 6 and 35 kg and its storage within the cardiomyocytes 
is minimal, only sufϐicient to sustain the heart beat for a few seconds, so a tight coupling 
between ATP production and myocardial contraction is essential for normal cardiac 
function [67].
The heart is capable of using all classes of energy substrates, including carbohydrates, 
lipids, amino acids, and ketone bodies for ATP production in the mitochondria [68, 69].
It is widely accepted that fatty acids are the predominant substrate used in the adult 
heart; however, the cardiac metabolic network is highly ϐlexible in using other substrates 
when they become abundantly available [70].
Under pathological conditions metabolic ϐlexibility is impaired and a shift takes place 
in myocardial substrate utilization that limits the potential of adaptation of the heart to 
supply ATP for continuous cardiac contraction.
3.2.2.a) Changes in cardiac metabolism with pathological hypertrophy and failure
Cardiac metabolism undergoes a reprogramming in response to pathological 
hypertrophy, characterized by increase dependency on glucose metabolism and decreased 
fatty acid oxidation (FAO) what implies a reversion to the fetal energy substrate preference 
pattern [71]. This shift in substrate preferences is associated with the downregulation 
of the transcriptional mechanisms for FAO and mitochondrial biogenesis mediated via 
PPARα and PGC1α [72]. 
Metabolic remodeling in the hypertrophied heart is associated with decreases in the 
overall ATP synthesis by oxidative metabolism because, although glycolysis is increased, 
its contribution to total ATP synthesis is limited as glycolytic ATP accounts for less than 
5% of the total energy used by the heart [73]. Nevertheless, a shift from FAO to glucose 
could be considered beneϐicial for HF caused by chronic ischemic cardiomyopathy, since 
it improves oxygen efϐiciency for ATP synthesis in a condition where oxygen supply is 
limited [74].
Another aspect to consider is that HF may itself promote metabolic changes such as 
IR in part through neurohumoral activation. The failing heart invokes compensatory SNS 
and RAS activation, which increase blood FFAs thereby promoting IR and vasoconstriction 
in peripheral tissues which may lead to endothelial dysfunction perpetuating the vicious 
cycle: HF → metabolic alterations → HF [67]. 
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3.2.2.b) Metabolic cardiomyopathy associated with obesity and diabetes mellitus: 
Glucotoxicity and Lipotoxicity
Cardiomyocytes are capable of metabolizing a spectrum of substrates which are, 
however, unable to enter the cardiomyocyte by simple diffusion and must be taken up 
by facilitated transport. Fatty acid uptake is mediated by FAT (fatty acid translocase, also 
known as cluster of differentiation 36, CD36), and glucose intake is accomplished by 
GLUT4 (glucose transporter type 4). In response to availability of nutrients or increased 
cardiac work, plasma insulin concentrations rise [75]. This, in turn, provokes GLUT4 as 
well as FAT/CD36 translocation to the myocyte sarcolemma. During the development of 
IR and T2DM, FAT/CD36 becomes preferentially sarcolemma-localized, whereas GLUT4 
is internalized. This reciprocal positioning of GLUT4 and FAT/CD36 is central to aberrant 
substrate uptake in the diabetic heart, where fatty acid metabolism is chronically 
increased at the expense of glucose [76].
In obese or individuals with T2DM, cardiac dysfunction observed independently 
of macro- and microvascular disease is considered a consequence of diabetic 
cardiomyopathy. It is characterized by an increased FA uptake and oxidation associated 
with reduced glucose oxidation, either because of an increase in FA supply through 
the diet, an insulin-resistant state that promotes the uptake and oxidation of FA or the 
combination of both (see Figure 5). Noteworthy, although FAO is the main source of ATP 
in cardiomyocytes, increased rates of FAO may be detrimental to cardiac function due to 
the increase in myocardial oxygen consumption, reduced cardiac efϐiciency by uncoupling 
of the mitochondria and increased oxidative stress [31]. Interestingly, when the supply 
of substrates exceeds the needs for ATP synthesis, lipids accumulate in the heart. The 
increase in the rate of FAO eventually leads to its own downregulation, accumulation of 
toxic lipid intermediates as ceramides, and contractile failure, what is known as lipotoxic 
cardiomyopathy [77]. The maintenance of high levels of mitochondrial β-oxidation 
are critical to reduce the excessive fat accumulation and storage leading to obesity; 
furthermore lipid overload involving triacylglycerol accumulation in non-adipose tissues 
characterizes disorders such as heart dysfunction both in humans and in animal models 
of obesity and IR [78].
On the other hand, high levels of circulating glucose (hyperglycemia) promote several 
cardiovascular complications as a result of cardiac and vascular tissue responses to toxic 
metabolites from glucose metabolism, which has been referred to as cardiac and vascular 
glycotoxicity. Glucose could enter in the cardiomyocyte through insulin-independent 
glucose transporter GLUT1 or Na+-dependent glucose transporter (SGLT) 1 and 2 [79]. 
Indeed SGLT1 expression has been found increased in the cardiomyocytes of ob/ob 
mice [80], and because of the shift towards FAO, glycolitic intermediates fuel alternative 
metabolic pathways with deleterious effects to the cardiomyocytes. Multiple molecular 
mechanisms have been suggested to mediate glycotoxic effects on cardiovascular tissues 
such as increased polyol pathway, activation of the diacylglycerol/PKC pathway, increased 
oxidative stress, overproduction and action of advanced glycation end-products, and 
increased hexosamine pathway. In addition, the alterations of signal transduction 
pathways induced by hyperglycemia or toxic metabolites can also lead to cellular 
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dysfunctions and damage vascular tissues by altering gene expression and protein 
function. Hyperglycemia might also inhibit some endogenous cardiovascular protective 
factors such as insulin, VEGF and PDGF, which play important roles in maintaining 
vascular homeostasis [81].
4. MOLECULAR SIGNALING PATHWAYS IN CVS PHYSIOLOGY
4.1. GPCR SIGNALING 
G protein-coupled receptors (GPCRs) are a conserved family of seven transmembrane-
spanning receptors that constitutes the largest class of receptors targeted by medicinal 
drugs [82]. Ligand binding induces a conformational change in the GPCR, which triggers 
coupling with heterotrimeric guanine-nucleotide regulatory proteins (G proteins). The 
four primary families of Gα-proteins (Gα
s,
 Gα
i
, Gα
q/11
, and Gα
12/13
) diverge with respect to 
downstream signaling molecules and subsequent physiological responses (see Figure 6). 
Figure 5: Metabolic remodeling of the heart under different pathological conditions. A healthy heart, under 
a balanced nutrient disposal, obtained its energy as ATP preferentially from fatty acid oxidation. It accounts for 
the 65% of total ATP whereas glucose metabolism represents 30%. The pathologically hypertrophied heart is 
characterized by the downregulation of the transcription factor PPARα and the transcriptional cofactor PGC1α  what 
downmodulates fatty acid uptake and catabolism. On the other hand, glucose metabolism is reduced to glycolisis, 
what limits ATP synthesis, and fuels accessory pathways that result in the production of metabolites that are of 
important biological function although do not directly contribute to energy supply. Therefore the hypertrophied 
heart is considered an energy-starved model with high risk of suffering heart failure. On the contrary, in the metabolic 
cardiomyopathy characteristic of obese and/or insulin-resistant individuals, the abrogation of insulin signaling is 
the main feature, and is enhanced upon excessive dietary fat. The cardiomyocyte increases fatty acid uptake and 
oxidation leading to increased oxygen consumption and ROS production, what impairs mitochondrial function. An 
excessive ϐlux of fatty acids to the cell promotes the accumulation of toxic intracellular fatty acid species in a process 
known as lipotoxicity. Also, hyperglycemia promotes glycotoxicity fueling alternative metabolic pathways for 
glucose that generate increased redox stress, O-glycosilated proteins and so on, leading to alterations in vascular and 
cardiac structure and function. G6P indicates Glucose-6-phospate; TCA cycle, tricarboxylic acid cycle; CPT, Carnitine 
palmitoyltransferase; Ox Phos, oxidative phosphorylation; InsR, insulin receptor.
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Upon ligand binding, the activated GPCR interact with the G protein and serves as 
a guanine-nucleotide exchange factor to promote GDP dissociation and GTP binding to 
Gα. This results in the activation of the heterotrimeric G protein and the dissociation of 
the Gα from the Gβγ subunits to mediate downstream signaling [83]. Gβγ subunits signal 
via effectors such as PI3K, AC, PLC, potassium channels, and GRKs [84]. Endocytosis 
of GPCRs leads to their removal from the plasma membrane, after which they are 
sorted to either lysosomes for degradation or to recycling endosomes for subsequent 
reinsertion into the plasma membrane. GRK-dependent recruitment of β-arrestins to 
the phosphorylated receptor is crucial for clathrin-dependent endocytosis, which is the 
predominant internalization pathway described for the majority of GPCRs. Interestingly, 
some receptors are regulated by a single GRK, whereas others appear to be regulated 
by many GRKs. In fact, recent reports suggest that distinct phosphorylation patterns by 
different GRKs establish a signaling barcode that determines β-arrestin functionality [85, 
86]. Desensitization of GPCRs can also be initiated by their phosphorylation by second 
messenger-dependent kinases such as PKA and PKC, that can be activated by other 
receptors, an so called heterologous desensitization, in contrast to GPCR desensitization 
by GRKs in which only agonist-bound receptors are desensitized and is referred to as 
homologous desensitization [82].
4.1.1. GPCRs and cardiac func? on
Among the estimated 200 cardiac GPCRs, drugs targeting adrenergic and angiotensin 
GPCR signaling pathways alone account for the majority of prescriptions for CVD 
treatments.
Figure 6: GPCRs in the 
cardiovascular system. The main 
characteristics of GPCR signaling 
are represented related to the Gα 
protein to which they are coupled. 
In each case its main effects in 
both heart and vessels and some 
important GPCRs are highlighted. 
AC indicates adenylyl cyclase; 
PLCβ, phospholipase C β; cAMP, 
cyclic adenosine monophosphate; 
RhoGEF, guanine nucleotide 
exchange factors for Rho GTPase; 
DAG, diacylglycerol; IP
3
, Inositol 
trisphosphate;  PKA, protein kinase 
A; PKC, protein kinase C.
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Adrenergic receptors connect the sympathetic nervous and CVS, playing an integral 
role in the rapid regulation of myocardial function. In response to the reduced cardiac 
output of the failing heart, the SNS releases neurohormones to both activate cardiac 
pumping and retain salt and water [87]. However, in heart failure, chronic catecholamine 
stimulation of ARs may contribute to pathologic cardiac remodeling, including myocyte 
apoptosis and hypertrophy [65]. Cardiac myocytes express at least six types of ARs, 
including three types of β-ARs (β
1
, β
2
, and β
3
) and three types of α
1
ARs (α
1A
, α
1B
, and α
1D
) 
[88]. 
Systemic release of catecholamines (epinephrine and norepinephrine) stimulates 
β-ARs of the myocardium, increasing heart rate, enhancing contraction, and improving 
cardiac performance [83]. However sustained β-AR stimulation can be deleterious with 
time, causing receptor desensitization and downregulation due to, among other factors, 
increased levels of GRK2. The resulting loss of responsiveness to catecholamines fuels 
contractile dysfunction [89]. β
1
-ARs couple primarily to Gα
s
 proteins to regulate heart rate 
and contractility [83]. However, during heart failure, the β
1
-adrenergic receptor subtype is 
downregulated in response to increased catecholamine stimulation. Chronic activation of 
this receptor results with time in myocyte apoptosis, cardiac hypertrophy and decreased 
contractility [88, 90]. β
2
-ARs couple to G
s
 proteins, but can also switch to G
i
-coupling after 
receptor phosphorylation by PKA [91]. β
2
-AR stimulation initially activates G
s
 signaling 
pathways in a pattern analogous to β
1
-AR activation. This stimulatory pathway is quickly 
overshadowed by the delayed activation of the G
i
 pathway, which negatively regulates 
contractility in response to prolonged β-AR activation [92]. In the healthy heart, β
1
- and 
β
2
-adrenergic receptor subtypes are expressed at a ratio of 70:30 [93]. This ratio changes 
in the failing heart reaching 60:40 what contributes to HF [94]. 
β
2
-ARs are also important for mediating smooth muscle relaxation and appear to 
have an anti-apoptotic effect in cardiomyocytes mediated by the Gβγ subunits of G
i
 which 
activate the PI3K/Akt axis [88]. Other proteins such as the AMPK, mTOR, and ERK1/2 
have recently been suggested to be targets of β
2
-ARs [95]. Finally, β
3
-AR have been 
described to mediate negative inotropic effects in cardiac myocytes [96] and differ from 
the other two subtypes in: i) their resistance to homologous desensitization [97] (they 
are not phosphorylated by GRK2); ii) their upregulation in pathological conditions, such 
as ischemic or dilated cardiomyopathies in humans; and  iii) in their quantity, being the 
less abundant subtype in the heart -although they have been detected in microvascular 
endothelial cells and cardiac myocytes from normal and diseased human hearts [98]-. 
Experimental studies have shown β
3
-AR couple to G
s
 and G
i
 proteins [99].
Angiotensin II receptors (AT1R) are upregulated in the ischemic and hypertrophic 
states of the diseased heart [100], and downregulated during end-stage HF [101]. Ang II 
engages signal transduction pathways that differ between cell types. In cardiac ϐibroblasts 
Ang II activates MAP kinases through a pathway including the Gβγ subunits of G
i
, Src, Shc, 
Grb2, and Ras, while G
q
 and PKC are activated in cardiac myocytes [102]. Similar to AT1R 
the expression of endothelin-1 receptor (ET
A
) is upregulated in the diseased heart and its 
chronic activation in this condition promotes hypertrophy and pathological remodeling 
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[103]. Importantly, the overactivation of these and other G
q
-coupled receptors have 
deleterious effects to the cardiac tissue. Furthermore, cardiac overexpression of G
q
-
coupled receptors or Gα
q
 itself constituvely active in transgenic mice leads to myocardial 
hypertrophy [104, 105], apoptosis and heart failure [104, 106]. On the contrary, α
1
-ARs 
that are also G
q
-coupled receptors mediate important protective and adaptive functions in 
the heart [107] however they are only a minor fraction of total cardiac ARs. Interestingly 
chronic activation of β-AR and α
1
-AR stimulates cardiac myocyte hypertrophy in animals 
and in cultured cells [90] and both are involved in norepinephrine-induced MAP kinase 
activation.
4.1.2. GPCRs and vascular func? on
Regional blood ϐlow can be efϐiciently regulated at the local level by the intrinsic 
ability of vessels to respond to various mechanical forces such as wall tension and shear 
stress but also to chemical triggers such as metabolites and local oxygen pressure. 
While endothelium regulates local vascular tone by a delicate balance in the release of 
vasoactive molecules, the VSMCs are mainly regulated by neural control mechanisms, the 
renin–angiotensin pathway and the vasopressin pathway that interact closely to maintain 
normal levels of blood pressure [37]. 
Numerous GPCR agonists -including Ang II, endothelin, norepinephrine, and 
epinephrine- provide the neurohormonal inputs that modulate vascular smooth muscle 
contraction and blood pressure. More speciϐically, vasoconstriction through Ang II, 
endothelin, and α
1
-adrenergic receptor activation is counteracted by β-AR mediated 
vasodilation, ϐinely-tuning vascular tone. 
Typical vasoconstrictor receptors such as AT1R, ET
A
R and α
1
-ARs are G
q/11
-coupled 
and enhance intracellular Ca2+ concentration leading to myosin light chain kinase (MLCK) 
activation. Increased intracellular Ca2+ levels are not only due to IP
3
-mediated Ca2+ release 
from the sarcoplasmic reticulum, but also to Ca2+ inϐlux through cation channels or 
voltage-gated Ca2+ channels. In addition, many G
q/11
-coupled receptors have been shown 
to activate RhoA, thereby contributing to Ca2+-independent smooth muscle contraction 
[108]. 
Most of the known physiological effects of Ang II are mediated by AT1Rs, which 
are widely distributed in all organs. AT1R has two isoforms that are functionally and 
pharmacologically indistinguishable [109] however in vivo experiments show that 
the AT1
A
R isoform may be more important than AT1
B
R in regulation of blood pressure 
[110]. Even though most of the vasoactive effects of Ang II occur via AT1Rs, AT2Rs have 
been shown to exert anti-proliferative and pro-apoptotic changes in VSMCs, mainly by 
antagonizing AT1Rs. AT2R expression declines after birth, thus may play an important 
role in fetal development, and can be induced later in adult life under pathological 
conditions. Interestingly, AT2R does not internalize upon agonist binding [111]. 
Similarly, endothelin, produced primarily in the vascular endothelium, signals through 
two GPCRs, ET
A
 and ET
B 
promoting different effects in the vessels. The ET
A
 receptor is 
Introduction
57
expressed predominantly at the surface of VSMCs, where it mediates proliferation 
and smooth muscle contraction. It is coupled to G
q/11
 but also to G
s
 and G
12/13
 leading 
to stimulation of AC, PLC/PKC pathway and small RhoA [112]. On the other hand ET
B 
exerts an important role in the clearance of ET, release of nitric oxide and prostacyclins 
from endothelial cells which affect endothelial cell survival, the inhibition of endothelin 
converting enzyme and vasorelaxation [113]. The ET
B
 has two subtypes, ET
B1
 which is at 
the surface of endothelial cells and responsible of the effects of endothelin over this cell 
type, and ET
B2
 which is expressed in smooth muscle cells and is coupled to G
i
 and G
q/11 
thus implicated in the contraction of this cells. 
Vascular smooth muscle relaxation is mediated by a variety of mechanisms, one of 
them being direct activation of G
s
-coupled receptors like the adenosine A
2
 or β
2
-adrenergic 
receptors on the surface of smooth muscle cells. Another key mechanism in regulating 
vascular smooth muscle tone is the nitric oxide (NO)-cGMP system. Vascular endothelial 
cells normally produce NO, which diffuses to adjacent VSMCs where it activates soluble 
guanylate cyclase leading to increased formation of cGMP and vasodilation. cGMP can 
activate a cGMP-dependent protein kinase, inhibit calcium entry into the vascular smooth 
muscle, activate K+ channels, and decrease IP
3
 [114]. NO effects depend, among others, on 
NO concentration, compartmentation of NOS enzymes and local redox conditions of cells 
and tissues [115].
Nevertheless the production of NO in endothelial cells may also be governed by GPCRs 
on the endothelial surface such as B
2
-bradykinin receptor or acetylcholine M
3
-muscarinic 
receptor. Their stimulation activate intracellular pathways such as IP
3
/Ca2+/calmodilin 
pathway downstream G
q,
 that modulate eNOS activity post-translationally through heat 
shock protein 90 (Hsp90) or Akt-phosphorylation [115]. 
 
Both neurotransmitters and hormones released from the autonomous nervous 
system cooperate to preserve the balance between vasoconstriction and vasorelaxation 
and to control cardiac muscle cells function, and it is now generally accepted that NO 
exerts a critical role in this context in the CVS [116].
4.2. INSULIN SIGNALING
A substantial body of evidence has reported that insulin has direct actions on the 
CVS independent of its systemic effects on plasma glucose or lipids. The speciϐic binding 
of insulin to its cognate cell surface receptor initiates activation of complex signal 
transduction networks that regulate diverse cellular functions [117]. 
Then, upon insulin binding to its receptor, a ligand-activated tyrosine kinase, the 
phosphorylation of intracellular substrates takes place including IR substrate (IRS) family 
members and Shc that serve as docking proteins for downstream signaling molecules. 
Most insulin signals are produced or modulated through tyrosine phosphorylation of 
IRS1 or its homolog IRS2. IRS1 is involved in the control of body growth and peripheral 
insulin action, whereas IRS2 helps regulate brain growth, body weight, glucose 
homeostasis, and female fertility [118]. Tyrosine phosphorylation of IRS family members 
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at multiple sites creates Src homology 2 (SH2)-domain binding motifs for numerous SH2 
domain-containing effectors including PI3K and Grb2. PI3K converts PIP
2
 (an inositol 
phospholipid of the plasma membrane) to PIP
3
 that recruits Akt and 3-phosphoinositide 
dependent protein kinase–1 (PDK1) to the plasma membrane where PDK1 activates Akt. 
In turn, Akt phosphorylates and subsequently activates many substrates responsible 
of the metabolic actions of insulin. It is also responsible for GLUT4 translocation to the 
membrane and mTOR/p70S6K activation that promote protein synthesis which is one of 
the signaling pathways implicated in physiological heart hypertrophy.  In the endothelial 
cells of the vasculature, Akt also leads to the phosphorylation and subsequent activation 
of eNOS, promoting the production of NO [44]. 
In addition to PI3K-dependent insulin signaling, another major insulin signaling 
branch involves tyrosine-phosphorylated IRS1 or Shc binding to the SH2 domain of Grb2 
that results in activation of the preassociated GTP exchange factor Sos. This activates the 
small GTP binding protein Ras, which then initiates a kinase phosphorylation cascade 
involving Raf, MEK, and ERK [119]. This MAPK-dependent branch of insulin signaling 
pathways generally regulates biological actions related to growth, mitogenesis, and 
differentiation but in endothelial cells this branch also promotes the acute expression of 
ET-1 [120]. 
In sum, the PI3K-dependent branch of insulin signaling in vascular endothelium 
regulates the vasodilator actions of insulin, whereas the MAPK-dependent branch tends 
to promote the prohypertensive actions of insulin in various tissues. Therefore under 
healthy conditions, the various cardiovascular actions of insulin exist in a balance that 
contributes to cardiovascular homeostasis and result in a minimal net hemodynamic 
effect on blood pressure (Figure 7). 
These two major branches of insulin signaling pathways also regulate distinct 
biological functions related to regulation of cardiovascular homeostasis. For example, in 
VSMC the PI3K/Akt insulin signaling branch attenuates contractility by two mechanisms: 
regulating agonist-induced increases in cytosolic calcium through voltage-sensitive 
calcium channels, and altering the activity of myosin light chain phosphatases [121]. 
Altogether, these effects result in an overall decrease in vasoconstrictor tone [122].
Insulin signal transduction pathways are arranged in highly complex networks that 
include multiple feedback loops, cross-talk between major signaling branches, and cross-
talk from signaling pathways of heterologous receptors [123]. A key feature of insulin 
resistance in the vessels is that it is characterized by a speciϐic impairment of PI3K-
dependent signaling pathways, whereas other insulin signaling branches including Ras/
MAPK-dependent pathways are unaffected [124]. Therefore under IR conditions causing 
metabolic alterations, endothelial dysfunction becomes a precipitating factor in the 
development of CVDs.
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5. GRKS IN THE CARDIOVASCULAR SYSTEM
G protein-coupled receptor kinases (GRKs) are emerging as important integrative 
nodes in many cellular processes. They regulate numerous GPCRs by phosphorylating 
the intracellular domain of the active receptor, leading to the recruitment of the 
multifunctional adaptor proteins, arrestins, to the receptors leading to the attenuation 
of intracellular G protein-dependent signaling by desensitization and internalization of 
the receptor [125]. Moreover, emerging evidence suggests that GRK2, the most widely 
studied member of this family of kinases, modulates multiple cellular responses in 
various physiological contexts by either phosphorylating non-receptor substrates or by 
directly interacting with signaling molecules [126] including components of the insulin 
signaling pathway (article #2). 
In particular, GRK2 emerges as a signaling hub which display a very complex 
interactome, whose expression and function is tightly regulated and with changes in 
its levels or functionality highly related to the onset or development of CVDs and/or its 
comorbidities [126-129]. 
Figure 7: Insulin signaling in the cardiovascular system. General features of insulin signal transduction 
pathways are represented. The PI3K branch of insulin signaling regulates glucose metabolism and protein synthesis 
while stimulating NO production and vasodilation in vascular endothelium. The MAPK branch of insulin-signaling 
pathways generally regulates growth and mitogenesis and controls secretion of endothelin (ET-1) in vascular 
endothelium. The IRS1/PI3K/Akt axis, responsible for the metabolic and cardiovascular protection pathways, is 
impaired under IR conditions leading to cardiac hypertrophy, oxidative stress, apoptosis, cardiac remodeling and 
alterations in contractility, altogether contributing to endothelial and myocardial injury and dysfunction.
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5.1. THE G PROTEIN-COUPLED RECEPTOR KINASE (GRK) FAMILIY
GRKs are a family of serine-threonine kinases composed of seven members (GRK1-
7) that share a global homology of 60-70% and are grouped in three subfamilies: GRK1 
(rhodopsin kinase) and GRK7 (cone opsin kinase) are the so called visual GRKs and are 
present in the retina, the β-Adrenergic receptor kinase family (β-ARK) that comprise 
GRK2 (β-ARK 1) and GRK3 (β-ARK 2) which are ubiquitous, and a third subfamily, which 
includes GRK4 -present in testis, cerebellum and kidney- and GRK5 and 6 which are 
ubiquitous as well [89].
GRKs share structural and functional similarities: a well-conserved central catalytic 
domain is ϐlanked by N-terminal domain, that, except for visual GRKs, includes a region 
of homology to regulators of G-protein signaling (RH) with weak homology among the 
members of the different subfamilies and that in the case of GRK2 and GRK3 has been 
shown to allow the interaction with Gα
q/11
 proteins [130], and C-terminal domain of 
variable length, which have little or no sequence homology between the different GRKs. 
It is more variable in extension and function and determines the localization of these 
proteins at the plasma membrane [131, 132]. A pleckstrin homology domain (PH) in 
GRK2 and GRK3 mediates their agonist-induced translocation from the cytosol to the 
plasma membrane through interactions with phospholipids (PIP
2
) and with Gβγ subunits 
at the membrane surface [133, 134]. On the contrary, GRK5 is predominantly associated 
to cellular membranes by means of basic sequences at the N-and C-terminus of the 
protein. GRK1, 4, 6 and 7 are constitutively anchored to the plasma membrane, visual 
GRKs through short C-terminal prenylation sequences and GRK4 and GRK6 through 
palmitoylation sites [135].
Activation of GRKs is achieved by direct interaction with Gβγ subunits [134] and 
also through docking to active GPCRs in a process involving allosteric interactions with 
receptor domains and membrane lipids which promote intracellular rearrangements and 
lead to increased enzymatic activity  [135].
5.2. GRKs IN CVD 
GRK2, 3 and 5 are important modulators of the CVS functionality. They are expressed 
ubiquitously but most highly in myocardial and endothelial cells [136, 137]. However 
only GRK2, 5 and 6 are detected in rat mesenteric smooth muscle cells [138]. 
The two more widely studied GRKs, as far as their impact on CVD is concerned, 
are GRK2 and GRK5. It has been recently reported that both are required for heart 
development in zebra ϐish with overlapping and opposing functions regulating different 
morphological outcomes [139]. Interestingly, increased expression and activity of any of 
them is associated with human and experimental models of CVD such as ischemic [140] 
or idiopathic dilated cardiomyopathy [137], cardiac ischemia [141], hypertension [142, 
143](article #1), LVH [144] and HF [145-148]. Intriguingly, as members of different GRK 
subfamilies, they have different structural and functional characteristics, subcellular 
localization, and kinase activity regulation [149-151].
Introduction
61
GRK2 is predominantly cytoplasmic and is targeted to the membrane upon agonist 
stimulation by interacting with free Gβγ dimers which recruit GRK2 to the agonist-
bound GPCR, culminating in the phosphorylation of the receptor [134]. A mitochondrial 
localization for a small population of GRK2 has also been reported [151, 152] as well as 
an association of GRK2 to microsomal endomembranes [153]. In contrast, GRK5 lacks the 
PH domain, is not modulated by Gβγ, and consequently does not undergo agonist-induced 
membrane translocation. Instead, the carboxyl terminus of GRK5 contains a PIP
2
-binding 
domain and basic amino acids which interact with plasma membrane phospholipids, 
constitutively localizing GRK5 to cell membranes. A nuclear localization for GRK5 has 
also been reported [149] [144, 154]. This particular feature, together with divergent 
receptor speciϐicity, seems to be directly relevant to GRK5-mediated regulation of gene 
transcription through its role as a histone deacetylase kinase under hypertrophic stimuli 
what is critical for its contribution to CVD [144]. Indeed, although they share certain 
characteristics, GRK2 and GRK5 are non-redundant enzymes with speciϐic functional and 
regulatory properties. For example, GRKs 2 and 5 attenuate cardiac contractile responses 
to β-AR stimulation, but only GRK2 affects Ang II receptor-mediated contraction [155, 
156]. Besides, phosphorylation of the Ang II receptor by GRK2 modulates β-arrestin-
mediated GPCR internalization, whereas phosphorylation by GRK5 regulates β-arrestin-
dependent signalling to MAPK [157]. There are 4 polymorphisms described for human 
GRK5, one of which substitutes the amino acid leucine for glutamine at position 41 
(in close proximity to a regulatory domain at the N-terminus) and leads to enhanced 
desensitization of β
2
-AR upon agonist treatment [158], but no relevant mutations or SNPs 
have been described so far for GRK2 in humans. This fact, together with the embryonic 
lethality of the GRK2 knockout (GRK2 KO) mice, may reϐlect its overall importance in 
physiology.
In sum, GRKs expressed in the CVS are not functionally redundant, but rather serve 
distinct physiological purposes that coincide with their unique structural and substrate 
properties.
5.3. GRK2 AS A SIGNALING NODE IN CVD
5.3.1. Importance of GRK2 in the CVS
Gene ablation of GRK2 is embryonic lethal by day 10.5 [159]. A number of cardiac 
abnormalities have been described in GRK2 knockout embryos, including myocardial 
hypoplasia, chamber dilation, and diminished ventricular contraction as assessed by 
intravital echocardiography [159, 160]. However, because the heart is the ϐirst organ to 
form in the developing embryo, cardiac abnormalities are common even in embryonic 
lethal mouse models that do not have a primary cardiac defect [161]. In fact cardiac-
speciϐic GRK2 KO or GRK2 hemizygous mice developed normally and exhibited no 
adult cardiac phenotype at baseline other than modestly enhanced contractile function 
[160] what demonstrated that GRK2 has a broader extra-cardiac role in embryogenesis. 
Consistently, GRK2 KO mice have marked vascular malformations involving impaired 
recruitment of mural cells [162]. Also, GRK2 regulates cell cycle in different ways [163, 
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164] and Smoothened-dependent proliferation and patterning during embryonic 
development [126, 165]. Altogether, these evidences lead to the conclusion that GRK2 
is a relevant signaling hub able to regulate several important cellular processes during 
embryogenesis.
The overall importance of GRK2 to the CVS has been demonstrated through 
several studies with genetically engineered mice. The global loss of GRK2 (GRK2-/-) by 
homologous recombination leads to embryonic lethality with cardiac malformations 
and dysplasia [159], however the conditional cardiac speciϐic GRK2 KO mice developed 
normally [160]. On the other hand, in a conditional cardiac GRK2 ablation mouse model 
in which cardiac myocyte GRK2 expression was normal during embryonic development, 
but was ablated after birth (αMHC-Cre × GRK2ϐl/ϐl), improved function and prevention 
of HF development was observed after MI. Moreover, when the downregulation of GRK2 
is induced in the cardiomyocytes after HF development by tamoxifen administration 
(αMHC-MerCreMer×GRK2ϐl/ϐl), there is an active reverse remodeling and improved 
cardiac function [166]. On the contrary, cardiac-speciϐic GRK2 overexpressing mice 
display a loss of β-AR-mediated inotropic reserve, as well as desensitized Ang II receptors 
(AT1R) in their hearts [155].
To study the contribution of GRK2 to different cellular processes of CVD, animal 
models that overexpress a carboxy-terminal peptide of GRK2 (termed βARKct since GRK2 
was previously called β-adrenergic receptor kinase) have been extensively used. βARKct 
overexpression seems to act by inhibiting endogenous GRK2 activation by competing 
with Gβγ binding. Transgenic βARKct mice have increased function at baseline and in 
response to the β-AR agonist isoproterenol [155], but this improved performance causes 
no myocardial damage. In fact overexpression of βARKct rescued several mouse models 
of HF such as after LV pressure overload induced by TAC (transverse aortic constriction) 
[167] or after acute myocardial ischemia/reperfusion injury [168]. Furthermore the cross 
breeding of βARKct mice with different animal models of chronic HF induced by genetic 
manipulation also rescued overt cardiac failure in these animals [146, 147].  
Other important animal model for the study of the role of GRK2 in the CVS is that 
for endothelial cell-speciϐic GRK2-downregulation using a Tie-2-Cre (Tie2Cre-GRK2ϐl/
ϐl), which resulted in abnormalities and changes in vasculogenesis since GRK2 is deleted 
prenatally in this murine model [162].
Despite the variety of animal models used to study the role of GRK2 in CVS, we have 
chosen hemizygous GRK2 mice (GRK2+/-) for our work. Heterozygous GRK2 knockout 
mice with circa 50% less GRK2 in all tissues show increased cardiac function and 
responses to adrenergic input [146], present increased energy expenditure due to a more 
functional BAT tissue [169] and are also more sensitive to insulin and resistant to age, 
TNF-α or HFD-induced IR, obesity and adiposity [170]. This model represents, in our 
view, the best model to study the consequences that an overall decrease in GRK2, such as 
the one that could be obtained upon treatment with a yet to be identiϐied selective GRK2 
inhibitor, can have specially in cardiovascular perturbations derived from metabolic 
alterations (see below).
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5.3.2. Regula? on of GRK2 func? on in the CVS
5.3.2.a) Control of GRK2 func? on
While, quantitatively, the most important activators of GRK2 are GPCR intracellular 
domains and free Gβγ subunits [171], several proteins important for cardiac 
physiopathology are also able to associate with GRK2 and appear to control GRK2 activity 
and determine the complex subcellular distribution of the kinase such as α-actinin [172], 
clathrin [173], calmodulin [174, 175], caveolin [130] or RKIP [176]. 
Phosphorylation of GRK2 is also emerging as a key mechanism to dynamically 
modulate its interaction with cellular partners. GRK2 can be phosphorylated by different 
kinases to either enhance -PKA [177], PKC [178, 179] and Src [180]- or decrease -ERK 
[181]- membrane targeting and/or the catalytic activity of GRK2 thus opening the 
possibility of transmodulation by different signaling pathways. 
GRK2 can also be S-nitrosylated by NO, which resulted in the inhibition of GRK2 
activity on β-AR signaling and other downstream targets [182].
5.3.2.b) Control of GRK2 levels
Regarding the regulation of GRK2 expression, increased levels of GRK2 could be 
promoted by an increase in mRNA levels, thereby suggesting that transcriptional 
control mechanisms are taking place, or by an imbalance between transcriptional and 
posttranscriptional mechanisms (protein stability) that can lead to increased GRK2 
protein expression. 
In aortic smooth muscle cells, the agents that induce physiological vasoconstriction 
and hypertrophy markedly enhance GRK2 promoter activity, whereas pro-inϐlammatory 
cytokines promote the opposite effect, suggesting that the expression of GRK2 is 
strongly controlled at the transcriptional level by the interplay between various signal 
transduction pathways [183]. TGF-β also induces GRK2 expression in VSMCs [184]. 
However, whether these mechanisms apply to other cell types such as cardiomyocytes in 
the CVS awaits further investigation. Nevertheless, in the myocardium, long-term in vivo 
stimulation of β-ARs results in the impairment of cardiac β-AR signaling and increases 
the level of expression (mRNA and protein) and activity of GRK2 but not those of GRK5 
[185]. 
Moreover, regulation of GRK2 stability may provide an important mechanism for 
modulation of its expression levels. Our group has reported that GRK2 is rapidly degraded 
by the proteasome pathway, and that GRK2 ubiquitination and turnover is enhanced by 
β
2
-AR activation as a result of phosphorylation of GRK2 by c-Src and MAPK in a β-arrestin-
dependent manner [186, 187]. Besides, Mdm2, an E3-ubiquitin ligase involved in the 
control of cell growth and apoptosis, that promotes survival and attenuates hypertrophy 
of cardiac myocytes [188], plays a key role in GRK2 degradation. Mdm2 and GRK2 
association and subsequent proteolysis are facilitated by the β-arrestin scaffold function 
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upon β
2
-adrenergic receptor stimulation. The Mdm2 action on GRK2 is dependent on the 
previous phosphorylation of GRK2 at Ser670 by MAPKs, while tyrosine phosphorylation 
was dispensable [189]. On the contrary, activation of the PI3K/Akt pathway by agonists 
such as IGF-1 alters Mdm2 phosphorylation and triggers its nuclear localization thus 
hampering Mdm2-mediated GRK2 degradation and leading to enhanced GRK2 stability 
and increased kinase levels in epithelial cells [190]. 
The presence of β-agonists has been reported to up-regulate GRK2 mRNA, whereas 
ischemia might promote GRK2 degradation by the proteasome in some experimental 
models [191-193]. However, there is limited knowledge of the mechanisms modulating 
GRK2 expression in cardiovascular cells in pathological settings such as during metabolic 
syndrome.
5.3.3. Non-Canonical role: GRK2 beyond GPCR desensi? za? on 
In addition to its canonical GPCR kinase activity, emerging data suggest that GRK2 may 
have other functions by building an extensive network of interactions with a variety of 
signal transduction partners, in a stimulus, cell type, or context-speciϐic way. For example, 
GRK2 has been reported to functionally interact with p38 [194], MEK [195], Epac [196], 
IκBα [197], Cdk2, Pin1 [164], caveolin [198] and HDAC6 [199] in several tissues, although 
we will focus here on the GRK2 interactome in a cardiovascular context.
During conditions of oxidative stress, ERK is activated and phosphorylates GRK2 at 
Ser670, facilitates the binding to Hsp90, which results in the translocation of GRK2 to the 
mitochondria and the decrease in mitochondrial Ca2+ uptake capacity which could play a 
role in the suggested pro-death effects of GRK2 [152]. 
Additionally, GRK2 is a microtubule-associated kinase that directly phosphorylates 
tubulin following β-AR stimulation [200] therefore GRK2 levels can affect agonist-induced 
internalization by a mechanism involving microtubule stability [201] Furthermore, 
GRK2 phosphorylation of tubulin facilitates its polymerization into microtubules, and 
an increased ratio of microtubules to tubulin in the heart has been reported to be pro-
hypertrophic [202].
GRK2 could also bind to and phosphorylate Smad2/3, which could have a signiϐicant 
impact on TGFβ-mediated ϐibrosis and remodeling post MI [203]. GRK2 expression 
levels are up-regulated upon TGFβ stimulation in hepatic cells, initiating a negative 
feedback loop which results in the phosphorylation of Smad and impaired activation and 
translocation of this protein to the nucleus. Moreover, it has been reported that the TGFβ-
mediated increase in GRK2 levels antagonizes Ang II-induced VSMC proliferation and 
migration, thus, GRK2 potentially mediates the crosstalk between both signaling cascades 
[184].
GRK2 can also interact directly with Akt in liver endothelial cells, reducing eNOS 
phosphorylation and NO production thus contributing to portal hypertension [204]. 
On the other hand, it was very recently described that GRK2 coprecipitates with eNOS 
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in mouse hearts and that ischemia and oxidative stress increases this interaction 
[205]. Interestingly, GRK2 and eNOS negatively regulate one another: eNOS promotes 
S-nitrosylation of GRK2 and GRK2 inhibits eNOS activation by an as yet unknown 
mechanism [205].
Finally, our group and others have contributed to the knowledge of GRK2´s role as 
modulator of insulin signaling by its interaction with IRS1. This is analyzed in detail in 
the article #2 of the compended articles of this thesis which is entitled “G protein-coupled 
receptor kinase 2 (GRK2): A novel modulator of insulin resistance.” 
The role of GRK2 in the modulation not only of GPCRs but also of insulin signaling 
highlights the importance of GRK2 as a transversal target able to prevent the development 
of not one but several of the most important of the CV risk factors which coexistence 
result in maladaptation and lead to overt CVD.
6. CHOOSING THE APPROPRIATE MODEL OF STUDY
The physiological scenario that regulates CVS is complex and difϐicult to mimic in 
its extension in a closed system as an in vitro model. In vivo models are the only ones 
that allow to study changes in molecular signaling and tissue structure in association 
with organ function, and to model the effect of either physiological inputs or of stresses 
relevant to human disease on the CVS. For this reason, the most suitable way to study the 
mechanisms of adaptation of the CVS to different pathological outputs is to use animal 
models.
It is a challenge to directly compare the ϐindings reported for human patients with 
those derived from animal studies. For example, cardiac physiology such as heart rate is 
different in rodents and humans but, although the murine heart is far smaller than the 
human, the heart to body weight ratio is similar in both species, as is the relative thickness 
of the right and left ventricular walls [206]. On the other hand rodent models are less 
likely to develop atherosclerotic disease in coronary arteries and spontaneous ischemia, 
which exists in many human patients with T2DM. Important differences also exist in 
the hormonal milieu and the concentration of lipids [31]. Regarding the vasculature, 
humans and mice share many features from the anatomical and histological point of view. 
However, they have important differences including the location of coronary arteries 
and the thickness of the walls of mouse arteries, much thinner compared to their human 
counterparts [206].
Nevertheless, animal models provide the opportunity to conduct mechanistic studies 
and allow for “proof of concept” experiments that are often impossible to perform in 
humans. Besides, end-organ effects of obesity that require a long-term treatment to 
become evident are much easier to study and observe in small rodents with a life span 
of 1-2 years that in other animal models more related to humans with a much longer life 
span. 
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Another important question to address is the experimental tools selected to modulate 
the levels or activity of the protein of study. Essentially there are two options: the use 
of a chronic or acute pharmacological stimulator or inhibitor, or, alternatively, utilize a 
genetically-engineered animal model.
Regarding pharmacological inhibitors of GRK2, much research effort has been 
dedicated to identify a selective compound that could inhibit GRK2 with enough potency 
and efϐicacy. Although there are several recent promising results, the drugs obtained so 
far are not selective for GRK2 [207-210]; have poor potency [211]; or have non drug-like 
properties like polyanions [212]. Takeda Pharmaceuticals, Inc. have developed potent 
inhibitors apparently selective for the GRK2/3 subfamily that bind the active site of the 
enzyme [213] but these have not advanced to pre- or clinical trials. Some authors use 
a commercial chemical compound (methyl[(5-nitro-2-furyl)vinyl]-2-furoate) in their 
studies but it its selectivity and efϐicacy towards the GRK2 isoform has not been tested 
solidly in vivo and thus off-target effects over other GRK isoforms or kinases cannot be 
discarded [214-220].
Taken all this into account, in this thesis we have used GRK2 hemizygous mice to study 
the effect that an overall decrease of GRK2 could have in the CVS pathophysiology. We 
chose to utilize male and middle-aged adult mice (9-10 months old) in order to minimize 
hormonal inϐluence and to imitate the conditions in which CV events are ϐirst detected 
in the human setting, respectively (see below). To mimic primary hypertension we have 
used Ang II infusion during 7 days by osmotic minipumps and 12 weeks or 33 weeks of 
HFD feeding in order to promote diet-induced insulin resistance or obesity, respectively. 
Noteworthy, to test acute insulin sensitivity in the heart we have performed intravenous 
injections of insulin through the tail vein because this delivery route directly reaches the 
heart and more precisely mimics the effects of an internal burst in insulin levels produced 
by pancreatic cells although it is technically more difϐicult than other techniques such as 
intraperitoneal injection that are also more widely used. This administration route is also 
the most appropriate to detect the differences in insulin signaling in the very fast and 
acute phase of insulin signaling (ϐirst ϐive minutes after injection). 
6.1. GRK2+/- mice
The most suitable way to study the effects of a putative selective inhibitor of GRK2 
at this moment is to use genetically-modiϐied animal models. In this particular case we 
needed an animal model that could mimic the effects of a putative pharmacological GRK2 
inhibitor that would systemically down-modulate the action of GRK2, but avoiding its 
complete abrogation, therefore we used the hemizygous GRK2+/- mice. We hypothesized 
that decreasing GRK2 levels would be beneϐicial to avoid the development of pathological 
CVS remodeling and dysfunction as has been shown to occur using transgenic βARKct 
mice and tissue-speciϐic GRK2 knock outs under other pathological situations.
In the GRK2 hemizygous mice, in contrast to what happens in βARKct mice, we 
are studying not only the activity of GRK2 as a kinase but also its role as a scaffolding 
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protein. Also, as opposed to tissue-speciϐic GRK2 knockout mice, in GRK2+/- animals the 
consequences of a GRK2 downregulation in other organs and tissues that directly affect 
CVD can be taken into account, so we consider it is nowadays the most suitable model to 
evaluate the importance of GRK2 as a therapeutic target.
6.2. Adult 9/10 month-old mice
The age of the animals is also another crucial step in the process of designing the 
best experimental system, particularly to try to more precisely mimic the onset of the 
MetS and of CVD in humans. Although the incidence of these pathological events is 
signiϐicantly higher in the adult-elderly population relative to young individuals, most of 
the preclinical studies are usually performed in very young animals (2-3 months old) that 
do not reproduce the physiological environment and conditions present in older animals, 
much less in adult or elderly human patients. We have used, even when more cost- and 
effort-demanding, 9 month-old mice in order to study the effects of decreasing GRK2 
levels when CV events are ϐirst detected in humans, that is in adulthood. In fact, 9 month-
old C57BL/6 wild-type mice exhibit a prediabetic state with signiϐicantly higher levels of 
blood glucose and insulin at baseline compared with 3 month-old mice [170], what more 
precisely resembles the clinical setting of age-derived MetS in human patients. 
6.3. Ang II infusion-induced hypertension
To study the role of GRK2 in hypertension we have use an Angiotensin II chronic 
infusion model by means of mini osmotic pump intradermal implantation for seven 
days. Overactivation of RAS contributes to human hypertension in a majority of patients, 
therefore, the use of Ang II infusion to induce the experimental model is a well established 
approach resembling the human clinical setting. Apart from chronic Ang II infusion, 
there are other ways to induced RAS overactivation but they include invasive surgery 
(renovascular and neurogenic hypertension models), or take too much time to develop 
(dietary-induced hypertension) [221]. While this model is probably the most widely used 
pharmacological murine model for human hypertension, it remains different from the 
human setting since RAS overactivation frequently coexist in human patients with other 
environmental and genetic factors that help develop the hypertensive condition.
6.4. HFD-induced insulin resistance and obesity
To study the effect of GRK2 down-modulation in obese individuals we have chosen to 
use a diet-induced obesity model in which the animals are fed a high fat diet (30% of crude 
fat by weight which provides 51-54% of the total calories). This experimental design tries 
to mimic the human lifestyle in developed and in even some underdeveloped countries of 
the 21st century, where the obesity is mainly caused by an excess intake of calories from 
fat, whilst genetic models deϐicient in the leptin receptor (db/db) or leptin synthesis 
(ob/ob) are not fully representative of the varied and complex human pathophysiology 
of obesity. However, stricto sensu, diet-induced obesity cannot be strictly categorized 
as an animal model of metabolic syndrome because dieting an animal with high fat 
diet rarely causes the complete clinical picture that comprises the cardiovascular and 
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metabolic disease in humans. For example, in some cases, obesity-induced hypertension 
is achieved [222, 223], but this is not commonplace, and most research papers do not 
report an increase in blood pressure values after HFD feeding. There are several factors 
that could be implicated in these differences between different experimental approaches 
as the mouse genetic background, the diet and its percentage of fat, the gender, exercise 
vs sedentarism, and so on.
In sum, we have evaluated the efϐiciency of GRK2 as a therapeutic target against 
the development of hypertension and IR since this kinase has been identiϐied as a key 
modulator of GPCR-dependent or independent pathways such as Ang II or insulin 
signaling pathways, related to the different characteristics of the CVD. The experimental 
work presented in this thesis unveils GRK2 as an integrative sensor that increases its levels 
upon several pathological inputs thus helping fuel metabolic and cellular vicious cycles 
with deleterious effects on the CVDC. Therefore, targeting GRK2 levels or activity could 
represent a feasible therapeutic strategy for the treatment or prevention of hypertension 
and insulin resistance under different conditions, able to stop the inexorable progression 
along the CVDC.
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Objectives
GRK2 is emerging as a signaling hub which displays a very complex interactome and 
key roles in the regulation of both GPCR-dependent responses, such as those triggered 
by catecholamines or angiotensin, or in the insulin-modulated intracellular cascade. 
Moreover, increased GRK2 levels or functionality appear to be highly related to the 
onset or development of several cardiovascular diseases (CVD) and/or its comorbidities. 
Conversely, several studies have suggested a cardioprotective role of genetic GRK2 
downmodulation or inhibition. However, the molecular mechanisms underlying both 
the deleterious and beneϐicial effects of such changes in GRK2 levels in cardiovascular 
function are not fully understood.
In order to shed new light on such mechanisms, the general objective of this work 
is to investigate the impact of altering GRK2 levels on key signaling pathways and 
phenotypic features under relevant CVD pathological contexts such as hypertension, age 
and high fat diet-induced obesity and insulin resistance. For this purpose, we have used 
as an experimental setting adult hemizygous GRK2 (GRK2+/-) mice, an animal model 
that would better mimic the conditions in which CV events are ϐirst detected in humans.
Specifi c objec? ves:
1. Analyze the impact of altered GRK2 genetic dosage on vascular responses, 
vascular structure and on the induction of a primary hypertension phenotype triggered 
by Angiotensin-II infusion in adult mice, and the molecular mechanisms involved. 
2. Explore the interconnections among GRK2 dosage, cardiac insulin sensitivity, 
cardiac gene expression patterns and heart physiopathology in adult mice or animals fed 
with high-fat diet, two conditions known to promote insulin resistance. 
3. Analyze the impact of altered GRK2 genetic dosage on the cardiac remodeling 
associated to obesity promoted by long-term high fat diet feeding in adult animals. 
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Article #1
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INTRODUCTION TO ARTICLE #1
The ϐirst article presented is entitled Increased Nitric Oxide Bioavailability in 
Adult GRK2 Hemizygous Mice Protects Against Angiotensin II -Induced Hypertension 
(Hypertension. 2014; 63(2):369-75).
In order to investigate the impact of altering GRK2 levels on key signaling pathways 
related to vascular function and on the phenotypic features characteristic of hypertension, 
we set a collaborative project between our group and that of Prof. Mercedes Salaíces 
(Pharmacology Department, Faculty of Medicine, UAM), a renowned expert in the ϐield. 
This was the ϐirst study aimed to characterize the effect of a systemic reduction in GRK2 
levels on vascular structure and biomechanics, both in basal and in AngII-treated adult 
mice.
The responses of conductance and resistance arteries to different stimuli were 
investigated in adult 9 month-old mice of two different genotypes (WT and GRK2+/-) 
that differ in the systemic dosage of GRK2. The initial results pointing  to an increased 
bioavailability of NO in GRK2 hemizygous mice, led us to analyze the phenotypic and 
biochemical features of these animals upon induction of primary hypertension by chronic 
Ang II infusion through miniosmotic pumps. We observed that lower levels of GRK2 
are related to a preserved activation of the eNOS/Akt axis after a Ang II challenge, thus 
favoring an increased NO bioavailability, in turn leading  to protection against the vascular 
remodeling and severe hypertension developed in wild-type mice.
My main contribution to this article (in which I am shared ϐirst co-author) was 
centered in the detailed molecular characterization of the signaling pathways and protein 
and RNA expression markers in the aortic vessels both in basal and Ang II-infused 
conditions. I also participated in the surgical implantation of the osmotic pump and in the 
follow-up of blood pressure evolution and heart rate measurements. 
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Different receptors and signaling molecules are involved in the development of hypertension by hyper-contracting 
or hypo-dilating blood vessels in a deleterious manner and by 
affecting the structure and mechanical properties of vessels. 
Among them, the G protein–coupled receptor (GPCR) fam-
ily is of outmost importance. Adrenergic receptors and other 
GPCRs, such as angiotensin II (AngII), endothelin-1 (ET-
1), dopamine, and vasopressin receptors, are key for vascu-
lar physiopathology.1 AngII is a master regulator of vascular 
tone, and many animal models of hypertension are based on 
the chronic elevation of AngII levels.
GPCRs become inactivated to different extents when ago-
nist signals are persistent in time, a process termed desen-
sitization. This process is regulated by G protein–coupled 
receptor kinases (GRKs), a family of serine/threonine 
kinases able to phosphorylate intracellular domains of the 
receptors and initiate their uncoupling from the G protein, 
and thus signal termination.2 Among the 7 GRK isoforms, 
GRK2 is the most abundant in vessels together with GRK5 
and plays a determinant role in the control of systemic vas-
cular responses.3,4 The levels and activity of the GRK2 iso-
form are increased in animal models of hypertension and 
in lymphocytes from young patients with hypertension.5 In 
addition, GRK2 mRNA levels, but not those of GRK3 or 
GRK5, increase in correlation with systolic blood pressure 
in humans.6 GRK2 downregulates the in vivo effects of key 
vasoconstrictor receptors, such as ET7 and AngII8 receptors 
and α1D adrenoceptors.9 Therefore, the increase in vascu-
lar GRK2 could have represented a protective mechanism 
for adaptation against a hypertensive phenotype. However, 
transgenic mice overexpressing GRK2 in the vascular 
smooth muscle cells (VSMC) show increased resting blood 
pressure.8 Moreover, elevated GRK2 levels impair vasodila-
tor β adrenoceptors responses in different tissues and animal 
Abstract—G protein–coupled receptor kinase 2 (GRK2) is a ubiquitous serine/threonine protein kinase able to phosphorylate 
and desensitize the active form of several G protein–coupled receptors. Given the lack of selective inhibitors for 
GRK2, we investigated the effects elicited by GRK2 inhibition in vascular responses using global adult hemizygous 
mice (GRK2+/−). The vasodilator responses to acetylcholine or isoproterenol were increased in aortas and mesenteric 
resistance arteries from GRK2+/− mice compared with wild-type (WT) littermates. After angiotensin II (AngII) infusion, 
GRK2+/− mice were partially protected against hypertension, vascular remodeling, and mechanical alterations, even 
when resting basal blood pressures were not significantly different. AngII infusion also (1) increased GRK2 levels in 
WT but not in GRK2+/− vessels; (2) increased vasoconstrictor responses to phenylephrine in WT but not in GRK2+/− 
mice; and (3) decreased vasodilator responses to acetylcholine and vascular pAkt and eNOS levels more in WT than in 
GRK2+/− animals. Vascular NO production and the modulation of vasoconstrictor responses by endothelial-derived NO 
remained enhanced in GRK2+/− mice infused with AngII. Thus, GRK2+/− mice are resistant to the development of vascular 
remodeling and mechanical alterations, endothelial dysfunction, increased vasoconstrictor responses, and hypertension 
induced by AngII at least partially through the preservation of NO bioavailability. In conclusion, our results describe an 
important role for GRK2 in systemic hypertension and further establish that an inhibition of GRK2 could be a beneficial 
treatment for this condition.  (Hypertension. 2014;63:369-375.) • Online Data Supplement
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models and, interestingly, in human patients treated with 
β-blockers GRK2 levels return to baseline.4,10
Classically, the preferential desensitization by GRK2 of 
vasodilator receptor subtypes versus vasoconstrictor ones has 
been invoked to explain the effect of upregulated GRK2 lev-
els in human and in murine hypertension.8 However, novel 
results implicating GRK2 in non–GPCR-dependent pathways 
prompt to redefine the role of GRK2 in the regulation of vas-
cular tone. One such example is the described interaction of 
GRK2 with Akt that inhibits Akt-dependent activation of NO 
synthase, thus impairing NO production.11 Another important 
emerging question is the relative importance of endothelial 
GRK2 as compared with VSMC-GRK2 because depletion of 
GRK2 in VSMC is unable to prevent portal hypertension.9 
Our work tries to shed some light on these issues describ-
ing for the first time that a global reduction in GRK2 causes 
resistance to the development of systemic hypertension in 
adult mice. This antihypertensive effect of GRK2 downregu-
lation prevails even when responses to both vasodilator and 
vasoconstrictor receptors are enhanced and this is because of 
the increased NO bioavailability detected in GRK2+/− mice. 
Although extensive research has been performed on the 
effects of GRK2 overexpression or deletion in cardiac phe-
notypes, few studies have addressed how systemic changes in 
GRK2 levels can affect vascular function and to our knowl-
edge, this is the first report to address the effect of GRK2 in 
vascular structure and biomechanics.
Methods
The Materials and Methods are described in the online-only Data 
Supplement.
Results
GRK2 Deficiency Increases Vasoconstrictor 
Responses Without Influencing Receptor Levels
Partial deficiency of GRK2 increased vasoconstrictor 
responses to phenylephrine in aortas from male (Figure 1A; 
Table S1 in the online-only Data Supplement) and female 
(Figure S1A; Table S1) mice. ET-1 (0.1 μmol/L)–mediated 
vasoconstrictor responses were also increased in aorta from 
male GRK2+/− mice compared with WT littermates (Figure 
S2A; Table S1). After repeated exposure to ET-1, vasocon-
strictor responses were reduced in WT and GRK2+/− mice 
(Figure S2A). However, contractile responses to the second 
and third ET-1 administration remained larger in GRK2+/− 
compared with WT mice (Figure S2A), suggesting that partial 
deficiency in GRK2 prevents, in part, ET-1–induced desensi-
tization. GRK2 deficiency did not modify AngII (1 μmol/L)–
induced vasoconstrictor responses (Figure S2B; Table S1) or 
changed the reduced vascular responses after repeated expo-
sure to AngII (Figure S2B).
GRK2+/− mice displayed decreased vascular GRK2 gene 
and protein expression (Figures S2C and S3), but no differ-
ences in protein or gene expression of AT1, AT2, ETA, ETB, 
or α1D receptors were observed between WT and GRK2+/− 
mice in aortas, and a reduction of only AT2 receptor protein 
was observed in mesenteric resistance arteries (MRA) from 
GRK2+/− mice (Figures S2C and S3).
GRK2 Deficiency in Adult Mice Increases 
Endothelium-Dependent Vasodilator Responses  
and NO Release
The endothelium-dependent vasodilator responses induced 
by acetylcholine (ACh) or isoproterenol were increased in 
aorta from male and female GRK2+/− mice compared with WT 
mice (Figures 1B and 1C; Figure S1B and S1C). Accordingly, 
ACh-induced NO production was increased in aortas from 
GRK2+/− animals (Figures 1D; Figure S1D). In contrast, the 
endothelium-independent vasodilator responses induced 
by the NO donor diethylamine (DEA)-NO were similar in 
GRK2+/− and WT mice (Figures 1E; Figure S1E), suggest-
ing that the observed differences are probably due to altered 
endothelium-mediated NO production. Similar results were 
observed in MRA from male and female mice (Figure S4A–
S4F). ACh-induced NO production was also larger in MRA 
from male GRK2+/− mice (Figure S4G).
GRK2 Deficiency Reduces the Development of 
Hypertension and Prevents Vascular Remodeling 
After AngII Infusion
AngII infusion increased GRK2 levels in WT but not in 
GRK2+/− aortas (Figure 2A). Basal systolic blood pressure 
Figure 1. Effects of partial G protein–coupled receptor kinase 
2 (GRK2) deficiency on vasoconstrictor and vasodilator 
responses and in NO production in aorta from male adult 
mice. Concentration–response curve to phenylephrine (Phe; 
A), acetylcholine (ACh; B), isoproterenol (C), and diethylamine 
NONOate (DEA-NO; E) and quantification of ACh-induced NO 
release (D) in aorta from male wild-type (WT) and GRK2+/− mice. 
n=5 to 10. **P<0.01.
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(Figure 2B) and heart rate (Figure S5) were similar in untreated 
WT and GRK2+/− mice. Systemic infusion of AngII increased 
systolic blood pressure more in WT than in GRK2+/− mice 
(Figure 2B), but heart rate increase was indistinguishable 
between both groups (Figure S5).
Lumen and vessel diameter, wall thickness, and wall/
lumen ratio of MRA were similar in untreated WT and 
GRK2+/− mice (Figure S6A–S6D), and vascular stiffness 
was also similar, as shown by the stress–strain relation-
ship (Figure 3C), β parameter (WT, 4.87±0.3; GRK2+/−, 
4.98±0.37; n=5–6; P>0.05), and incremental distensibility 
(Figure S6E). After AngII infusion, lumen and vessel diame-
ter were smaller in WT and similar or slightly larger, respec-
tively, in GRK2+/− mice (Figure S7A–S7D). Wall thickness 
increased in both groups after AngII infusion (Figure S7E and 
S7F), and wall/lumen ratio was larger after AngII infusion in 
WT mice (Figure 3A) but not in GRK2+/− mice (Figure 3B). 
As expected, AngII increased vessel stiffness (Figure 3C, 
β parameter: WT, 8.31±0.51; GRK2+/−, 6.34±0.35; n=5–7; 
P<0.05 versus control mice) and decreased distensibil-
ity (Figure S8) in MRA from both strains. However, these 
effects were less pronounced in GRK2+/− than in WT mice 
(Figure 3C; Figure S8; β parameter, P<0.05 GRK2+/− versus 
WT mice).
In aorta, lumen and vessel diameters were similar in WT 
and GRK2+/− mice irrespective of AngII infusion (data not 
shown). However, media thickness (Figure 3D) and media/
lumen ratio (Figure 3E) increased after AngII only in WT and 
not in GRK2+/− mice, suggesting that partial deletion of GRK2 
protects against AngII-induced vascular remodeling.
GRK2 Deficiency Improves Vascular Function and 
NO Signaling After AngII Infusion
AngII treatment increased vasoconstrictor responses to 
phenylephrine in WT mice, as described,12 but not in 
GRK2+/− mice (Figure 4A and 4B). Because AngII infusion 
decreases NO availability in aorta,12 the lack of effect of 
AngII on phenylephrine responses in GRK2+/− arteries might 
be related to a lesser decrease in NO. As shown in Figure 4C 
and 4D, the NOS inhibitor N-nitro-l-arginine methyl ester 
(l-NAME; 100 µmol/L) enhanced phenylephrine contrac-
tion in GRK2+/− aortas more than in WT vessels after AngII 
(dAUC WT, 59±7; GRK2+/−, 237±31; P<0.05), suggesting 
that NO bioavailability after AngII was better preserved in 
GRK2+/− aortas. Interestingly, endothelium removal also 
increased phenylephrine contraction more in aorta from 
AngII-infused GRK2+/− than WT mice (Figure S9; dAUC 
WT, 149±17; GRK2+/−, 242±29; P<0.05), suggesting that 
in GRK2+/− mice there is an important contribution of the 
endothelium-derived vasodilator mediators, probably NO, 
on vascular contractile responses.
The endothelium-dependent vasodilator responses induced 
by ACh (Figure S10A and S10B) but not those triggered by 
the endothelium-independent vasodilator DEA-NO (Figure 
S10C and S10D) were reduced after AngII infusion. However, 
this deleterious effect of AngII infusion on endothelial func-
tion was less pronounced in GRK2+/− mice (% inhibition of 
maximal response induced by AngII; WT, 41.8±10; GRK2+/−, 
8.15±3; P<0.05). In agreement, aortic NO production induced 
by ACh (10 µmol/L) was greater in GRK2+/− than in WT mice 
infused with AngII (Figure 4E).
To determine whether the increase in NO bioavailability 
observed in aorta from GRK2+/− mice is a result of alterations 
of the eNOS-Akt pathway, we measured the activation of Akt 
(one of the most important upstream activators of eNOS) and 
eNOS levels. AngII infusion decreased Akt phosphorylation 
and eNOS protein expression in aortic homogenates from WT 
mice (Figure 4F and 4G). In contrast, we did not detect any sta-
tistically significant decrease in pAkt levels after AngII infu-
sion in GRK2+/− mice and the reduction on eNOS expression 
was lower than that observed in WT mice (Figure 4F and 4G).
Discussion
Vascular responses of adult GRK2+/− mice were character-
ized as a surrogate model of the effects exerted by a long-
awaited pharmacological GRK2 inhibitor. GRK2+/− mice 
show enhanced vasodilator and vasoconstrictor responses, 
with only particular differences toward certain contrac-
tile agonists. However, these mice are resistant to AngII-
induced systemic hypertension, vascular remodeling, and 
Figure 2. Partial G protein–coupled receptor kinase 2 (GRK2) 
deficiency reduces angiotensin II (AngII)–induced GRK2 
expression and hypertension. A, Densitometric analysis and 
representative blot of GRK2 protein expression in aortic 
segments from wild-type (WT) and GRK2+/− mice treated or not 
with AngII. Data were normalized to the values of control WT 
littermates. B, Effect of AngII infusion on systolic blood pressure 
(SBP) in WT and GRK2+/− mice. Data represent mean±SEM. n=5 
to 9. **P<0.01 vs untreated animals. ++P<0.01 vs WT either 
untreated (CONTROL) or treated with AngII.
 by guest on February 27, 2015http://hyper.ahajournals.org/Downloaded from 
372  Hypertension  February 2014
mechanical alterations. They better maintain endothelial 
function and display an attenuated AngII-induced decline 
in the Akt-eNOS route and in eNOS levels. These data fur-
ther build on previous results describing a role for GRK2 in 
the control of portal hypertension9,11 and in diabetes mel-
litus/obesity-triggered mild hypertensive conditions.13 This 
report is the first to characterize the role of an overall selec-
tive inhibition of GRK2 function in the development of sys-
temic hypertension and in the structure and biomechanics 
of the vessels.
Partial GRK2 deficiency is not enough to overcome the 
overt hypertensive phenotype completely achieved by chronic 
AngII infusion. However, results in diabetic and ob/ob mice13 
showed a full reversal of these types of mild hypertension by 
the use of a nonselective GRK2 inhibitor. This discrepancy 
might be explained by differences in the hypertensive mod-
els, the use of a wide spectrum GRK2 inhibitor as opposed to 
a reduction in of GRK2 levels in GRK2+/− mice, and by the 
lower blood pressure implicit to the diabetes mellitus/obesity 
study.13 Also, our mice have been aged until an adult stage (9 
months), a period more related to the human clinical setting 
of hypertension occurrence.
An apparent discrepancy exists between the fact that 
upregulation of GRK2 in mice models or hypertensive sub-
jects causes elevated blood pressure and results establish-
ing that increased GRK2 protein impairs vasoconstrictor 
signals.8 In fact, when GRK2 levels are decreased, desen-
sitization of certain GPCRs is impaired in vascular beds, 
but, in turn, GRK2 could be regulating vasodilator prefer-
entially over vasoconstrictor receptors.3 We observed that 
changes in vasoconstrictor responses induced by GRK2 defi-
ciency depend on the agonist studied, whereas vasodilator 
ones are always increased in both sexes and in both con-
ductance and resistance arteries. So, pathways alternative to 
Figure 3. Partial G protein–coupled 
receptor kinase 2 (GRK2) deficiency 
protects against angiotensin II 
(AngII)–induced vascular remodeling 
and stiffness. Wall/lumen ratio (A and 
B) and stress–strain relationship (C) 
in mesenteric resistance arteries from 
untreated and AngII-infused wild-type 
(WT) and GRK2+/− mice. Media thickness 
(D) and media/lumen ratio (E) in aorta 
from WT and GRK2+/− mice untreated 
or treated with AngII. Representative 
photographs of hematoxylin-eosin aortic 
sections are shown. Data represent 
mean±SEM. n=5 to 11. *P<0.05, **P<0.01 
vs untreated animals. +P<0.05 vs WT in 
the presence of AngII.
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GPCR-derived routes could be playing a role. For instance, 
GRK2 was described to interact with Akt, to impair eNOS 
activation, and to decrease NO bioavailability and GRK2 
silencing reducing renal portal hypertension by increasing 
the Akt-NOS route,11 and also a role for GRK2-mediated 
regulation of NOS in maintaining vascular responses,14 
and during diabetic- or obesity-triggered changes in blood 
pressure has been reported.13 Our results represent the first 
demonstration that NO bioavailability is key to explain 
the antihypertensive phenotype derived from GRK2 down-
regulation because NO production is increased basally in 
GRK2+/− aortas and mesenteric arteries, and adult GRK2+/− 
mice are capable of attenuating the AngII-induced drop in 
NO production much more efficiently than WT littermates. 
Accordingly, endothelium removal or l-NAME incubation 
enhanced phenylephrine contraction more in AngII-infused 
GRK2+/− than in WT aortas. Also, GRK2+/− mice are partially 
protected from AngII-induced vascular stiffness and remod-
eling, important determinants of high blood pressure,15 both 
in the resistance and in the conductance vasculature. Of note, 
an increase in GRK2 protein levels in hypertensive WT but 
not GRK2+/− vessels is observed. This could be ascribed to 
Figure 4. Partial G protein–coupled receptor kinase 2 (GRK2) deficiency protects against angiotensin II (AngII)–induced increased 
vasoconstriction by increasing endothelial-derived NO production. Effect of AngII infusion on the concentration–response curve to 
phenylephrine (Phe) in wild-type (WT) and GRK2+/− aortic segments (A and B). Effect of l-NAME (C and D) on the concentration–response 
curve to Phe in aortic segments from WT and GRK2+/− treated with AngII. E, Quantification of acetylcholine (ACh)-induced NO release in 
aortic segments from AngII-treated mice. Densitometric analysis and representative blots of phosphoAkt (pAKt) and Akt (F) and eNOS 
and GAPDH (G) in WT and GRK2+/− aortas from mice untreated or treated with AngII. Results are expressed as ratio of phosphoAkt to 
total Akt or between eNOS to GAPDH and normalized to values obtained for untreated WT mice. Data represent mean±SEM. n=4 to 13. 
*P<0.05, **P<0.01, ***P<0.001 vs the corresponding control. +P<0.05 vs WT infused with AngII.
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the lower hypertension detected in GRK2+/− animals and sup-
ports a pathological role of elevated vascular GRK2 levels in 
the hypertensive phenotype.
An increased basal blood pressure is found in mice over-
expressing GRK2 in VSMC,8 whereas mice deficient in 
muscular GRK2 show a lack of resistance to renal-induced 
hypertension.9 Thus, the restoration of vasodilation achieved 
by VSMC-GRK2 targeting may not be sufficient to over-
come the blunted relaxation responses elicited by endothe-
lial cells. Moreover, Cohn et al9 described no changes in 
vasoconstrictor AngII-induced vascular responses in endo-
thelial-deprived vessels or in AngII-induced acute increases 
in blood pressure in VSMC-GRK2–deficient mice. In con-
trast, our results using global GRK2+/− mice demonstrate 
that these animals are partially resistant to AngII-induced 
hypertension. Comparison of these results clearly estab-
lishes that to achieve a therapeutic effect, endothelial GRK2 
should be targeted, and that the control of NO bioavailabil-
ity by GRK2 is crucial. GRK2 directly binds and inhibits 
Akt,11 and we detect a maintenance of Akt activation after 
AngII treatment only in GRK2+/− mice, whereas WT ani-
mals efficiently inhibit this route. This preserved activation 
of Akt is also detected in other tissues in GRK2 hemizy-
gous mice during aging-induced, high fat diet–induced, or 
tumor necrosis factor α–induced insulin resistance.16 These 
changes cannot be tampered by changes in total Akt protein 
because, as opposed to other systems,13 we do not detect sig-
nificant changes in total Akt levels but rather an attenuation 
of the AngII-induced decline in total eNOS levels. Recently 
published studies have identified a novel role for GRK2 in 
mitochondria function and biogenesis. GRK2 removal from 
skeletal muscle cells reduces ATP production and impairs 
tolerance to ischemia.17 However, elevated mitochondrial 
GRK2 in cardiomyocytes increases cellular injury, thus 
identifying GRK2 as a prodeath kinase.18
In conclusion, a partial deficiency of GRK2 differen-
tially alters vasoconstrictor responses to different ago-
nists. Nevertheless, vasodilator responses seem to be 
homogeneously increased in GRK2+/− arteries what prob-
ably explains the lack of changes in basal blood pressure 
observed in GRK2+/− mice. In addition, vascular structure 
and mechanics are similar in both genotypes. However, 
after an AngII challenge, lower GRK2 levels help to main-
tain the activation of eNOS through the Akt pathway, thus 
leading to preserved NO bioavailability. In this situation, 
NO-dependent vasodilation overcomes constriction which, 
together with the lesser deterioration of vascular structure 
and mechanics, explains why GRK2+/− mice are resistant to 
hypertension (Figure S11) and further highlights GRK2 as a 
therapeutic target for hypertension.
Perspectives
Our results provide novel evidences suggesting that a global 
GRK2 decrease could become an efficient treatment for 
hypertension and further highlight the importance of target-
ing endothelial GRK2 for an effective control of this condi-
tion, thus establishing that GRK2 targeting needs to include 
the endothelial compartment if reversal of hypertension is to 
be achieved.
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What Is New?
•	Partial deficiency in G protein–coupled receptor kinase 2 (GRK2) affects 
vasoconstrictor responses and desensitization in a differential manner 
depending on the agonist studied without apparent changes in recep-
tor levels. However, endothelium-dependent vasodilator responses are 
homogeneously increased in adult GRK2+/− conductance and resistance 
arteries via an increased NO availability.
•	After AngII challenge, the lower GRK2 levels in adult GRK2+/− mice main-
tain the activation of eNOS by preserving phosphorylation of Akt. This 
better maintains NO bioavailability and protects vascular function in 
GRK2+/− mice. These facts, together with a less deteriorated vascular 
structure and mechanics after AngII challenge in GRK2+/− mice, might 
explain their resistance to the development of hypertension.
•	This is the first report to characterize the effect of a systemic reduction in 
GRK2 levels on vascular structure and biomechanics, both in basal and 
in AngII-treated adult mice.
What Is Relevant?
•	Our results provide new evidences for a novel therapeutic effect of low-
ering GRK2 levels/activity through the modulation of vascular function 
and NO bioavailability.
Summary
Partial deficiency of GRK2 differentially alters vasoconstrictor re-
sponses to different agonists, whereas vasodilator responses are 
homogeneously increased. After an AngII challenge, GRK2+/− mice 
maintain endothelial function, exhibit diminished vasoconstrictor 
responses, and display improved vascular structure and vessel 
stiffness compared with age-matched wild-type littermates. More-
over, GRK2+/− mice display an impaired AngII-induced decline in 
both the activation of the Akt-eNOS route and in total levels of the 
eNOS protein, thus leading to a preserved NO availability and a 
resistance to the development of hypertension.
Novelty and Significance
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METHODS 
Animal models 
Male and female mice either wild type (WT) or GRK2 hemizygous (GRK2+/-) were generated on 
the C57BL/6 genetic background as described.1 Four groups of 9 month-old mice were used: 1) 
WT; 2) GRK2+/-; 3) WT infused with AngII (1.44 mg/Kg/day, 1 week, subcutaneously by 
osmotic minipumps, Alza Corp., CA, USA); 4) GRK2+/- infused with AngII. In a pilot study, we 
observed that minipump surgery followed by infusion with saline did not alter systolic blood 
pressure or vascular contractile responses in WT or GRK2+/- mice (data not shown). 
Blood pressure and heart rate were measured by tail-cuff plethysmography. The Animal Care 
and Use Committee of our Institution, according to the guidelines for ethical care of 
experimental animals of the European Community, approved all experimental procedures. The 
study was conducted in accordance with the National Institutes of Health (NIH) Guide for the 
Care and Use of Laboratory Animals (NIH Publication No. 85-23, revised 1996) and the current 
Spanish and European laws (RD 223/88 MAPA and 609/86). 
Reactivity Experiments 
Reactivity of mouse aorta and first-order branches of the mesenteric artery (MRA) was studied in 
a wire myograph, as previously described.2 After a 30-min equilibration period in oxygenated 
Krebs Henseleit solution (KHS), arterial segments were stretched to their optimal lumen 
diameter for active tension development. Contractility of segments was then tested by an initial 
exposure to KCl (120 mM). The presence of endothelium was determined by the ability of 10 
µmol/L acetylcholine (ACh) to relax arteries precontracted with phenylephrine at approximately 
50% K+-KHS contraction. Concentration-response curves to ACh, isoproterenol or diethylamine 
NONOate (DEA-NO) were performed in segments precontracted with phenylephrine. In other 
segments, concentrations response curves to phenylephrine in the presence or the absence of L-
NG-Nitroarginine Methyl Ester (L-NAME, 100 µmol/L) were performed. L-NAME was added 
30 min before phenylephrine. A single concentration-dependent curve was performed in each 
segment. In other set of experiments, three consecutive administration of Angiotensin II (1 
µmol/L) or Endothelin-1 (0.1 µmol/L) were given, at intervals of 30 min, with removal always 
after each dose of the drug present in the medium. In a separate group of arteries, endothelial 
layer was mechanically removed by rubbing the intimal surface.  
Vasoconstrictor responses were expressed as a percentage of the tone generated by KCl. KCl-
induced responses were similar in aorta from WT and GRK2+/- male and female mice (Table S1). 
Vasodilator responses were expressed as a percentage of the previous tone generated by 
phenylephrine. To compare the effect of L-NAME or endothelial removal on phenylephrine 
responses in segments from the different experimental groups, some results were expressed as 
‘differences of area under the concentration-response curves’ (dAUC) in the absence and the 
presence of L-NAME or in the presence and in the absence of endothelial layer. AUCs were 
calculated from the individual concentration-response curve plots; the differences were 
expressed as a percentage of the AUC of the corresponding control situation. 
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NO Release  
After an equilibration period of 60 min in HEPES buffer (in mmol/L: NaCl 119; HEPES 20; 
CaCl2 1.2; KCl 4.6; MgSO4 1; KH2PO4 0.4; NaHCO3 5; glucose 5.5; Na2HPO4 0.15; pH 7.4) at 
37°C, aortic and mesenteric arteries segments of all the experimental conditions were incubated 
with the fluorescent probe 4,5-diaminofluorescein (DAF-2; 2 µmol/L) for 45 min. Then, the 
medium was collected to measure basal NO release. Afterwards these segments were incubated 
with phenylephrine 1 µmol/L and relaxed with ACh 10 µ µmol/L. At the end of this stimulation, 
the medium was collected to measure induced NO release. The fluorescence of the medium was 
measured at room temperature using a spectrofluorimeter (FLUOstar OPTIMA BMG 
LABTECH) with excitation wavelength set at 492 nm and emission wavelength at 515 nm. 
The induced NO release was calculated by subtracting basal NO release from that evoked by 
ACh. Also, blank samples were collected in the same way as from segment-free medium in order 
to correct for background emission. The amount of NO released was expressed as arbitrary 
units/mg tissue. Data were expressed as % of results obtained for WT mice. 
Pressure myography 
The structural and mechanical properties of MRA were studied with a pressure myograph 
(Danish Myo Tech, Model P100, J.P. Trading I/S, Aarhus, Denmark), as previously described.3 
Briefly, the vessel was placed on two glass microcannulae and secured with surgical nylon 
suture. After any small branches were tied off, vessel length was adjusted so that the vessel walls 
were parallel without stretch. Intraluminal pressure was then raised to 120 mm Hg and the artery 
was unbuckled by adjusting the cannulae. The segment was then set to a pressure of 45 mm Hg 
and allowed to equilibrate for 60 min at 37ºC in calcium-free Krebs Henseleit Solution (0Ca2+ 
KHS; omitting calcium and adding 1 mmol/L EGTA) intra and extra-vascular perfused gassed 
with a mixture of 95% O2 and 5% CO2. Intraluminal pressure was reduced to 3 mm Hg. A 
pressure-diameter curve was obtained by increasing intraluminal pressure in 20 mm Hg steps 
between 3 and 120 mm Hg. Internal and external diameters were continuously measured under 
passive conditions (Di0Ca, De0Ca) for 3 min at each intraluminal pressure. The final value used 
was the mean of the measurements taken during the last 30 seconds when the measurements 
reached a steady state.  
Calculation of passive structural and mechanical parameters  
From internal and external diameter measurements in passive conditions the following structural 
and mechanical parameters were calculated: 
Wall:lumen =(De0Ca-Di0Ca)/ 2Di0Ca 
Circumferential wall strain (ε)= (Di0Ca -D00Ca)/D00Ca, where D00Ca is the internal diameter 
at 3 mm Hg and Di0Ca is the observed internal diameter for a given intravascular pressure both 
measured in 0Ca2+ medium. 
Circumferential wall stress (σ)= (P x Di0Ca)/(2WT), where P is the intraluminar pressure (1 mm 
Hg = 1.334 x 103 dynes/cm2) and WT is wall thickness at each intraluminar pressure in 0Ca2+-
KHS. 
Arterial stiffness independent of geometry is determined by the Young’s elastic modulus 
(E=stress/strain). The stress-strain relationship is non-linear; therefore, it is more appropriate to 
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obtain a tangential or incremental elastic modulus (Einc) by determining the slope of the stress-
strain curve (Einc=δσ/δε). Einc was obtained by fitting the stress-strain data from each animal to 
an exponential curve using the equation: 
βεσ=σ eorig where σorig is the stress at the original diameter (diameter at 3 mmHg). Taking 
derivatives on the above equation we see that Einc=βσ. For a given σ value, Einc is directly 
proportional to β. An increase in β implies an increase in Einc which means an increase in 
stiffness. 
Histological analysis and vessel morphometry  
Aortas were fixed with 4% paraformaldehyde and embedded in Tissue Tek OCT medium. 10-
µm cross sections from fixed aortas were stained with hematoxylin-eosin. All images were 
acquired at room temperature using a microscope (DM2000; Leica) with 10× objective. 
Morphometric determinations of the lumen and vessel areas were performed by using 
Metamorph image analysis software (Universal Imaging, Molecular Devices Corp. 
Downingtown, PA, USA). All microscopic images of the sections were traced for the 
calculations of the areas. To determine the luminal area, the cross-sectional area enclosed by the 
internal elastic lamina was corrected to a circle by applying the form factor l2/4π to the 
measurement of the internal elastic lamina, where l is the length of the lamina. Vessel area was 
determined by the cross-sectional area enclosed by the external elastic lamina corrected to a 
circle, applying the same form factor (l2/4π) to the measurement of the external elastic lamina. 
The media area was calculated as the difference between the corrected vessel and luminal areas. 
Internal and external diameters were calculated from luminal and vessel areas, respectively. This 
method avoids miscalculations of areas caused by eventual collapse of the immersion-fixed 
arteries.4  
Western Blot 
Frozen aortas and mesenteric arteries were pulverized using liquid nitrogen and a smasher and 
homogenized in RIPA buffer (100 mmol/L Tris-HCl pH 7.4, 0.6 mol/L NaCl, 2% Triton x-100 
(v/v), 0.2% SDS, 1% DOC) completed with protease and phosphatase inhibitors (100 μmol/L 
PMSF, 1 μmol/L Benzamidine, 10 μg/mL STI, 16 μU Aprotinine, 10 μg/mL Bacitracine and 
Phosphatase Inhibitor Cocktail (PhosSTOP, Roche) following the manufacturer´s protocol for 1 
h. at 4ºC. Next, samples were centrifuged at maximum speed and supernatants were quantified. 
To determine protein expression, 30-40 μg of protein were resolved on a 7.5% SDS-PAGE gel 
and transferred to nitrocellulose. The membrane was immunoblotted using primary antibodies 
against eNOS (BD Transduction Laboratories) (1:1000), phospho-Akt (Ser473) (Cell Signaling) 
(1:1000), Akt (Cell Signaling) (1:1000), GRK2 (Santa Cruz) (1:1000), AT1 (Santa Cruz) 
(1:200), AT2 (Santa Cruz) (1:200) and GAPDH (Abcam) (1:5000). Blots were developed using 
fluorescently labelled secondary antibodies and measured the signal on a LiCOR Odyssey 
scanner. Data were normalized to GAPDH or total protein values, and expressed as % over 
results obtained for untreated or WT mice. 
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qRT-PCR  
mRNA from frozen aortas were extracted using metal beads (2 min, 30 Hz) in a Tissue Lyser and 
Fibrous Tissue RNeasy Mini Kit, both from QIAGEN. For quantitative PCR, total RNA was 
reverse transcribed using SuperScript® III First-Strand Synthesis System (Invitrogen) according 
manufacturer´s protocol. cDNAs were quantified by real-time PCR on an Applied Biosystems 
7900HT Fast Real-Time PCR System, using specific primers for mouse Adra1d: 5′-GTC TTC 
GTC CTG TGC TGG TT-3′ and 5′-CTT GAA GAC GCC CTC TGA TG-3′, Agtr1a: 5′-TCT 
GCT GCT CTC CCG GAC T-3′ and 5′-TGC TGT GAG TTA TCC CAG ACA AAA TG-
3′, Agtr1b: 5′-GTG ACA TGA TCC CCT GAC AGT-3′ and 5′-AGT GAG TGA ACT GTC TAG 
CTA AAT GC-3′, Agtr2: 5′-GGG AGC TGA GTA AGC TGA TTT ATG A-3′ and 5′-AGC AAC 
TCC AAA TTC TTA CAC CTT TTT A-3′, Ednra: 5′-ACC CTC GTT CTC CAG CTC A-3′ and 
5′-TTG GTC TCA CGC CTT TCT TT-3′, Ednrb: 5′-AAT GGT CCC AAT ATC TTG ATC G-
3′ and 5′-TCC AAA TGG CCA GTC CTC T-3′, Adrbk1: 5′-GCA GTT TGT CCT GCA GTG TG 
-3′ and 5′-TTC ATC TTG GGT ACT CGC TGT-3′,  Hprt: 5′-CCT GGT TCA TCA TCG CTA 
ATC-3′ and 5′-TCC TCC TCA GAC CGC TTT T-3′, Rps29: 5′-CTG AAC ATG TGC CGC CAG 
T-3′ and 5′-TCA AGG TCG CTT AGT CCA ACT TAA T-3′, Gapdh: 5′-CTC CCA CTC TTC 
CAC CTT CG-3′ and 5′-CAT ACC AGG AAA TGA GCT TGA CAA-3′, β-actin: 5′-CTA AGG 
CCA ACC GTG AAA AG-3′ and 5′-ACC AGA GGC ATA CAG GGA CA-3′  and 18S: 5′-CTC 
AAC ACG GGA AAC CTC AC-3′ and 5′-CGC TCC ACC AAC TAA GAA CG-3′. PCR 
amplification was performed in a volume of 10 μl containing 2.5 μmol/L of each primer and 5 μl 
Power Sybr Green PCR Master Mix (Applied Biosystems). The conditions were 95 °C for 
10 min, followed by 40 cycles of 15 s at 95 °C, 60 s at 60 °C,  followed by 15 s at 95 ºC, 15 s at 
60 ºC and 15 s at 95 ºC. Adra1d, Agtr1a, Agtr1b, Agtr2, Ednra and Ednrb mRNA levels were 
subsequently normalized to Hprt, Rps29 and Gapdh mRNA which were the better for 
normalization according NormFinder software because of their stability through the different 
groups under study. The results obtained were analysed by GenEx 5.3.7 software. 
Data Analysis and Statistics 
All data are expressed as mean values±SEM and n represents the number of animals. Results 
were analyzed by two-way ANOVA for repeated measures followed by Bonferroni’s post hoc 
test for the concentration response curves data, and by unpaired Student’s t-test, Mann-Whitney 
or one-way ANOVA for the other measurements. Statistical symbols in the concentration 
response curves indicate differences in the two way ANOVA when placed close to the curve and 
differences in the post hoc test when placed above or below individual doses. A p<0.05 was 
considered significant.   
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Table S1. Effect of partial GRK2 deletion (GRK2+/-) on vasoconstrictor responses in 
aortic rings from male and female mice.  
 
 Male Female 
Vasoconstrictor 
drug 
WT GRK2+/- WT GRK2+/- 
KCl (mN/mm) 2.50±0.31 2.82±0.45 2.59±0.12 2.61±0.19 
 
Phe (Emax) 
(mN/mm) 
0.69±0.12 1.14±0.17* 1.25±0.18 1.83±0.16* 
 
 
ET-1 (Emax) 
(mN/mm) 
0.08±0.05 0.26±0.05* - - 
     
Ang II (Emax) 
(mN/mm) 
0.07±0.02 0.08±0.06 - - 
  
Data are expressed as mean±SEM. n=4-12. *P<0.05 vs WT.  
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Figure S1. Effects of partial GRK2 deficiency on vasoconstrictor and vasodilator responses and in 
NO production in aorta from female adult mice. Concentration-response curve to phenylephrine 
(Phe) (A), acetylcholine (ACh) (B), isoproterenol (C), and diethylamine NONOate (DEA-NO) (E) 
and quantification of ACh-induced NO release (D) in aorta from female wild type (WT) and 
GRK2+/- mice. n=7-10. *P<0.05, **P<0.01, ***P<0.001.  
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Figure S2. Vasoconstrictor responses to endothelin-1 (ET-1) (A) and Angiotensin II (AngII) (B) 
administered three consecutive times at intervals of 30 min in aortas from WT and GRK2 +/- mice. 
(C) Gene expression of GRK2 (Adrbk1), Angiotensin receptors type 1a and b and 2 (Agtr1a, 
Agtr1b, Agtr2), endothelin-1 A and B receptors (Ednra, Ednrb) and α1D receptor (Adra1d) in aorta 
from WT and GRK2+/- adult mice. Data were normalized to values of WT mice. Data represent 
mean±SEM. n=5-9. *P<0.05; **P<0.01 vs WT. +p<0.05, ++p<0.01 vs first administration.  
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Figure S3. Effects of partial GRK2 deficiency on protein expression of GRK2 and AT1 and AT2 
receptors. Representative Western Blot and quantification of the protein expression of GRK2 and 
AT1 and AT2 receptors (AT1R, AT2R) in aorta (A) and mesenteric resistance arteries (MRA) (B) 
from WT and GRK2+/- mice. Data were normalized to GAPDH and to values of WT mice that were 
considered as 100%.  n=4-7. *P<0.05 vs WT.  
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The second article presented is the review entitled G Protein-coupled receptor kinase 
2 (GRK2): A novel modulator of insulin resistance (Arch Physiol Biochem. 2011; 117 
(3):125-30). 
This article reviewed the state of the art prior to our study in the heart and highlighted 
the role of GRK2 in the modulation of insulin signaling in several tissues important for 
systemic metabolism control, with potential impact and connections in cardiovascular 
function.
I participated (as second co-author) in the literature search, general organization and 
structuring of the manuscript, and in reviewing the text. I also prepared the summary 
ϐigure accompanying the article.
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1Introduction
G protein-coupled receptor kinases (GRKs) were first 
described to participate together with other cytoplasmic 
proteins termed arrestins in the regulation of multiple G 
protein-coupled receptors (GPCR), a superfamily of mem-
brane sensors with central roles in physiology and as phar-
macological targets. GPCR transduce extracellular signals 
inside the cell through activation of heterotrimeric G pro-
teins, and/or via other G protein-independent signalling 
pathways more recently identified. Upon agonist binding, 
GPCR become specifically phosphorylated by GRKs in their 
intracellular domains (reviewed in Premont & Gainetdinov, 
2007; Penela et al., 2010). This event promotes the associa-
tion of arrestins, leading to uncoupling from heterotrimeric 
G proteins, thus abrogating further G protein-dependent 
signal propagation. As a result of beta-arrestin binding, 
phosphorylated receptors are also targeted for clathrin-
mediated internalization (DeWire et al., 2007).
Phosphorylation of GPCR by GRKs and recruitment of 
arrestins serves not only to block G protein-dependent 
signal transduction, but also to initiate alternative sig-
nalling pathways, what has become a paradigm shift in 
the field in the past few years. Arrestins can act as scaf-
fold proteins for several signalling mediators such as 
c-Src, components of the MAPK cascades, the cAMP 
phosphodiesterase PDE4, Akt, components of the NFkB 
signalling pathway or the Mdm2 ubiquitin ligase, among 
others (Kovacs et al., 2009; Luttrell & Gesty-Palmer, 2010). 
Therefore, arrestin recruitment is critical for triggering 
the modulation of important intracellular signalling 
cascades by GPCR, contributing to the overall cellular 
response to the presence of a messenger.
On the other hand, cellular roles of GRKs are not 
limited to promoting beta-arrestin binding to activated 
GPCRs. Seven GRK genes are known in mammals, sub-
divided into three different groups:visual GRK subfamily 
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(GRK1 and GRK7), the beta-adrenergic receptor kinase 
subfamily (GRK2/GRK3) and the GRK4 subfamily 
(GRK4, GRK5 and GRK6). Except visual GRKs and GRK4, 
GRKs are almost ubiquitously expressed, showing differ-
ent protein levels depending on the tissue and cell type 
(Premont & Gainetdinov, 2007; Penela et al., 2010).
Functionally speaking, GRK2 appears to be the 
most important isoform as judged by the lethality of 
homozygous GRK2-deficient mice (Jaber et al., 1996). 
In addition to the regulation of GPCR, this protein is 
related to the control of several members of the recep-
tor-tyrosine kinase (RTK) family (reviewed in Hupfeld 
& Olefsky, 2007), phosphorylates a variety of non-re-
ceptor substrates and dynamically interacts with other 
important signal transduction partners in a kinase 
activity-independent way (see references in Peregrin 
et al., 2006; Ribas et al., 2007; Penela et al, 2010). The 
relevance of GRK2 in cell biology and physiology is 
further stressed by the fact that it participates in basic 
cellular processes such as differentiation/development 
(Molnar et al, 2007), cell migration (Penela et al., 2008), 
cell cycle progression (Penela et al, 2010), and by the 
fact that its levels are tightly controlled by very complex 
mechanisms and vary substantially in different patho-
logical situations (Penela et al., 2003; Salcedo et al., 
2006). In this line, changes in GRK2 expression and 
activity have been described to occur during the onset 
or progression of several relevant inflammatory and 
cardiovascular diseases, suggesting that those altera-
tions may contribute to the triggering or development 
of these pathologies (Penela et al. 2006; Dorn, 2009, 
Vroon et al. 2006).
Taking into account these considerations, and in the 
midst of the aforementioned shift in paradigm (from GRKs 
being considered as mere negative modulators of GPCR 
signalling to realizing their more complex role as key nodes 
of many intracellular transduction pathways) our labora-
tory started a few years ago a collaboration with the group 
lead by Margarita Lorenzo to address the potential role for 
GRK2 in the modulation of insulin signalling. Margarita 
was a brilliant scientist, full of energy and drive, an excel-
lent professor, an inspiring mentor for her students, and, 
above all this, a close friend for many years, from the time 
we both were PhD students at the Universidad Autonoma 
in Madrid. We really made the most, during this collab-
orative project, of her insight and profound knowledge of 
the insulin signalling research field, and enjoyed a lot dis-
cussing the exciting data obtained by both laboratories, 
even when she was already courageously fighting her dis-
ease. Margarita leaves all us an enduring scientific legacy 
and the example of the way she enjoyed both science and 
life. This review is dedicated to her memory. We will miss 
and remember her very much.
GRK2 as a modulator of insulin signalling?
Initial works on the characterization of the insulin path-
way in 3T3L1 adipocytes reported that insulin-induced 
GLUT4 translocation required at least two signals in 
these cells, one mediated through phosphatidylinositol 
3-kinase (PI3K) and another via Gαq/11 subunits, and 
that the activated insulin receptor (IR) could promote 
Gαq/11 phosphorylation on tyrosine residues, thus 
leading to activation of cdc42 and PI3K and glucose 
transport stimulation (Kanzaki et al., 2000; Imamura 
et al., 1999; Usui et al., 2003). Based on the fact that 
GRK2 can bind Gαq/11 and prevent its interaction with 
effectors (Mariggio et al., 2007 and references therein), 
Dr. Olefsky’s laboratory showed in 2004 that GRK2 
can act as an inhibitor of insulin-mediated glucose 
transport stimulation in 3T3L1 adipocytes by interfer-
ing with Gαq/11 function independently of its kinase 
activity (Usui et al., 2004). Moreover, GRK2 was able to 
inhibit basal and insulin-stimulated glycogen synthesis 
in mouse liver FL83B cells (Shahid & Hussain, 2007). 
In this context, we set out to analyse the modulation of 
insulin signalling by GRK2 in relevant insulin-targeted 
cell types. In adipocytes and myoblasts, overexpression 
of GRK2 or GRK2-K220R (a catalytically inactive kinase 
mutant) inhibited insulin-stimulated glucose uptake 
and insulin-dependent signalling (IRS1 tyrosine phos-
phorylation, Akt and ERK activation) in a kinase-activ-
ity independent manner (García-Guerra et al., 2010). 
Conversely, GRK2 silencing enhanced these responses. 
A similar picture emerged when investigating such 
parameters in vivo in adipose tissue from wild-type or 
GRK2- hemizygous mice, expressing half the amount of 
GRK2 protein related to wild type littermates (Jimenez-
Sainz et al, 2006; Kleibeuker et al., 2008). Faster kinet-
ics in insulin-mediated IRS1 and AKT phosphorylation 
were detected in GRK2± mice in insulin-responsive 
tissues in vivo (García-Guerra et al., 2010).
Interestingly, we observed that basal IRS1 protein 
levels were increased in cells in which GRK2 had been 
silenced, and less IRS1 protein was found in cells with 
elevated kinase dosage, suggesting the existence of a 
functional relationship that co-ordinately regulates the 
expression of these two proteins. It was previously shown 
that enhanced GRK2 levels favour insulin resistance 
induced either by endothelin-1 in 3T3L1 cells (Usui et al., 
2005) or by chronic β-adrenergic receptor stimulation 
in HEK-293 cells (Cipolletta et al., 2009). GPCR agonists 
promote GRK2 interaction with Gαq and also with IRS1, 
resulting in decreased insulin-stimulated glucose trans-
port, in IRS1 inhibitory phosphorylation at serine resi-
dues, and in IRS1 degradation. Our data in cultured cells 
as well as in adipose tissue in vivo show that IRS1 levels 
as well as the amount of basal GRK2-IRS1 complexes 
depend on the levels of GRK2 expression, and that insulin 
stimulation rapidly disrupts basal IRS1/GRK2 complexes, 
a process that is hampered in situations where the levels 
of GRK2 are elevated (García-Guerra et al., 2010).
The mechanisms modulating this dynamic GRK2/IRS1 
association in physiological conditions and the potential 
implication of phosphorylation events on GRK2-mediated 
IRS1 modulation are key issues for future research. Control 
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of cellular IRS1 expression levels has been described to 
involve proteasome-mediated degradation, phosphatase-
mediated dephosphorylation (Boura-Halfon & Zick, 
2009), and phosphorylation of IRS1 on serine residues, 
what also reduces the ability of IRS1 to associate with the 
insulin receptor and thereby inhibits downstream signal-
ling and insulin action (see references in Nieto-Vazquez 
et al., 2008). It was recently described that basal and 
insulin-stimulated Ser307 phosphorylation of IRS1 was 
significantly decreased in GRK2-deficient liver FL83B 
cells (Shahid & Hussain, 2007). Also, Usui et al. (2005) and 
Cipolletta et al (2009) have proposed that GRK2 mediates 
endothelin-1 and adrenergic-induced insulin resistance 
respectively by enhancing IRS1 serine phosphorylation 
and degradation. Whether this is a direct or an indirect 
effect of GRK2/IRS1 association is not straightforward. A 
catalytically inactive GRK2 mutant is able to inhibit insu-
lin-triggered glucose transport and signalling (Usui et al., 
2004; García-Guerra et al., 2010) and leads to decreased 
IRS1 levels in adipocytes and myocytes (García-Guerra 
et al., 2010), whereas Cipolleta et al. (2009) have sug-
gested that IRS1 is a direct target of GRK2 kinase activity 
in HEK-293 cells. These authors also report, in apparent 
discrepancy with our data, an increased GRK2-IRS1 co-
precipitation after 30 minutes of insulin treatment in this 
cell type and in tissues from spontaneously hypertensive 
SHR rats. These discrepancies may arise from the different 
cell source used or reflect a more complex nature of the 
GRK2/IRS1 dissociation/association/phosphorylation 
dynamics upon insulin receptor and/or GPCR activation 
than previously anticipated.
In sum, the available data suggest that altered GRK2 
levels could lead to modulation of insulin signals through 
GRK2-Galphaq/11 binding, GRK2-IRS1 association and/
or phosphorylation, modulation of IRS1 stability, or 
altered GPCR-mediated transmodulation of the insulin 
pathway engagement (Figure 1). The precise contribution 
of such mechanisms to different physiological and path-
ological conditions remains to be investigated in detail in 
the future.
GRK2 plays a key role in the modulation of 
insulin resistance and obesity in vivo
Insulin resistance, a diminished ability of cells to respond 
to the action of insulin, is a key feature associated with the 
pathogenesis of metabolic disorders such as type-2-dia-
betes and obesity (Biddinger & Kahn, 2006). Alterations 
in any of the key components of the insulin signaling cas-
cade, including negative regulators, have been proposed 
to contribute to insulin resistance. However, the full com-
plexity underlying the origin and the mechanism(s) that 
mediate insulin resistance in different physiopathologi-
cal conditions are not completely understood (Biddinger 
& Kahn, 2006; Hoehn et al., 2008).
We reasoned that if GRK2, as an established negative 
modulator of insulin signalling in cellular models (see 
above), was to play a physiological role in the modula-
tion of insulin sensitivity in vivo, two conditions should 
be met:(a) the expression of this kinase should be altered 
in situations characterized by insulin resistance; (b) low-
ering GRK2 levels should protect against the induction of 
systemic insulin resistance.
Interestingly, we observed that GRK2 expression was 
enhanced by approximately 2-fold in insulin-resistant 
cultured human adipocytes, in white adipose tissue of the 
ob/ob model of obese mice, and in adipose and muscle 
tissues of either TNFα-, age- or high fat diet-induced insu-
lin resistance mice models (García-Guerra et al., 2010). 
In addition, since lymphocytic GRK2 levels have been 
reported to mirror changes in kinase expression in other 
organs under several physiopathological circumstances 
(Iaccarino et al., 2005), we analysed the levels of GRK2 
in peripheral blood mononuclear cells obtained from 
Figure 1. Insulin acts by binding to its receptor (IR) which recruits insulin receptor substrate proteins (IRS) to activate the phosphatidyl-
inositol 3-OH kinase (PI3K)/Akt pathway, or alternatively heterotrimeric Gq proteins (G protein) in both cases leading to glucose uptake 
and metabolic regulation. GRK2 protein can bind to Gq or to IRS, thereby impairing downstream insulin signals. On the other hand, G 
protein-coupled receptors can transmodulate insulin pathway signals and this crosstalk could also be regulated by GRK2 levels.
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patients with diverse degrees of insulin resistance. We 
found that GRK2 levels were higher in insulin-resistant 
patients compared to control individuals (García-Guerra 
et al., 2010). Consistent with our findings, enhanced 
GRK2 expression has also been reported in tissues from 
obese Zucker rats (Trivedi et al., 2005). Overall, these 
results are consistent with GRK2 as an important player 
of the process leading to insulin-resistant conditions in 
vivo.
Importantly, we found that GRK2 haploinsufficient 
mice maintain glucose tolerance and insulin signalling in 
the major insulin-responsive tissues under either TNFα, 
ageing or high fat diet conditions (García-Guerra et al., 
2010), a phenotype reminiscent to that of mice deficient 
in other well established negative regulators of insulin 
signalling such as PTP1B (Nieto-Vázquez et al., 2007 
and references therein). These data support the notion 
that GRK2 can be regarded as a bona fide novel negative 
regulator of insulin action. The fact that a 50% down-
regulation of kinase levels in hemizygous GRK2± mice 
is sufficient to protect against the induction of insulin 
resistance strongly suggests that enhanced GRK2 expres-
sion, at least above a certain threshold, would markedly 
impair insulin signalling in vivo, and argues for a key 
role for GRK2 in the modulation of insulin sensitivity in 
physiological and pathological conditions.
The results obtained to date raise an important 
question to be addressed in future studies, namely the 
identification of the mechanisms and stimuli that trig-
ger enhanced GRK2 expression under insulin-resistant 
conditions. We have previously shown in other cell 
types that activation of the PI3K/AKT pathway by IGF-1 
increases GRK2 levels (Salcedo et al., 2006), and also 
chronic insulin has been reported to increase GRK2 
levels in HEK-293 and liver FL83B cells (Cipolleta et al., 
2009; Shahid & Hussain, 2007). Thus, one possible 
mechanism for increased GRK2 levels during insulin 
resistance is that the hyperinsulinemia associated to 
these conditions (and clinically to obesity and type-2
-diabetes) would trigger the observed up-regulation 
of GRK2. In this context, it is interesting to note that 
β-arrestin-2, another protein closely related to GRKs in 
their canonical function as GPCR regulators, has been 
recently put forward as a positive regulator of insulin 
sensitivity, by serving as a scaffold of AKT and Src to 
the IR (Luan et al., 2009). It is tempting to speculate 
that enhanced GRK2 levels could also interfere insulin 
signalling by altering the recently described IR-arrestin 
functional interface, either by re-directing arrestin to 
other partners, such as GPCR or, given that GRK2 can 
directly interact with AKT or Src (Sarnago et al, 1999; 
Liu et al., 2005), by GRK2-dependent inhibition of the 
formation of the arrestin/AKT/Src complexes required 
for efficient insulin signalling.
In animal models and in human patients with insulin 
resistance, β-arrestin2 levels are downregulated (Luan 
et al., 2009). Therefore, it is tempting to suggest that the 
combined effects of an up-regulation of GRK2 and a 
down-regulation of β-arrestin2 in insulin-resistant con-
ditions could lead to major alterations in insulin signal-
ling pathways and in GPCR-IR cross-talk. In this context, 
it is worth noting that elevated levels of insulin and IGF-1 
have been shown to exert differential effects on GRK2 and 
β-arrestin2 expression (Dalle et al., 2002; Hupfeled et al., 
2003; Salcedo et al., 2006). The role of hyperinsulinemia 
in modulating both GRK2 and beta-arrestin expression in 
different relevant cell types is being actively investigated 
in our laboratory.
Alternatively, or in addition, an altered cytokine 
expression pattern, typical of insulin-resistant states, 
could also contribute to enhance GRK2 expression 
levels in these circumstances. TNFα or IL-6 have been 
reported to increase the expression of other negative 
modulators of the insulin signalling cascade like PTP1B 
(Nieto-Vázquez et al., 2007 and 2008), and we found 
that TNFα infusion also enhances GRK2 protein con-
tent in adipose tissue and muscle of wild-type mice in 
the presence of mild hyperinsulinemia (García-Guerra 
et al., 2010). Pro-inflammatory mediators can modulate 
endogenous GRK2 expression in a cell-type specific 
fashion (Ramos-Ruiz et al., 2000; Eijkelkamp et al., 
2010), and an increase in GRK2 protein is found upon 
chronic IL-1beta treatment in astrocytes (Kleibeuker 
et al., 2008). Interestingly, GRK2 appears to have a rel-
evant role in the aetiology and/or in the development 
of several inflammatory diseases (Vroon et al., 2006), 
so the role for GRK2 in states of insulin resistance 
associated to inflammatory diseases deserves further 
investigation.
GRK2 levels as modulators of age- and diet-
induced adiposity
It is becoming increasingly clear that impaired insulin 
actions in adipose tissue are key to the overall insulin 
resistance characteristic of adult and/or obese animals. 
Adipocyte-conditioned medium impairs insulin signal-
ling in muscle cells and hepatocytes, and mice that exhibit 
reduced adiposity typically display improved glucose tol-
erance and increased insulin sensitivity (Guilherme et al., 
2008; Sabio et al., 2008; Fernandez-Veledo et al., 2008). 
On the other hand, GRK2 hemizygous mice subjected 
to a HFD gain less weight and have smaller adipocytes 
compared with wild type littermates, and 9 month-old 
hemizygous animals display reduced adiposity and 
lower circulating levels of insulin and leptin than wild 
type controls (García-Guerra et al., 2010). Therefore, it is 
possible that part of the insulin hypersensitivity detected 
in GRK2± mice and the protection afforded to the devel-
opment of insulin resistant conditions in these animals 
is related to the observed changes in adiposity. Further 
analysis of the specific role of GRK2 in muscle tissue, the 
mechanisms of GRK2 in regulating adipogenesis and the 
use of cell type/tissue-specific GRK2 down-regulation 
models will provide new insights into the role of GRK2 in 
obesity and insulin resistance.
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concluding remarks
Recently published data add to those already present in 
the literature to support the identification of GRK2 as an 
important negative regulator of insulin effects, key to the 
etiopathogenesis of insulin resistance and obesity, thus 
uncovering this protein as a potential therapeutic target 
in the treatment of these disorders. A sustained systemic 
inhibition of kinase functionality could be recapitulated 
in adult GRK2± mice. Since these animals do not develop 
insulin resistance in response to a variety of triggers of 
this condition, it could be hypothesized that sustained 
GRK2 inhibition may constitute a good therapeutic strat-
egy against these disorders. In fact, one study in animal 
models of type-2-diabetes has shown that GRK2 inhibition 
through systemic delivery of small peptides derived from 
its catalytic domain results in improved glucose homeosta-
sis (Anis et al., 2004). However, it remains to be established 
whether inhibition of GRK2 prior or during the develop-
ment of insulin resistance is required for an amelioration of 
the condition or, alternatively, whether a GRK2 reduction 
can have a therapeutic effect even after insulin resistance is 
overtly established. Also, from a mechanistic point of view, 
it will be interesting to study whether inhibition of catalytic 
activity, down-regulation of protein expression or targeted 
disruption of the specific interaction of GRK2 with insulin 
signalling pathway components are the more appropriate 
strategies for specifically improving insulin sensitivity.
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INTRODUCTION TO ARTICLE #3
The third article presented herein was entitled Downregulation of G protein-
coupled receptor kinase 2 levels enhances cardiac insulin sensitivity and switches on 
cardioprotective gene expression patterns (Biochim Biophys Acta. Molecular Basis of 
Disease 2014; 1842:2448–2456).
The aim of this work was to investigate in detail the interconnections among GRK2 
dosage, cardiac insulin sensitivity, cardiac gene expression patterns and heart phenotype 
in adult mice or animals fed with high-fat diet, two conditions known to promote insulin 
resistance. 
This is the ϐirst study to indicate a cardioprotective role for lowering GRK2 levels in 
adult 9 month-old mice and the ϐirst to report alterations in cardiac GRK2 levels under 
different insulin-resistance conditions such as HFD feeding and ob/ob animals.
Building on data obtained by Dr. María Jurado Pueyo´s in her Doctoral Thesis, this 
work characterized the activation of insulin signaling pathways, tissue remodeling in the 
heart and cardioprotective gene expression patterns in young and adult WT and GRK2+/− 
mice. In addition, we investigated the effect of systemic insulin-resistance-promoting 
conditions such as high-fat diet feeding on cardiac GRK2 levels and its impact on cardiac 
insulin responses. Our data point at new molecular links between GRK2 up-regulation 
in insulin-resistance-related situations and maladaptive cardiac remodeling in the adult 
mouse heart. 
 As ϐirst shared co-author of this work, I performed the study of insulin signaling 
cascade activation in both WT and GRK2+/- adult mice,  contributed to the study of GRK2 
alterations under insulin resistance conditions and  its implications for cellular signaling 
and corroborated the protective role of lowering GRK2 levels under diet-induced insulin 
resistance conditions. The initial gene microarray data as well as the morphological and 
physiological analysis of adult cardiac tissue was part of Dr. María Jurado´s thesis, while 
I performed gene expression validation experiments and further analysis of the results 
obtained from the arrays.
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G protein-coupled receptor kinase 2 (GRK2) has recently emerged as a negative modulator of insulin signaling.
GRK2 downregulation improves insulin sensitivity and prevents systemic insulin resistance. Cardiac GRK2 levels
are increased in human heart failure, while genetically inhibiting GRK2 leads to cardioprotection in mice. How-
ever, themolecular basis underlying the deleterious effects of GRK2 up-regulation and the beneﬁcial effects of its
inhibition in the heart are not fully understood. Therefore, we have explored the interconnections among a sys-
temic insulin resistant status, GRK2 dosage and cardiac insulin sensitivity in adult (9 month-old) animals.
GRK2+/−mice display enhanced cardiac insulin sensitivity and mild heart hypertrophy with preserved systolic
function. Cardiac gene expression is reprogrammed in these animals, with increased expression of genes related
to physiological hypertrophy, while the expression of genes related to pathological hypertrophy or to diabetes/
obesity co-morbidities is repressed. Notably, we ﬁnd that cardiac GRK2 levels increase in situations where
insulin resistance develops, such as in ob/obmice or after high fat diet feeding. Our data suggest that GRK2down-
regulation/inhibition can help maintain cardiac function in the face of co-morbidities such as insulin resistance,
diabetes or obesity by sustaining insulin sensitivity and promoting a gene expression reprogramming that con-
fers cardioprotection.
© 2014 Elsevier B.V. All rights reserved.
1. Introduction
G protein-coupled receptor kinases (GRKs) were initially identiﬁed
as serine–threonine kinases able to phosphorylate agonist-activated G
protein-coupled receptors (GPCRs), triggering the binding of arrestins
to the receptor, which impairs G protein coupling in a process known
as desensitization [1]. However, very recent ﬁndings suggest that the
GRK2 isoform is also a key controller of insulin receptor signaling [2].
GRK2 downregulation can prevent the development of metabolic disor-
ders, modulating energy expenditure and brown fat function [3] and
also insulin actions in peripheral tissues [2]. Notably, GRK2+/− mice
(expressing 50% less protein than control littermates) show improved
systemic insulin sensitivity, display enhanced activation of the insulin-
mediated Akt pathway inmuscle, adipose tissue and liver, and are resis-
tant to the induction of insulin resistance (IR) in three different mouse
models of this condition [2]. Remarkably, such differences in insulin
sensitivity between wild type (WT) and GRK2 hemizygous mice were
noted in the adult stage but were not evident in young animals [2].
GRK2 has also been described to play a relevant role in cardiovascular
physiopathology. Increased cardiac GRK2 levels have been reported in
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Abbreviations:GPCR, G protein-coupled receptor; GRK2, G protein-coupled receptor
kinase 2; IR, insulin resistance; HF, heart failure;HFD, high fat diet;WT,wild type
⁎ Correspondence to: F. Mayor Jr., Centro de BiologíaMolecular Severo Ochoa, c/Nicolás
Cabrera, 1, Universidad Autónoma, 28049Madrid, Spain. Tel.: +34 91 1964626; fax: +34
91 196 4420.
⁎⁎ Correspondence to: C. Murga, Centro de Biología Molecular Severo Ochoa, c/Nicolás
Cabrera, 1, Universidad Autónoma, 28049 Madrid, Spain. Tel.: +34 91 1964641; fax: +34
91 196 4420.
E-mail addresses: fmayor@cbm.uam.es (F. Mayor), cmurga@cbm.uam.es (C. Murga).
1 Equal contribution to this work.
http://dx.doi.org/10.1016/j.bbadis.2014.09.004
0925-4439/© 2014 Elsevier B.V. All rights reserved.
Contents lists available at ScienceDirect
Biochimica et Biophysica Acta
j ourna l homepage: www.e lsev ie r .com/ locate /bbad is
patients with ischemic or idiopathic dilated cardiomyopathy, cardiac is-
chemia, hypertension, volume overload and left ventricular hypertrophy
[1,4,5]. Also, enhanced GRK2 expression induced by neurohormonal
activation has been associated with lower cardiac function and poorer
prognosis in human heart failure (HF) and appears as an early event in
maladaptive cardiac remodeling in HF [5–7], altogether putting forward
GRK2 as a relevant therapeutic target in this myocardial disease
(reviewed in ref. [6]). Consistently, genetic inhibition of GRK2 is
cardioprotective in different animal models ([1,5–8] and the references
therein), and hemizygous GRK2 mice are hyper-responsive to catechol-
amines and display enhanced cardiac contractility and function, whereas
transgenic mice overexpressing different levels of this kinase show an
impaired adrenergic cardiac response [9]. However, the detailed molec-
ular mechanisms and the relevant functional interactions underlying
the deleterious effects of elevated GRK2 levels in cardiac function and
the beneﬁcial effects of its inhibition remain to be fully established.
In principle, up-regulation of GRK2 in HF would further exacerbate
the marked β-adrenergic desensitization observed in such condition.
However, chronic adrenergic activation appears to bemore detrimental
than beneﬁcial for heart disease and, most importantly, β-blockers
represent a successful standard treatment for this disease. In this
context, the fact that GRK2 inhibition acts in a synergic manner with
established β-blocker treatments (reviewed in [6,7]) suggests that
these two therapeutic strategies must have independent mechanisms
of action. Thus, the functional impact of altered GRK2 levels might also
be related to the interactions of this protein with cellular partners
other than β-adrenergic receptors [10].
In this regard, adding to the data showing that GRK2 up-regulation
inhibits insulin signaling in muscle or adipose tissue [2], recent ﬁndings
have suggested that cardiac-speciﬁc overexpression of GRK2 inhibits
glucose uptake and promotes IR after myocardial ischemia in young
mice [11]. However, the potential interconnections among a systemic
IR status, GRK2 levels and the cardiac maladaptive remodeling linked
to cardiac dysfunction have not been addressed to date.
In this report, we have characterized the activation of insulin signal-
ing pathways, tissue remodeling in the heart and cardioprotective gene
expression patterns in young and adultWT and GRK2+/−mice. This ex-
perimental model allows us to explore the consequences of a chronic,
physiological-range change in GRK2 levels with age (a risk factor for
the onset of most cardiovascular pathologies) that would mimic the
long sought pharmacological systemic inhibition of GRK2 as a potential
drug target. In addition, we have investigated the effect of systemic
IR-promoting conditions on cardiac GRK2 levels and its impact on
cardiac insulin responses. Our data point at new molecular links be-
tween GRK2 up-regulation in IR-related situations and maladaptive
cardiac remodeling in the adult mouse heart.
2. Materials and methods
2.1. Animals
Experiments were performed on male wild type and hemizygous-
GRK2 (GRK2+/−)micemaintained on the hybrid 129/SvJ C57BL/6 back-
ground. The animals were bred and housed on a 12-hour light/dark
cycle with free access to food and water. GRK2+/− mice, as well as
male leptin-deﬁcient obese ob/ob mice (C57BL/6J-Lepob/Lepob) and
their corresponding wild types (C57BL/6J, The Jackson Laboratory, Bar
Harbor, ME, USA)were fed ad libitum since weaning on either a normal
chow diet (providing 13% of total calories as fat, 67% as carbohydrate
and 20% as protein; 2014S Rodent Maintenance Diet, Teklad, Harlan,
Barcelona, Spain) or a high fat diet (providing 45% of total calories as
fat, 35% as carbohydrate and 20% as protein, Rodent Diet D12451,
Research Diets, New Brunswick, NJ, USA). Animals were maintained at
a room temperature of 22 ± 2 °C on a 12:12 light–dark cycle (lights
on at 08:00 am) with a relative humidity of 50 ± 10% and under
pathogen-free conditions. All animal experimentation procedures
conformed to the EuropeanGuidelines for the Care andUse of Laborato-
ry Animals (Directive 86/609) and approved by the Ethical Committees
for Animal Experimentation of the Universidad Autonoma de Madrid
and the University of Navarra (protocols 013/08 and 041/08).
2.2. Plasmamembrane preparation andGLUT4 translocation quantiﬁcation
Relative quantiﬁcation of GLUT4 protein in the plasma membrane
fraction was achieved by a subcellular fractionation method modiﬁed
from Rett K. et al. [12]. Mice were injected intravenously in the tail
vein with insulin (1 unit/kg of body weight). After 25 min, mice were
sacriﬁced by cervical dislocation and hearts were homogenized using
metal beads in a Tissue Lyser using cooled buffer (200 mM Tris–HCl
pH 7.5, 10 mM EDTA, 255 mM Sucrose) with protease inhibitors
(100 μM PMSF, 1 μM benzamidine, 10 μg/ml STI, 16 μU aprotinin,
10 μg/ml bacitracin). Lysates were centrifuged at 9000 ×g for 20 min.
The pellet (P1) was resuspended in buffer, homogenized again and
centrifuged at 200 ×g for 20 min. The plasma membrane-enriched P2
was then resuspended and homogenized in RIPA buffer (100 mM
Tris–HCl pH 7.4, 600 mM NaCl, 2% Triton X-100, 0.2% sodium dodecyl
sulfate, 1% deoxycholate plus protease inhibitors) for Western Blot
analysis. Protein content was quantiﬁed using the Lowry procedure
and 40 μg of total protein was resolved on a 12% SDS-PAGE gel and
transferred to a nitrocellulose membrane. Blots shown here were
probed with speciﬁc antibodies against GLUT4 (EMD Millipore,
Darmstadt, Germany), Caveolin 3 (BD Transduction Laboratories,
Franklin Lakes, NJ, USA) and α-Tubulin (Santa Cruz Biotechnology,
Dallas, TX, USA).
2.3. Insulin treatments and Western Blots
Insulin (Actrapid®, Novo Nordisk, Bagsvaerd, Denmark) solution in
saline serum (1 unit/kg body weight) was administered by tail vein in-
jection for acute cardiac insulin pathway activation analysis. After either
3 or 5 min, mice were sacriﬁced by cervical dislocation and hearts were
quickly collected, washed and frozen at−70 °C. Heart tissue was ho-
mogenized using metal beads in a Tissue Lyser using hypotonic buffer
(20mMTris–HCl pH 7.5, 1mMEDTA, 1mMEGTA) completedwith pro-
tease and phosphatase inhibitors (100 μM PMSF, 1 μM benzamidine,
10 μg/ml STI, 16 μU aprotinin, 10 μg/ml bacitracin and Phosphatase In-
hibitor Cocktail—PhosSTOP (Roche, Indianapolis, IN, USA)—following
manufacturer's protocol). Then 0.1% (v/v) Triton X-100 was added and
the samples were agitated for 1 h at 4 °C, and centrifuged to measure
supernatant protein content using the Lowry procedure. For Western
Blot analysis, typically 40 μg of total cardiac protein was resolved per
lane on a 7.5% SDS-PAGE gel and transferred to a nitrocellulose mem-
brane. Blots were probed with speciﬁc antibodies against phospho-Akt
(Ser473), Akt, phospho-p70S6K (Thr389), phospho-ERK1/2 (Thr202/
Tyr204) (Cell Signaling Technology, Beverly, Ma, USA), p70S6K,
phospho-IRS1 (Tyr896) (BD Biosciences, Franklin Lakes, NJ, USA),
ERK-1, ERK-2, GRK2, Nucleolin (Santa Cruz Biotechnology, Dallas, TX,
USA), GAPDH (Abcam, Cambridge, UK) and IRS1-PH (kindly provided
by Deborah J. Burks, Spain) [13].
2.4. Cardiac morphometry
For the histological and morphometric analysis of the hearts, mice
were anesthetized with isoﬂurane and an intracardiac injection of cold
KCl solution was used to stop the heart in diastole before the heart col-
lection. Hearts were weighted for cardiac index determination, and the
medial section was ﬁxed in formaldehyde and embedded in parafﬁn
prior to transversal sectioning using a microtome. Masson's Trichrome
staining was performed for the morphometric analysis and Syrius red
staining for ﬁbrosis quantiﬁcation. Images were analyzed using the
AnalySIS® software (Soft Imaging System).
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2.5. Echocardiography
Tomeasure global systolic cardiac function and left ventricular mass
(LVM), echocardiographywas performed in 9month-oldWT and hemi-
zygous GRK2mice. Mice were anesthetized by inhalation of isoﬂurane/
oxygen (1.25%/98.75%) and examined by a 30 MHz transthoracic
echocardiography probe. Images were obtained with Vevo 770
(VisualSonics, Toronto, Canada). The internal diameter of the LV was
measured in the short-axis view from M-mode recordings in end
diastole and end systole and ejection fraction (EF) and fractional
shortening (FS) were calculated using the formulas as previously
described [14].
2.6. RNA isolation and microarray analysis
mRNA from frozen heart tissue was extracted using metal beads
(2 min, 30 Hz) in a Tissue Lyser and Fibrous Tissue RNeasy Mini Kit,
both from QIAGEN (Hilden, Germany). Three mice per condition were
used for the gene expression proﬁle analysis of GRK2+/− and WT mice
of 4 and 9 months of age. cDNA synthesis, labeling andmicroarray anal-
ysis were performed with the aid of the Bioinformatics group at the
National Center of Biotechnology (CNB, Madrid, Spain). Generation of
double-stranded cDNA, preparation and labeling of cRNA, hybridization
to GeneChip® Mouse Genome 430 2.0 Arrays (Affymetrix, Santa Clara,
CA, USA) and washing were performed according to the protocol
provided by Affymetrix. Probe sets were summarized using the
LiMMA algorithm. Results were analyzed and visualized using
Researcher's Digest software and FIESTA viewer respectively, as well
as Multiexperiment Viewer software (TM4 Microarray Software Suite).
2.7. Co-immunoprecipitation assays
Cell lysates obtained as previously described for Western Blot were
quantiﬁed using the Lowry procedure. Next, 500 μg total protein per ly-
sate was incubated with 10 μl of either rabbit IgG or IRS1 antibody
(Santa Cruz Biotechnology, Dallas, TX, USA) and 0.4 μg/μl BSA on a rotat-
ing shaker at 4 °C overnight and 15 μl of Protein G-Sepharose (50% in
lysis buffer) were added to each tube. After 2 h on a rotating shaker at
4 °C, tubes were centrifuged at 14,000 ×g for 5 s and the pellets
were washed with pre-chilled washing buffer (hypotonic-1% Triton)
for 10 times (1ml each). Pelletswere then boiled in 4× Laemmli loading
buffer for 5 min and used for Western Blot analysis. Blots were probed
with speciﬁc antibodies against IRS1-PH [13] and GRK2 (Santa Cruz
Biotechnology, Dallas, TX, USA).
2.8. RT-PCR and microarray validation
mRNA from heart tissue of at least 6 WT and 6 GRK2+/−mice was
isolated as described before. RT-PCRs were performed by the Genomic
Facility at CBMSO using Light Cycler equipment (Roche, Indianapolis,
IN, USA). Microarray validations were performed using both commer-
cial Taqman Gene Expression Assay probes (Applied Biosystems, Life
Technologies, Grand Island, NY, USA) and self-designed probes pur-
chased from Sigma with Syber Green technology. qPCRs and statistical
analysis of the data were performed by the Genomic Facility at CBMSO
using GenEx software.
2.9. Small-animal PET protocol
2-Deoxy-2-[18F]-ﬂuoro-D-glucose in isotonic saline solution was
injected through the intravenous catheter of WT and GRK2+/− adult
mice to characterize heart glucose utilization in basal and after 5-min
insulin stimulation. 90-minute dynamic imaging was performed with
a piPET scanner and tomographic images were reconstructed using a
three-dimensional ordered subset expectation maximization algorithm
as previously described [15]. Region of interest measurements were
made on multiple axial slices of the myocardium and tracer uptake
was quantiﬁed as standardized uptake values normalized by injected
dose and corrected for body weight.
2.10. Statistics
Data were analyzed by one-way ANOVA, followed by Bonferroni's
post hoc analysis, or by unpaired T-testing when speciﬁed, as appropri-
ate. For all tests, p b 0.05 was considered statistically signiﬁcant
after Bonferroni corrections, if needed, and all data are reported as
means ± SEM.
3. Results
3.1. Decreased GRK2 levels correlate with enhanced cardiac insulin
sensitivity
GRK2 can act as a negative modulator of insulin receptor signaling
pathways, and adult GRK2+/− mice show improved systemic insulin
sensitivity and are resistant to the induction of IR in peripheral tissues
[2]. In this context, we explored the possibility that GRK2 dosage
could modify heart insulin sensitivity in vivo in 9 month-old mice. The
translocation to theplasmamembrane of theGLUT4 glucose transporter
is a key early event in glucose uptake stimulated by insulin. As can be
observed in Fig. 1a, insulin-dependent GLUT4 translocation was signiﬁ-
cantly enhanced in adult GRK2 hemizygous mice, compared to wild-
type animals, as assessed by Western Blot analysis of membrane frac-
tions of cardiac tissue. These results are in agreementwith the increased
accumulation of labeled deoxyglucose in the hearts of GRK2+/− mice
quantiﬁed by PET (Supplementary Fig. 1S). A similar pattern was ob-
served for the rapid stimulation of Akt and its downstream target
p70S6K kinase detected with speciﬁc phospho-antibodies upon injec-
tion of insulin (Fig. 1b–e).
Of note, upstream insulin signaling events such as the amount of
phospho-Tyrosine(Tyr896)IRS1 were increased in GRK2+/− hearts
after insulin stimulation while the activation status of the ERK cascade
was not affected (Supplementary Fig. 1Sb–d). Together, these results
demonstrate that the metabolic and pro-survival signals downstream
of insulin were more potently activated in GRK2+/− hearts than in WT
mice.
3.2. GRK2+/− 9 month-old mice display mild, non-pathological heart
hypertrophy
Themodulation of the PI3K/Akt and the ERK pathways in the heart is
shared by insulin, IGF-1 and hypertrophic agonists such as angiotensin
II. The PI3K/Akt cascade relates mostly to physiological hypertrophy,
whereasMAPK signaling, together with PKC and calcineurin/NFAT, par-
ticipates in the development of the pathological hypertrophy typically
induced by angiotensin II (reviewed in ref. [16]).
We found that GRK2+/−mice showed a modest but signiﬁcant in-
crease in heart to body weight ratio and in the total cardiac area with
age compared to the change observed in WT animals (Fig. 2a and b).
We also found an enhanced increase in cardiomyocyte diameter in
GRK2+/− animals (Fig. 2c), an established indicator of cardiac hypertro-
phy. No differences in these parameters were found at 4 months of age
betweenWT and GRK2+/− animals. Echocardiographic analysis also re-
vealed a certain degree of hypertrophy in the 9 month-old hemizygous
mice, mainly referred to left ventricular mass (data not shown) in the
absence of any alterations in cardiac functionality, as deﬁned by frac-
tional ejection (EF) or fractional shortening (FS) parameters (Fig. 2d).
Consistently, ﬁbrosis was not increased in either 4 or 9 month-old
GRK2+/−mice compared with age-matched controls (Fig. 2e).
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3.3. Decreased GRK2 levels correlate with the expression of key genes
involved in physiological hypertrophy/cardioprotection
Insulin is known to play a protective role in cardiac physiology, via
the control of cardiac substrate utilization, cardiomyocyte growth, gene
expression, survival and contractility by means of the homeostatic stim-
ulation of the PI3K/Akt and other intracellular signaling pathways [17].
As an unbiased approach to assess the functional consequences of alter-
ing GRK2 levels in themodulation of insulin response and heart function,
we compared the transcriptional proﬁle of the cardiac tissue of WT and
GRK2+/−mice of 4 or 9 months of age usingmicroarray RNA expression
techniqueswithout subjecting the animals to prior speciﬁc treatments to
study the integrated response of the tissue to homeostatic endogenous
signals. Comparison of gene expression proﬁles between WT and
GRK2+/− animals at each group of age (database access number
GSE41706) revealed signiﬁcant differences only at 9 months (33 genes
signiﬁcantly up-regulated and 28 genes down-regulated in GRK2+/−
mice compared to WT) while no differences between genotypes were
detected at 4 months of age (Fig. 3a and Supplementary Table 1),
suggesting that the effects of GRK2 dosage on cardiac gene expression
require additional age-related changes to become apparent.
We next performed a detailed analysis of the function and character-
istics of the up or down-regulated genes. Several interesting patterns
were noted. First, GRK2+/−mice at 9 months of age showed decreased
expression of genes described to be up-regulated during pathological
heart hypertrophy and/or in well-characterized cardiovascular disease
co-morbidities such as diabetes and obesity. Eight out of the 28 genes
down-regulated in GRK2+/− mice (29%) belonged to this group (see
Fig. 3b). This list included the pivotal heart hypertrophy marker Acta1
(skeletal muscle alpha-actin) and the atrial natriuretic factor precursor
Nppa [18,19]; the cardiovascular heat shock protein Hspb7, with high
expression in ob/ob mice skeletal muscle [20] and polymorphisms
associated with development of idiopathic dilated cardiomyopathy
and heart failure [21]; the transcription factor promyelocytic zinc ﬁnger
protein (Plzf, also known as Zbtb16), a mediator of angiotensin 2-type 2
receptor-triggered cardiac hypertrophy [22]; the microﬁbril-associated
glycoprotein-2 (Magp-2, also known asMfap5), an angiogenic stimula-
tor upregulated in transgenic models of HF [23], or the tissue inhibitor
Fig. 1. GLUT4 translocation to themembrane and insulin signaling are upregulated in hearts from adult GRK2+/−mice. a). GLUT4 translocation in the plasmamembrane fraction after an
intravenous injection of insulin for 25min in 9month-oldWT and GRK2+/−mice (N=6–8 per genotype). Resultswere normalized to Caveolin 3 levels and are expressed as fold increase
over basal (non-insulin treatedmice). Representative blots are shown includingα-Tubulin blot as an indicator of the absence of cytosolic contamination. Quantiﬁcation of Akt phosphor-
ylation (Ser473) (b) and p70S6K phosphorylation (Thr389) (c) in the cardiac tissue lysates of WT or GRK2+/− 9 month-old mice after an intravenous injection of insulin for 3 or 5 min
(N= 3–5). Results are expressed as fold increase over control (non-insulin treatedmice). d) Representative Western Blots of the speciﬁed phospho-proteins and controls in heart tissue
3 or 5 min after insulin injection. Data are mean ± SEM of the indicated independent experiments. ***p b 0.001; *p b 0.05.
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Fig. 2.GRK2+/− 9month-oldmice showmild, non-pathological heart hypertrophy. a) Heartweight (mg) to bodyweight (g) ratio in 4 and 9month-oldWT and GRK2+/−mice (N= 7–14).
b) Total area of cross sections of each heart was measured from high-resolution images using the AnalySIS® software and expressed inmm2 forWT (white bars) and GRK2+/− (black bars)
mice (N= 5–9). c) Cardiomyocyte diameter (in μm) was measured in the cross-section of cells perpendicular to the slices stained with Masson's Trichrome in at least 20 cells per sample
using the AnalySIS® software (N = 5–9). d) Fold change of ejection fraction (EF) and fractional shortening (FS), with statistical analysis performed using T-test. e) Quantiﬁcation of the
ﬁbrotic area of heart cross sections stained with Syrius red, digitalized using the Axiovision software and analyzed using the AnalySIS® software. Representative pictures are shown when
applicable. Data are mean ± SEM of the indicated independent experiments. *p b 0.05.
Fig. 3. Comparison of cardiac gene expression proﬁles between young (4 month-old) or adult (9 month-old)WT and GRK2+/−mice. a) Genes whose expression varied signiﬁcantly be-
tweenWT andGRK2+/−mice are represented. Pairwise analyseswere performed and visualized using the FIESTA viewer for an FDR b 0.2 (fold change N 1.5 or≤1.5). No geneswere found
to change signiﬁcantly at 4 months of age, but, at 9 months of age, 61 genes were signiﬁcantly different betweenWT and GRK2+/−mice. Black, genes whose expression is increased in
GRK2+/− vsWT. Gray, genes whose expression is reduced in GRK2+/− vsWT. b) The table depicts genes reported to be upregulated during pathological heart hypertrophy or during co-
morbidities such as diabetes/obesity (see references in the text) found to be downregulated in adult GRK2+/−mice vs WT heart microarray, or genes for which the inverse relationship
occurs (left panel). Also, a list of genes upregulated/downregulated in the array and also during physiological heart hypertrophy or response to exercise is speciﬁed (right panel).
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of metalloproteinase 4 (Timp4), a proposed marker for left ventricular
remodeling and deteriorating HF [24]. Prostaglandin D synthase
(Ptgds), increased in the coronary circulation of angina patients [25]
and overexpressed in type 2 diabetes [26] and the p85 alpha PI3K regu-
latory subunit (Pik3R1), enhanced in the myocardium of mice develop-
ing diet-induced obesity [27] and a key negative regulator of insulin
signaling [28,29] were also decreased in 9 month-old GRK2+/− hearts.
A second interesting pattern found in GRK2+/−micewas that 10 out
of 33 genes thatwere up-regulated in these animals (30%)have been re-
ported to play a protective role in cardiovascular disease and are often
down-regulated in pathological heart hypertrophy and/or diabetes/
obesity co-morbidities (Fig. 3b). In this regard, the expression of
Ppargc1b, Hdac9, RRad, or Pde4b, reported as key negative regulators of
pathological heart hypertrophy, was enhanced in GRK2+/− mice.
PGC1beta (peroxisome proliferator-activated receptor (PPAR)-
gamma1beta co-activator) is essential for mitochondrial biogenesis
and energy homeostasis. Decreased Ppargc1b expression correlates
with cardiac insufﬁciency and cardiomyopathy and with obesity and
type-2 diabetes, whereas its genetic deletion accelerates the transition
to HF following pressure overload hypertrophy [30,31]. HDAC9 is an in-
hibitor of pathological (but not physiological) cardiac hypertrophy and
Hdac9-deﬁcient mice exhibit stress-dependent cardiomegaly [32].
RRAD (Ras associated with diabetes GTPase) levels are decreased in
human failing hearts and in animal and cellular models of cardiac hy-
pertrophy, and RRad-deﬁcient mice are more susceptible to this condi-
tion [33]. RRAD appears to prevent CAMK-II-dependent hypertrophy,
to inhibit cardiac ﬁbrosis and to modulate beta-adrenergic mediated
contractility [33,34]. Phosphodiesterase 4B (PDE4B) is an important,
protective negative modulator of beta-adrenergic-mediated contractili-
tywith decreased levels in cardiac hypertrophy [35]. Thrombospondin 1
(Thbs1), a protein that modulates extracellular matrix metabolism and
ﬁbroblast phenotype, suggested to act as a protective signal in the
stressed heart [36] was also enhanced in GRK2+/− mice, as was the
anti-angiogenic homeobox geneMeox2 [37].
The third relevant pattern of differential expression detected in
GRK2+/− mice reﬂects changes in the expression of genes similar to
those taking place upon exercise and in situations of physiological
heart hypertrophy (Fig. 3b). These include the up-regulation of the
central protective factors Ppargc1b and Nr4a1 (see above); the early re-
sponse genes FosB and Apold 1, reported to be enhanced in cardiac tissue
upon acute physical activity [38] and the downregulation of the tran-
scription factor C/EBPbeta (Cebpb), a member of the bHLH family. Im-
portantly, the latter has been recently identiﬁed as a master regulator
of physiological cardiac hypertrophy [39,40]. The mRNA expression of
C/EBPbeta is reduced circa 60% (in the same range of our data) in
mouse hearts in an exercise model allowing expression of an adaptive
gene proﬁle related to physiological hypertrophy, and mice with
reduced cardiac levels of this protein displayed resistance to cardiac
failure upon pressure overload [39]. The expression proﬁle of several
of the key genes supporting these patterns was validated by qPCR
(Supplementary Fig. 2S).
In sum, themicroarray analysis detected in GRK2+/−mice hearts an
increased expression of a limited group of important genes related to
physiological hypertrophy while the expression of genes key to the de-
velopment of pathological hypertrophy or related to diabetes/obesity
co-morbidities is repressed.
3.4. Increased cardiac GRK2 expression in adult obese (ob/ob) mice and in
high fat diet-fed animals
Since GRK2 levels increase in muscle and adipose tissue under insu-
lin resistance-promoting conditions [2] we tested whether this process
was also taking place in cardiac tissue. A clear increase in GRK2 protein
levelswas observed in hearts of 8month-old ob/obmice (Fig. 4a), an age
inwhich this strain ofmice is known tomanifest cardiac hypertrophy, IR
andmetabolic alterations involving alterations in the PI3K/Akt axis [41].
This increase in total GRK2 protein levels caused an increment in the
amount of GRK2 that could be detected in association with IRS1
(Fig. 4b), a situation that we have previously described to negatively
modulate insulin signaling. GRK2 levels were also increased upon
feeding young animals a high fat diet (HFD, Fig. 4c), a well-established
trigger for systemic IR that can promote cardiac remodeling and dys-
function and known to disrupt the insulin-stimulated IRS1/PI3K/Akt
cascade [42]. This increase is similar to that observed in other insulin-
sensitive tissues [2], and also had as a consequence a larger amount of
formation of IRS1–GRK2 complexes (Fig. 4d). We investigated insulin
responses in cardiac tissue of WT and GRK2+/− HFD-fed animals.
Fig. 4e–f shows that sensitivity to insulin is compromised in WT hearts
after HFD feeding, while it is strongly preserved in GRK2+/− hearts, in
the absence of changes in insulin-induced ERK phosphorylation.
Together these results suggest that the increase in GRK2 protein levels
observed upon HFD feeding or genetically-induced obesity promotes
GRK2-dependent sequestration of IRS1 and provides a mechanistic ex-
planation for the IR state of cardiac tissue in both experimental
conditions.
4. Discussion
We have addressed herein the potential interconnections among an
IR status, GRK2 dosage and cardiac remodeling by investigating the im-
pact of GRK2 down-modulation on cardiac insulin sensitivity and gene
expression patterns, and the effects of systemic insulin resistance-
promoting conditions on cardiac GRK2 levels.
First, we ﬁnd that decreased GRK2 levels speciﬁcally preserve meta-
bolic and pro-survival signals downstream of insulin (such as the Akt/
p70S6K pathway and glucose transport) in the hearts of 9 month-old
GRK2+/− animals, whereas the ERK activation status is not affected.
Second, with age, GRK2 down-regulation triggers physiological heart
hypertrophy and switches on a cardioprotective gene expression pat-
tern as detected in such adult mice. This pattern is characterized by an
increased expression of a limited group of key genes related to physio-
logical hypertrophy, while the expression of genes reported to lead to
the development of pathological hypertrophy or related to diabetes/
obesity co-morbidities is repressed, compared to WT individuals.
Third, we uncover that cardiac GRK2 expression levels increase in situ-
ations of systemic insulin resistance, such as in obese mice or after HFD
feeding, conditions in which larger amounts of GRK2–IRS1 complexes
are formed. Fourth, while insulin resistance develops in the hearts of
wild-type mice after HFD feeding, sensitivity to insulin was strongly
preserved in GRK2+/− cardiac tissue.
We have previously reported that GRK2+/− mice are protected
against HFD-induced obesity and systemic IR, and we cannot rule out
that this global protectionmay contribute to the observed enhanced in-
sulin signaling in the heart upon a HFD. However, given the enhanced
interaction of GRK2 with IRS1 that we ﬁnd in cardiac tissue of different
obesemicemodels, our data point at an important role for this kinase in
negatively regulating insulin signaling in the heart, coherent with what
was previously published by Garcia-Guerra et al. [2] involving the
sequestration of IRS1 protein in GRK2 complexes thus impairing down-
stream signaling from the insulin receptor.
Previous reports have determined the importance of insulin
signaling in cardiac physiopathology [43]. In particular, results in
cardiomyocyte-speciﬁc deletion of the insulin receptor (CIRKO mice)
have revealed that insulin can control cardiac gene expression patterns
since loss of its receptor promotes a genomic reprogramming [44]. Insu-
lin signals also control the size of the heart and cardiomyocytes, and de-
letion of insulin receptor decreases cardiac size by 20–30% [45]. These
results are in agreement with the phenotype we ﬁnd in GRK2 hemizy-
gous mice in which the increased sensitivity for insulin signals results
in gene expression reprogramming and an increased cardiac size.
The fact that GRK2 downregulation potentiates the insulin-triggered
PI3K/Akt pathway in the adult mice heart is then consistent with the
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mild hypertrophic phenotype conferred by age to GRK2+/− animals
being physiological rather than pathological, This is in agreement with
the morphometric analysis and functional results, and with an overall
cardio-protective gene expression pattern (decreased presence of path-
ological genes, enhanced expression of critical protective genes) in the
heart of GRK2+/− 9 month-old mice. It is worth noting that GRK2+/−
animals displayed changes in the expression of several genes reported
to be similarly modulated by insulin in the heart or other tissues
(Nr4a1, Tcﬂ2, Rrad, Aqp7, Cebpb, Ppargc1b, Egr1), and a relevant propor-
tion of genes whose expression is altered in hemizygous animals can be
related to: i) the modulation of insulin sensitivity; ii) the PI3K/Akt
pathway; and iii) diabetes/obesity-related pathological situations.
Insulin activation of the PI3K/Akt cascade is protective in the heart
by inhibiting apoptosis and oxidative stress [46], whereas myocardial
IR has been suggested as a key factor in the development of HF [47,
48]. In this context, our results strongly suggest the novel concept that
cardiac GRK2 levels could act as an integrative sensor of different path-
ological inputs and affect cardiac function by simultaneously altering
beta-adrenergic and insulin signaling (see suggested model in Fig. 5).
Thus, the increase in cardiac GRK2 levels previously reported to take
place in myocardial infarction or hypertension as a consequence of
excessive neurohormonal stimulation [5,6], would also take place as a
consequence of insulin resistance-promoting conditions such as a HFD
or obesity, by mechanisms that remain to be investigated. Also,
enhanced cardiac GRK2 would promote, in addition to the canonical ef-
fects described for GPCR signaling, an insulin-resistant state of the heart
leading to alterations of key metabolic and cardioprotective pathways
[11], further fuelling a dysfunctional cycle and allowing progression to
maladaptive remodeling.
A detrimental vicious cycle has been postulated [48,49] in which the
compensatory hyper-adrenergic state characteristic of reduced cardiac
output would promote lipolysis in the adipose tissue. This would lead
to increased circulating levels of free fatty acids, which in turn would
inhibit cardiac glucose transport, switching energy substrate use and
triggering heart lipotoxicity. Conversely, many mechanisms have been
suggested to explain the increased incidence of HF in diabetic patients,
including hyperinsulinemia, hyperglycemia, lipotoxicity, obesity, vascu-
lar alterations, increased oxidative stress or hyperactivation of neurohu-
moral systems ([47,48,50] and the references therein). Our data suggest
that GRK2 could participate as an important integrative node in such
complex mechanisms linking HF, diabetes and IR.
Such central role of GRK2 also fosters its potential as a therapeutic
target and diagnostic marker. Our study suggests that strategies leading
to a systemic reduction in GRK2 levels/function, even when used in a
sustained temporal frame and in adult tissue, could facilitate the activa-
tion of deﬁned cardioprotective routes, such as the insulin pathway.
This would promote a physiological hypertrophy-like gene expression
pattern that could contribute to explain the beneﬁcial outcome of
GRK2 inhibition.
This discovery could help explain the reported reinforcement be-
tween the therapeutic effects of down-regulating cardiac adrenergic
input (using beta-blockers) and GRK2 down-modulation.
Fig. 4. Expression of the GRK2 protein is increased in myocardial tissue of obese or high fat diet-fed mice which correlates with higher levels of IRS1/GRK2 complexes, whereas GRK2+/−
animals are resistant to high fat diet-induced insulin resistance in cardiac tissue. a) The expression levels of GRK2were analyzed byWestern Blot in cardiac tissue of 8month-old ob/ob or
WTmice and quantiﬁed by densitometry analysis. Resultswere normalized byGAPDHprotein levels and expressed as percent over control (WTmice) (N=5). b) Total protein fromheart
tissue (500 μg)was immunoprecipitatedwith the anti-IRS1 or anti-IgG antibodies, and the resulting immune complexeswere analyzedbyWestern Blotwith the corresponding antibodies
against GRK2 and IRS1 (N= 3). Precipitated GRK2 amount was normalized with immunoprecipitated IRS1 amount. Same for 3 month-old HFD-fed mice represented over standard diet-fed
animals in (c) and (d) (N=9). Representative blots are shown. Data aremean± SEMof the indicated independent experiments. **p b 0.01; *p b 0.05. e) RepresentativeWestern Blots of the
speciﬁed phospho-proteins and controls in heart tissue after 12 weeks of HFD feeding or SD and 3 min insulin injection in WT or GRK2+/−mice. f) Quantiﬁcation of Akt phosphorylation
(Ser473), p70S6Kphosphorylation (Thr389) or ERK1/2 phosphorylation (Thr202/Tyr204) in cardiac tissue lysates ofWT andGRK2+/−mice after 12 weeks ofHFD feeding after an intravenous
injection of insulin for 3 min (N= 3–4). Results are expressed as fold increase over basal (untreated mice). Statistical analysis was performed using T-test. Data are mean± SEM of the indi-
cated independent experiments. +++p b 0.001;+p b 0.05 referred to basal (untreatedmice); **p b 0.01; *p b 0.05 referred to fold increase upon insulin stimulation over HFD fedWTmice.
2454 E. Lucas et al. / Biochimica et Biophysica Acta 1842 (2014) 2448–2456
Since our data and previous report by other laboratories [1,6,7] indi-
cate that reduced GRK2 revels are beneﬁcial for cardiac function and
also for maintaining vascular tone [4], and systemic insulin sensitivity
[2], it could be argued that GRK2 hemizygosity would confer an overall
beneﬁt. However, the fact that a GRK2+/+ genotype has been positively
selected for by evolution suggests that the expression level generated by
such genotypemust be overall adaptative. Nevertheless, unlimited food
availability, a condition that humans nowadays share with caged ani-
mals, was not at all present during evolution and therefore this might
explain why GRK2 downregulation was not selected for.
GRK2 inhibition has been shown, in mouse models, to delay the re-
duction in glucose uptake and preserve insulin signaling in the heart
after myocardial ischemia [11] and to prevent the development of sys-
temic IR [2]. It is also worth noting that, apart from its catalytic kinase
activity (target for potential GRK2 inhibitors), GRK2 plays an important
functional role via protein–protein interactions. Our gene expression
data cannot dissect which biological function of GRK2 needs to be re-
duced for therapeutic purposes, and it could well be possible that inhi-
bition of the enzymatic activity of GRK2 might not reproduce the
beneﬁcial effects observed upon its under-expression. Thus, a better
knowledge of means to reduce GRK2 levels in vivo, such as increasing
its degradation rate or decreasing transcription, should be built before
an effective GRK2 downmodulation therapy can be designed. Interest-
ingly, ventricular assist device implantation, known to downregulate
GRK2 levels [51], also reverses IR and normalizes cardiac metabolism
in patients with advanced HF [52]. This is consistent with a beneﬁcial
role for GRK2 inhibition in this context. Notably, the reduction in
GRK2 protein levels observed in lymphocytes of HF patients after an
exercise-training program can predict long-term survival [53]. On the
other hand, enhanced GRK2 levels in peripheral lymphocytes mimic
myocardial levels during hypertension, myocardial ischemia and heart
failure [6] and are also increased in patients with metabolic syndrome
[2]. Therefore, it will be interesting to explore the potential use of
GRK2 as a prognostic cardiovascular risk marker when co-morbidities
such as diabetes, IR and obesity are present.
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Supplemental Table 1S. Detailed list of genes showing differential expression 
between WT and GRK2+/- adult hearts. 
SUPPLEMENTAL TABLES AND FIGURES 
Genes whose expression varied with an FDR<0.2 and a Fold change >1.5 or <-1.5 are 
listed.  
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Supplemental Figure 1S 
 
 
 
Suppl. Fig.1S.- Glucose uptake and insulin signalling are upregulated in hearts 
from adult GRK2+/- mice without differences in pERK activation. a) Positron 
emission tomography (PET) analysis of insulin-dependent 18F-Fluoro deoxy-glucose 
uptake in the hearts of 9 month-old WT and GRK2+/- mice (N=3 per genotype). 
Quantification of IRS1 phosphorylation (Tyr896) (b) and ERK1/2 phosphorylation 
(Thr202/Tyr204) (c) in the cardiac tissue lysates of WT or GRK2+/- 9 month-old mice 
after an intravenous injection of insulin for 3 or 5 minutes (N=3-5). Results are 
expressed as fold increase over control (non-insulin treated mice). d) Representative 
Western Blots of the specified phospho-proteins and controls in heart tissue 3 or 5 min 
after insulin injection. Data are mean±SEM of the indicated independent experiments.  
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Supplemental Figure 2S 
 
Suppl. Fig.2S.- Validation by qRT-PCR analysis. A qRT-PCR analysis was performed 
for certain genes whose changes in expression are described to correlate with 
physiological or pathological cardiac hypertrophy or other cardiac responses important 
for cardiac physiopathology as discussed in the main text. * p<0.05, # 0.2>p>0.05. 
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INTRODUCTION TO ARTICLE #4
The fourth article presented is entitled Obesity-related cardiac hypertrophy is 
modulated by G protein-coupled receptor kinase 2. (In preparation for submission)
The main objective of this work was to determine whether low levels of GRK2 would 
protect from obesity-induced cardiac remodeling. For this purpose we fed mice with HFD 
for 33 weeks (animals were 10 month-old at the end of the study), followed by analysis 
of the cardiac tissue once long-term obesity has been established. We concluded that a 
partial deϐiciency of GRK2 promotes a leaner and insulin-sensitive systemic phenotype 
and preserves from cardiac ectopic fat accumulation and hypertrophy. 
This could be the ϐirst report indicating a protective role of GRK2 downmodulation in 
obesity-induced cardiac remodeling, what could be of great importance to the ϐield given 
the rising incidence of obesity in the population and its implications in cardiovascular 
diseases.
As ϐirst author of this manuscript I have been involved in all aspects of this work and 
have been the principal responsible researcher for all the experimental work and design. 
Obesity-related cardiac hypertrophy is modulated by 
G protein-coupled receptor kinase 2
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ABSTRACT
Obesity is a growing problem that has become a public health and clinical challenge 
worldwide. The “obesity epidemic” is principally driven by an imbalance between energy 
intake and energy expenditure. Although obesity is related to type 2 diabetes and certain 
types of cancer, the leading cause of death among the obese population is heart failure and 
stroke. Moreover, obesity is strongly associated with the development of major risk factors for 
cardiovascular disease such as hypertension, dyslipidemia and diabetes promoting structural 
and functional changes in the heart. The molecular mechanisms that underlie obesity-related 
cardiac remodeling are complex, and include hemodynamic and metabolic alterations that 
ultimately impact the myocardium. G protein-coupled receptor kinase 2 (GRK2) is a ubiquitous 
serine/threonine protein kinase able to phosphorylate and desensitize the active form of 
several G protein-coupled receptors (GPCR) and known to play an important role in cardiac 
GPCR modulation.  GRK2 has also been recently identifi ed as a negative modulator of insulin 
signaling and systemic insulin resistance. In this context, we investigated the effects elicited 
by GRK2 down-regulation in obesity-related cardiac remodeling using adult 10 month-old mice 
fed with a high fat diet (HFD) for 33 weeks. We fi nd that GRK2+/- mice, which display circa 
50% lower levels of this kinase, are protected from obesity-promoted cardiac hypertrophy, as 
assessed by using both molecular markers and morphometrical measurements of cardiac 
tissue and cells. These mice are also resistant to the excessive intracellular lipid accumulation 
in cardiomyocytes (cardiac steatosis) triggered by HFD in control littermates. Interestingly, HFD 
signifi cantly increased cardiac GRK2 levels in wild type but not in GRK2+/- mice, suggesting 
that the benefi cial phenotype observed in hemizygous animals correlates with keeping  GRK2 
levels below a pathological threshold. Our data open new avenues of research to further 
defi ne the cellular processes and molecular mechanisms by which GRK2 down-regulation is 
cardioprotective during diet-induced obesity 
INTRODUCTION
The dramatic increase in the incidence of obesity and its strong association with 
cardiovascular disease and overall mortality has resulted in an unprecedented interest in 
understanding the effects of obesity on the cardiovascular system Obesity, or “Globesity”, as 
it has been referred by the World Health Organization given the ever-increasing prevalence 
of obesity world-wide, is a complex condition that affects virtually all age and socioeconomic 
groups and threatens to overwhelm both developed and developing countries. It has been 
estimated that by 2015, approximately 2.3 billion adults will be overweight and more than 700 
million will be obese [1]
Although obesity is most commonly caused by a disruption in energy homeostasis due to 
the imbalance between dietary energy consumption (calorie-dense food and drinks) relative 
to energy expenditure (energy loss via metabolic and physical activity), the etiology of obesity 
is highly complex and includes genetic, physiologic, environmental, psychological, social 
and economic factors that interact in varying degrees to promote the increase in body fat 
mass and the development of obesity [2]. Besides an altered metabolic profi le, a variety of 
adaptations/alterations in cardiac structure and function occur in the individual as adipose 
tissue accumulates in excessive amounts, even in the absence of comorbidities such as type 
2 diabetes and hypertension [3]. For instance, the mass of the left ventricle has been shown to 
grow and correlate proportionally with body weight [4]. Finally, prolonged existence of obesity 
causes both left ventricular systolic and diastolic functions [5].
In humans, increased cardiac mass has been postulated to result from increased 
epicardial fat and fatty infi ltration of the myocardium [6]. Moreover triglyceride content in 
human myocardium was found signifi cantly increased in obese compared with normal-weight 
subjects [7]. Increased accumulation of intramyocellular triglycerides in the heart is also a 
commonly described feature of most animal models of obesity [8-10] and the accumulation of 
myocardial triglyceride and lipid metabolites such as ceramides has been found to be lipotoxic 
as it has been associated with cardiomyocyte apoptosis [11]. 
Another common feature in the obese heart is impaired insulin signaling. It starts to develop 
within two weeks of high fat diet (HFD) [12] and therefore represents an early adaptation 
of the heart to caloric excess that promotes the development of diabetic cardiomyopathy. 
This condition not only alters cardiac metabolism but also increases myocardial oxygen 
consumption, reduces cardiac effi ciency by uncoupling of the mitochondria and increases 
oxidative stress [13].
G protein-coupled receptor kinase 2 (GRK2)  is a serine/threonine kinase originally 
discovered to regulate G protein-coupled receptor (GPCR) desensitization and known to play 
an important role in cardiac function and dysfunction and to display increased levels in cardiac 
hypertrophy and heart failure. In addition, GRK2 is emerging as an important signaling hub 
with a complex interactome [14, 15], and has recently been identifi ed as a direct modulator 
of insulin signaling in several tissues, including the heart [16, 17]. Interestingly, GRK2+/- mice 
(expressing some 50% less protein than control littermates) show improved systemic insulin 
sensitivity in different mice models [17, 18]. On the other hand, we have recently described 
that GRK2 levels are increased in the hearts of adult ob/ob mice as well as in mice fed with 
a high-fat diet (HFD) for 12 weeks [17].  Given the emerging role of GRK2 as a regulatory 
hub in heart physiology we have explored the role of GRK2 dosage in the development of 
obesity-induced cardiac remodeling and steatosis in 10-month old mice, considering that is in 
adulthood when obesity-related cardiac pathological events become more apparent.
MATERIALS AND METHODS
Animals: Experiments were performed on male wild type (WT) and hemizygous-GRK2 
(GRK2+/-) mice maintained on the hybrid 129/SvJ C57BL/6 background. The animals were 
bred and housed on a 12-hour light/dark cycle with free access to food and water. GRK2+/- 
mice and their corresponding wild types (C57BL/6J, The Jackson Laboratory, Bar Harbor, 
ME, USA) were fed ad libitum since weaning either on a normal chow diet or standard diet 
(SD, providing 13% of total calories as fat, 67% as carbohydrate and 20% as protein; 2014S 
Rodent Maintenance Diet, Teklad, Harlan, Barcelona, Spain) or a high fat diet (HFD, providing 
45% of total calories as fat, 35% as carbohydrate and 20% as protein, Rodent Diet D12451, 
Research Diets, New Brunswick, NJ, USA) for 33 weeks. Animals were maintained at a 
room temperature of 22±2 ºC with a relative humidity of 50±10% and under pathogen-free 
conditions. Body weight and food intake were measured weekly. All animal experimentation 
procedures conformed to the European Guidelines for the Care and Use of Laboratory Animals 
(Directive 86/609) and approved by the Ethical Committees for Animal Experimentation of the 
Universidad Autónoma de Madrid.
Metabolic assays: Insulin tolerance test (ITT) was performed as previously described [19]. 
Animals were fasted for 4 hours (10:00–14:00), and baseline blood samples were collected 
from the tail of fully conscious mice. Insulin (0.8 U/kg body weight) was administered by i.p. 
injection, and blood samples were taken from the tail at 15, 30, 45, and 60 minutes after 
injection. Glucose concentration (mg/dl) was determined in tail blood samples using an 
automatic analyzer (One Touch Ultra), from Life Scan. 
Heart collection and processing: Mice were euthanized using CO2 and weighted. 
Hearts were surgically removed and immediately weighted. Auricles were removed and 
ventricles were sliced transversally in four portions. The two central slices were fi xed in 4% 
paraformaldehyde and embedded in paraffi n or Tissue-Tek® OCT for histological analysis. The 
other two portions were frozen in liquid nitrogen for protein and gene expression analysis.
Cardiomyocyte hypertrophy determination: Paraffi n blocks of heart slices were cut 6 μm 
thick and stained with Masson´s trichrome for the evaluation of cardiomyocytes area. For 
each experimental group, four sections were stained per animal. Digital images of those areas 
in the heart ventricle where cardiomyocytes were transversally cut were captured using a 
light microscope (Olympus, Germany) at 20X magnifi cation. For each condition four mice 
hearts were employed and three fi elds were analyzed per mouse. Individual cardiomyocyte 
areas within each fi eld were determined using image analysis software (ImageJ). Relative 
cardiomyocyte size was calculated by quantifi cation of 150-200 cells per fi eld.
Gene expression analysis: mRNA from heart tissue of at least 6 mice per condition was 
isolated as described in [17]. RT-PCRs were performed by the Genomic Facility at CBMSO 
using Light Cycler equipment (Roche, Indianapolis, IN, USA). Gene expression quantifi cations 
were performed using both commercial Taqman Gene Expression Assay probes (Applied 
Biosystems, Life Technologies, Grand Island, NY, USA) and self-designed probes purchased 
from Sigma labeled with Syber Green. qPCRs and statistical analysis of the data were 
performed by the Genomic Facility of our institute using GenEx software.
Western Blot analysis: Heart tissue was homogenized as described in [17]. Tyipically 40 
μg of total cardiac protein was resolved per lane on a 7.5% SDS-PAGE gel and transferred 
to a nitrocellulose membrane. Blots were probed with specifi c antibodies against GRK2 and 
nucleolin (Santa Cruz Biotechnology, Dallas, TX, USA).
Intracellular lipid droplet quantifi cation: OCT frozen blocks of heart tissue were cut in 6 
μm thick slices, mounted on 10% glycerol in PBS-DAPI (5 ng/μl) to visualize the nucleus, and 
stained with Oil red O as described (Koopman R et al, 2001). All sections were examined 
using a Fluorescence Resonance Energy Transfer (FRET) equipment coupled to an inverted 
Axiovert200 (Zeiss, Germany) microscope. Oil red O-stained sections were examined in 
epifl uorescence using a DsRed (500–650 nm) and DAPI (359-371 nm) excitation fi lter. Digital 
images of arbitrary fi elds were captured at 100x magnifi cation. For each condition three 
different hearts and 10 fi elds per mouse were analyzed. Total lipid droplet content per total 
cellular area was determined using image analysis software (ImageJ) which was also used for 
the characterization and quantifi cation of thresholded droplet areas within each fi eld.
Stadistical analysis: All data are expressed as mean values ± SEM and N represents 
the number of animals. Statistical signifi cance was analyzed by using unpaired Student’s t 
test or one-way ANOVA followed by Bonferroni’s post hoc test. Differences were considered 
statistically signifi cant when P value <0.05.
RESULTS
Decreased levels of GRK2 a? enuates the diet-induced obesity phenotype
Two months after birth mice were fed either a standard diet (SD) or high fat diet (HFD) 
for 33 weeks. Both genotypes signifi cantly gained weight after HFD feeding compared with 
SD-fed mice (Fig. S1), but GRK2+/- mice maintained a leaner phenotype compared with wild 
type (WT) in the absence of differences in food intake (Fig. 1a and b). Since systemic insulin 
resistance is a common comorbidity in obese individuals, we performed insulin tolerance 
tests (ITTs) in animals of each genotype. We observed that GRK2+/- adult mice were more 
sensitive to insulin than their WT littermates when fed a SD (Fig. 1c), in line with previously 
published results [18]. Interestingly, such enhanced insulin sensitivity detected upon GRK2 
downregulation was even more signifi cant after a long-term HFD feeding (Fig. 1d). Indeed, 
insulin tolerance in long-term HFD-fed GRK2+/- mice was comparable to that of SD-fed WT 
mice as refl ected by analyisis of the area under the curve (Fig. 1e). These results build on 
previous data from our laboratory that showed improved maintenance of body weight and 
insulin sensitivity in GRK2+/- mice after a 12-week HFD, indicating that these animals are 
able to preserve weight gain and maintain insulin sensitivity compared to WT littermates even 
after a long-term 30 week HFD feeding when they are already 10 month-old.
Lower levels of GRK2 protect hearts from high fat diet-induced hypertrophy
In a previous work [17] we reported that lower levels of GRK2 could protect the heart 
from 12 weeks HFD-induced insulin resistance. However, such short period of HFD feeding 
seemed not to be suffi cient for the development of cardiac hypertrophy in WT mice (Fig. S2). 
So, in order to determine if obesity-induced cardiac remodeling could be affected by GRK2 
dosage, we set out to study the heart morphometry in the longer-term model of 33 weeks on 
HFD. We fi rst observed that HFD feeding provoked cardiomegaly in WT animals while HFD-
fed GRK2+/- mice heart sizes were indistinguishable from those of SD-fed mice (Fig. 2a). 
Interestingly, a similar effect was also observed at a cellular level where a reduction in GRK2 
prevented the increase in cell size that was clearly observed in WT mice after 33 weeks of 
HFD (Fig. 2b), even considering that hemizygous animals display a mild, non-pathological 
cardiomyocyte hypertrophy in SD conditions, in agreement with previous reports [17]. In sum, 
decreased levels of GRK2 abrogate obesity-induced cardiomyocyte and heart hypertrophy 
after a long-term HFD feeding in adult 10 month-old mice.
Higher levels of GRK2 protein correlate with the expression of pathological hypertrophy-
related markers 
In consistency with previous results [17] we found that a 33-week long HFD induced a 
increase of cardiac GRK2 levels, but this increase was only signifi cant in WT mice, while 
GRK2+/- animals maintained lower levels of GRK2 after such long term HFD feeding (Fig 3a).
In order to characterize whether the obesity-induced cardiac hypertrophy that we detected 
was of a pathological nature, we quantifi ed the mRNA expression levels of several established 
markers of this condition such as α-skeletal actin (Acta1), a prototypical marker of cardiac 
hypertrophy, sarco/endoplasmic reticulum Ca2+ ATPase (SERCA2), a marker of cardiac 
Figure 1: GRK2+/- animals show an attenuated obese phenotype after long-term HFD feeding. (a) Comparison of body 
weight evolution and body weight gain (expressed in g) between WT and GRK2+/- after 30 weeks of HFD feeding. (b) Daily 
food intake (expressed in g) (N=7). (c-d) Intraperitoneal insulin tolerance tests (ITT) in SD- and HFD-fed mice and (e) histogram 
showing the product of ITTs area under the curve (AUC) (N=6-10). Data are means ± SEM of the indicated independent 
experiments. * P<0.05, **P<0.01, ***P<0.001.
functionality that is decreased in most cases of hypertrophied failing hearts, and B-type 
natriuretic peptide (BNP), a highly sensitive marker of cardiac pathology/stress. We included 
GRK2 mRNA in the analysis in order to study if the observed increase in GRK2 protein levels 
resulted from changes in the transcriptional control of this gene. The gene expression profi le 
for Acta1 precisely correlates with the degree of cardiomyocyte hypertrophy observed thus 
confi rming that HFD induced a marked cardiac hypertrophy in WT but not in GRK2+/- animals. 
We found no signifi cant changes in SERCA2 expression in either genotype of feeding regime, 
but there is a tendency towards an increased expression of SERCA2 in SD-fed GRK2+/- mice 
compared to SD-fed WT animals that would indicate an amelioration of cardiac functionality 
upon GRK2 downregulation in this model, what is in line with previously reported results [17, 
20]. Interestingly, GRK2+/- mice were also protected from the increase in BNP expression after 
long term HFD feeding. We detect no changes in GRK2 mRNA after HFD feeding (Fig. 3b) 
what suggests that the increase in cardiac GRK2 protein levels observed after HFD feeding 
probably responds to post-translational regulation. In sum, these data indicate that decreased 
GRK2 dosage would help to maintain a physiological gene expression profi le in conditions of 
long-term HFD feeding leading to the development of cardiac hypertrophy in WT animals.
GRK2+/- mice are protected from excessive intra-myocardial lipid accumula? on
One of the ultimate pathological features of hearts from obese individuals is the 
accumulation of lipid droplets in the cardiac cell that can promote lipotoxicity. Staining of fat 
depots with Oil red O (Fig. 4a) showed that the amount of intracellular lipid droplets was 
signifi cantly lower in either HFD- or SD-fed GRK2+/- mice hearts than in their littermate 
counterparts. Indeed, the amount of intracellular fat was almost the same for GRK2+/- mice 
after SD or after HFD, whereas it signifi cantly increased in WT cardiac cells after HFD feeding 
(Fig. 4b). Interestingly, the mean size of intracellular lipid depots was larger in HFD-fed WT 
cardiomyocytes than in any other condition (Fig. 4d). These results suggest that GRK2 
downregulation regulates cadiac lipid storage and prevents the pathological accumulation of 
lipid inside cardiac cells after a long-term HFD feeding.
Figure 2: Lower levels of GRK2 protect mice hearts from long-term (33 weeks) HFD-induced hypertrophy. (a) Heart 
weight to tibial length ratio in HFD-fed 10 month-old WT and GRK2+/- mice, compared with their littermates fed with standard 
diet (N= 9). (b)  Cardiomyocyte cross-sectional area from each genotype expressed in μm2 (N = 6). Representative images are 
shown in 20x magnifi cation. Scale bar, 50 μm. Data are means ± SEM of the indicated independent experiments. **P<0.01, 
***P<0.001.
Figure 3: Levels of GRK2 correlate with a 
hypertrophic marker profi le in long-term HFD-
fed animals. (a) GRK2 protein levels in cardiac 
tissue normalized by Nucleolin levels are expressed 
as fold-increase over SD-fed WT animals (N=3-
4). (b) Expression of several markers of heart 
hypertrophy (Acta1), cardiac functionality (Serca2) 
and cardiac stress (BNP) were quantifi ed by qPCR. 
GRK2 was used as internal control (N=6). Data 
are means ± SEM of the indicated independent 
experiments. * P<0.05, **P<0.01, ***P<0.001.
Figure 4: Intracellular lipid accumulation 
is enhanced in WT compared with 
GRK2+/- littermates after standard 
or long-term HFD feeding. (a) Frozen 
heart sections were stained with Oil red 
O and DAPI to visualize and quantify 
intracellular lipid droplets and nuclei, 
respectively. Lipid droplets in each 
condition are shown in black and white 
after image processing. Results are 
from at least 10 photomicrographs from 
each heart (magnifi cation 100x) (N=3). 
(b) Percentage of the area occupied 
by lipid droplets in cardiomyocytes 
for each condition. (c) Lipid droplet´s 
area were classifi ed according to their 
sizes as medium (0.5-1 μm2) or large 
(>1 μm2). Total area of lipid droplets 
of each size was normalized with total 
area of lipid droplets. Statistical analysis 
was performed using T-test. Data are 
mean±SEM of the indicated independent 
experiments. *p<0.05
DISCUSSION
In this work we present some preliminary lines of evidence that point to a protective role 
of lowering GRK2 levels upon obesity-induced cardiac remodeling. First, we fi nd that adult 
GRK2+/- mice gained less weight than WT littermates after a long period (33 weeks) of HFD 
feeding. We have previously described [17, 18] that GRK2+/- mice display protection against 
12 weeks of HFD-induced obesity. In the current model the mice have been fed for a longer 
time with HFD hence they reached adulthood (10 months-old) in such conditions, contrary 
to most of the studies where animals are fed with HFD for shorter time frames and thus 
analysis are performed when they are still young (typically 5-6 month old). We claim that our 
experimental approach would more reliably mimic the current profi le of human obesity whose 
incidence in middle-age adults is higher than in the young population, as is the presence of 
associated comorbidities as cardiovascular disease [21]. Second, after a long-lasting HFD 
feeding period, the insulin sensitivity observed in GRK2+/- mice remains comparable to that 
observed in aged-matched SD-fed WT animals, indicating that a lower GRK2 dosage protects 
against the diet-induced insulin resistance detected in WT. These results are consistent with 
a previous work where GRK2+/- and WT mice were fed with a HFD for a short period of time 
[18]. Our new data further indicate that GRK2+/- mice are protected against insulin resistance 
even upon the coexistence of other important intolerance-promoting factor such as age. In 
sum, we can now suggest that GRK2 is an important modulator of insulin tolerance even 
after a long-term HFD feeding, and also that lowering GRK2 levels is able to preserve insulin 
sensitivity even in the face of the co-occurrence of the two most important insulin resistance-
prompting conditions in humans, namely age and obesity.
We also put forward that GRK2+/- mice are protected against the pathological cardiac 
remodeling induced by obesity. These animals do not display cardiomegaly nor cardiomyocyte 
hypertrophy after long-term HFD feeding while both alterations are present in control WT 
mice. Obesity is characterized by an inappropriate expansion and dysfunction of the adipose 
tissue. Even in the absence of hypertension, adiposity induces structural and functional 
changes in the heart through hemodynamic (volume overload) and non-hemodynamic 
factors such as infl ammatory status, increased plasma glucose and insulin resistance, 
altered adipokine secretion pattern, increased levels of circulating free fatty acids, ectopic 
lipid deposition and lipotoxicity [22]. Independently of the specifi c role of GRK2 in cardiac 
metabolism and physiology, since decreased levels of GRK2 attenuate the “systemic” obese 
phenotype observed in WT, we cannot discard that the protection against obesity-induced 
cardiac remodeling observed in GRK2+/- mice could be promoted, at least in part, by the 
effect of GRK2 downregulation in other tissues helping to reduce adiposity and thus obesity. 
As a matter of fact, decreasing levels of GRK2 was shown to contribute to overall energy 
expenditure by the reduction of white adipose tissue lipogenesis and the improvement of 
thermogenic capacity of brown adipose tissue [23]. However, a benefi cial effect for GRK2 
downmodulation has been described in other types of cardiac hypertrophy, such as after 
thoracic aortic constriction, in genetically-based mice models of cardiac dysfunction and after 
myocardial infarction [24-26]. So, there are grounds to speculate that cardiac GRK2 could also 
be playing a direct role in modulating obesity-induced heart hypertrophy since the molecular 
mechanisms underlying cardiomyocyte cell growth in response to different pathological 
stimuli appear to have common features [27]. Consistent with this notion, we detect here an 
increase in cardiac GRK2 levels in WT (but not GRK2+/-) HFD-fed mice that correlates with 
enhanced cardiac hypertrophy. We can thus hypothesize that such increase in GRK2 amount 
is likely directly implicated in the cardiac remodeling observed (see below), as it was shown 
to be the case in cardiac hypertrophy of other etiologies [28], since GRK2 functionality has 
been implicated in cardiac tissue maintenance by different groups [29, 30] and its enhanced 
levels correlate well with different human and murine cardiac pathologies that implicate heart 
hypertrophy [26, 28, 31]. 
Notably, the HFD-induced increase in GRK2 levels in cardiac tissue appears to be an 
early event; in fact it was reported to be detected already after 12 weeks of HFD feeding in 
WT animals [17]. At this point insulin resistance is present, not only systemically [18] but also 
at a molecular level in the heart as determined after an acute intravenous insulin injection [17] 
but no hypertrophy is yet detected in terms of the heart weight/tibial length ratio. Interestingly, 
a similar phenotype has been reported by several studies using genetic animal models of 
obesity (db/db and ob/ob) in which insulin resistance is an early event associated to the onset 
of the obese phenotype that occurs later (5 to 10 weeks after weaning) while left ventricular 
hypertrophy is only detected in much older mice [32, 33]. The precise molecular mechanism 
underlying the HFD-promoted increase in cardiac GRK2 levels remain to be established, 
although in the absence of mRNA changes, it is tempting to suggest that insulin resistance 
may trigger mechanisms modulating kinase stability or degradation such as those already 
described to control the level of this kinase in other tissues and cells [34, 35].
Hence, we could hypothesize that in our model the increase in GRK2 levels may possibly 
result from the metabolic remodeling that is taking place in the heart. This alteration in 
GRK2 dosage would subsequently affect GPCR signaling pathways, such as β-adrenergic, 
contributing to disturb heart physiology and lead to cardiac remodeling. The increase in GRK2 
would also contribute to further impair cardiac insulin signaling and to switch cardiac catabolism 
towards the oxidation of lipids that are in excess because of the HFD. This could represent 
an initially adaptive mechanism which, after becoming chronic, results in maladaptation with 
detrimental consequences for the heart. In such scenario, GRK2 upregulation would be a 
relatively early event in the development of the metabolically-induced cardiomyopathy, as is 
the case for other cardiac conditions in which GRK2 levels increase in the fi rst stages of the 
heart disease (see references in [31]).
Previous data from our lab detected a shift in the global transcriptional profi le of the 
cardiac tissue promoted by GRK2 downregulation [17]. Several key genes related to cardiac 
functionality and pathophysiology were altered in GRK2+/- hearts even in the absence of a 
metabolic stress signal such as a HFD. In our current model we also detect some differential 
changes in the mRNA levels of several key markers of cardiac growth and functionality. An 
increase in BNP expression in the hearts of HFD-fed WT animals is not detected in GRK2+/- 
mice. Interestingly, BNP tends to be increased in hearts with depressed ventricular ejection 
performance or in overt heart failure, with or without hypertrophy (i.e., dilated cardiomyopathy). 
Likewise, increased α-Skeletal actin and decreased SERCA tend to be observed in hypertrophy 
models that progress to heart failure [36]. We detect here that HFD induced a marked increase 
in the mRNA for the Acta1 gene in WT animals, again not detected in GRK2+/- hearts. An 
increase in Acta1 transcription is however detected basally upon GRK2 downregulation, thus 
confi rming previous results in which a mild, non-pathological cardiac hypertrophy develops 
with age in GRK2+/- mice [17]. In sum, all these results suggest that the increase in cardiac 
hypertrophy markers observed after HFD in WT mice is absent or non-statistically signifi cant 
in GRK2+/- animals.
A last feature of HFD-induced cardiac remodeling is lipid accumulation in cardiomyocytes. 
Excessive lipid accumulation in the myocardium has been reported to positively correlate 
with the degree of obesity [37]. The increase in the percentage of fat from the diet promotes 
an excessive lipid exposure of the tissues that results in accumulation of triglycerides in the 
myocardium into cytoplasmatic lipid droplets. Inappropriate triglyceride deposition enlarges the 
intracellular pool of fatty acyl-CoA thereby providing substrate for oxidative and non-oxidative 
(for example ceramide synthesis) metabolic pathways leading to oxidative stress, cellular 
dysfunction and apoptosis [38]. However, such packaging of lipid excess into lipid droplets 
can be seen as an adaptive response to fulfi ll energy supply without hindering mitochondrial 
or cellular redox status while keeping low concentrations of lipotoxic intermediates [39]. We 
have observed that the amount of lipid droplets is larger in WT compared to GRK2+/- mice 
either after SD or HFD, so GRK2+/- mice hearts seem to be protected against excessive lipid 
accumulation. 
As GRK2+/- mice present a leaner phenotype, the dietary fat is not accumulating in 
adipose tissue and is probably metabolized more effi ciently than in WT mice. However, given 
the already mentioned role of GRK2 in fatty acid uptake and oxidation in white and brown 
adipose tissue [22], we cannot discard a similar direct effect of GRK2 dowmregulation in other 
organs such as the heart, where fatty acid oxidation is the main source of ATP. In fact, GRK2 
has been found to localize to mitochondria, whose function is critical in substrate oxidation. 
Some authors have described in fi broblast and endothelial cells that high levels of GRK2 
promote mitochondrial biogenesis and ATP production [40] while others reported that in 
cardiomyocytes, increased levels of GRK2 would lead to enhanced association to mitochondria 
causing increased Ca2+-induced opening of the mitochondrial permeability transition pore [30], 
a key step in cellular injury that abrogates ATP production. So, further studies are needed to 
evaluate the possible role of GRK2 in mitochondria in obese patients and its implication in 
cardiac metabolism. It is also worth noting that the amount of lipid droplets increases only in 
WT mice after HFD compared with their littermates fed with SD. Indeed HFD-fed WT mice 
showed the largest size of lipid depots. This event correlates with a worse phenotype in terms 
of left ventricular hypertrophy, so we would expect that the increased lipid sequestration is not 
only a marker but a mediator of lipotoxicity. In order to corroborate this hypothesis, it would be 
interesting to analyze the percentage of apoptosis and the redox status of cardiomyocytes in 
such conditions, a line of ongoing research in our group.
In summary, our results point to a protective role of lower levels of GRK2 upon obesity-
induced cardiac remodeling and steatosis.  The protection afforded by GRK2 downmodulation 
is apparent in the presence of concurrent relevant risk factors for insulin resistance and 
cardiovascular disease such as age and obesity, or after long-term HFD treatments. It 
is tempting to hypothesize that the increase in cardiac GRK2 protein levels triggered as a 
consequence of high-fat diet feeding or in different patophysiological situations, would play 
a central role allowing progression to maladaptive remodeling due to its unique ability to 
simultaneously alter cardiac β-adrenergic and  insulin signaling.
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SUPPLEMENTAL FIGURES
Figure S1: Weight gain induced by 33 weeks of HFD feeding in WT and GRK2+/- genotypes expressed as fold-increase 
over control SD-fed mice (N=5-7). Data are mean±SEM. ++p<0.01; +p<0.05 referred to SD-fed mice; *p<0.05 referred to fold 
increase between genotypes. 
Figure S2: Heart weight to tibial length ratio after 12 weeks in HFD-fed WT and GRK2+/- mice expressed as percent change 
towards WT littermates fed with standard diet (N= 6-7). Data are mean±SEM. *p<0.05
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As a main aim for this thesis we have tried to characterize the molecular and cellular 
mechanisms that underlie the impact of low GRK2 levels on key signaling pathways and 
phenotypic features on deϐined CVD pathological contexts such as vascular hypertension 
and obesity /insulin resistance (IR). Our results build on previous data describing the 
implication of GRK2 not only on the regulation of GPCR signaling, but also on non-
GPCR-dependent pathways important for CVS physiology. GRK2 has thereafter arisen 
as an integrative sensor that may link cardiovascular disease to at least some of its 
comorbidities.  Our data further indicate that lowering GRK2 levels help maintain some 
pathological features at bay and results protective for the CVS.
Along the next section we discuss the results describing the role of GRK2 on some 
of the signatures composing the cardiovascular disease continuum (CVDC), and on the 
impact of GRK2 levels in translating the inϐluence of deϐined risk factors, such as obesity 
or hypertension, on CVDC progression. 
1. GRK2 AND HYPERTENSION
Hypertension is a common condition that represents a well-known risk factor for the 
development of CVD. Increased peripheral vascular resistance to blood ϐlow and vascular 
remodeling are common features of hypertension. Vascular tone is mainly controlled by 
a balance between constriction and relaxation of vascular smooth muscle cells (VSMC), 
but the endothelium plays a pivotal role in this regulation, affecting vascular function and 
remodeling [36].
1.1 . GRK2 AND CELULLAR SIGNALING IN THE VASCULATURE
The physiology of both vascular cell types is ϐinely tuned by a wide range of 
neurohormonal agonists. Most of them transmit their signals via GPCRs, and therefore 
alterations in GRK2 levels can affect both vasodilator and vasoconstrictor outputs [223-
225]. Coherently, we have observed in aortas of GRK2+/- mice (article #1) that a partial 
deϐiciency of GRK2 enhances both acetylcholine and isoproterenol-induced relaxation, as 
well as phenylephrine-induced contraction. However, in our study, the increased sensitivity 
towards vasoconstrictor inputs upon GRK2 downregulation does not hold for all agonists. 
For instance, we do not observe differences in Ang II-induced contraction between 
GRK2+/- and WT mice aortas neither upon one acute dose nor after repeated exposure 
to Ang II. However, GRK2 has been described to help desensitize Ang II signals directly or 
indirectly in other systems [226-228]. Several aspects of GPCR pharmacodynamics could 
explain this apparent discrepancy. After discarding alterations in the expression of the 
Ang II receptors in aortic tissue (article #1), other parameters such as the concentration 
and timing of exposure to the agonist, the formation of receptor hybrids, the speciϐic 
intracellular signaling cascade activated, the relative afϐinity of GRK2 for different GPCRs 
or GRK2-independent desensitization mechanisms (see below) could be playing a role 
[229]. In any case, at least in our experimental conditions, the partial deϐiciency of GRK2 
is not enough to observe a direct effect on Ang II-induced contraction. However, and 
importantly, both chronic Ang II-induced increases in other contractile responses (such 
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as Phe-mediated constriction) or Ang II-triggered decreases in vasodilatory events (such 
as NO production) are prevented upon GRK2 downmodulation (see below). 
Noteworthy, Gα
s
-coupled GPCRs that mediate vasodilation are regulated by 
GRK2 solely via phosphorylation, whereas Gα
q/11
-coupled receptors that mediate 
vasoconstriction are regulated by GRK2 by both phosphorylation-dependent and 
-independent mechanisms since the GRK2 RGS homology domain promotes a Gα
q/11
-
selective uncoupling of the receptor [230]. Therefore, the possibility exists that Gα
s
-
coupled GPCRs may display a more general enhanced sensitivity to small increases in 
GRK2 expression than Gα
q/11
-coupled receptors what can contribute to the development 
of hypertension [224, 231, 232].  Interestingly, complete silencing of GRK2 expression in 
VSMC increases both vasoconstrictory and vasodilatory responses but those mediated by 
Gα
q/11
-coupled receptors to a greater extent [225]. 
In sum, in our study (article #1) the partial deϐiciency of GRK2 upregulates 
different types of GPCR-mediated vasodilatory stimuli under basal conditions, while 
vasoconstrictory signals are not homogenously affected.
1.2 . GRK2 MODULATION OF the Akt/eNOS AXIS
The main result of our study in article #1 is the characterization of the negative role 
of GRK2 in the regulation of the endothelial Akt/eNOS axis in an experimental animal 
model of primary hypertension. Whereas Akt activation is dramatically reduced in WT 
mice after a chronic Ang II infusion, lower levels of GRK2 preserve the phosphorylation 
of Akt, which in turn would activate eNOS, leading to higher levels of NO in GRK2+/- 
vessels (article #1). A negative role of GRK2 in endothelial NO production was previously 
described in portal hypertension, where a direct interaction between GRK2 and Akt was 
reported [204], and also in a type 2 diabetes model [215]. However neither the inϐluence 
of GRK2 levels in a “strong” model of systemic hypertension nor the effect of GRK2 on the 
Ang II-induced reduction in eNOS levels (article #1) had been previously reported. The 
mechanisms by which eNOS levels are preserved in GRK2+/- mice after a chronic Ang II 
insult opens an interesting ϐield of research.
eNOS levels have been shown to be regulated by transcriptional and post-
transcriptional mechanisms under different conditions [233, 234]. The RhoA/ROCK 
cascade downstream Gα
12/13
, and AT1R activation decreases eNOS expression through 
alteration in eNOS mRNA stability [235]. In fact, statins, which have been shown to 
increase eNOS mRNA stability and exert protective vascular effects beyond cholesterol 
reduction, inhibit RhoA geranylgeranylation and ROCK activity [236]. This mechanism 
could be responsible, at least in part, for the decrease in eNOS levels observed particularly 
in WT animals after Ang II infusion.
Alternative mechanisms modulating eNOS protein degradation may also be activated 
in our experimental model of hypertension. eNOS is a highly sensitive substrate of 
calpain, a ubiquitously expressed protease whose expression is induced by Ang II [238]. 
Following a brief exposure to Ca2+-loading, cytosolic eNOS interacts with the Hsp90 
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chaperone and recruits calpain forming a complex in which the synthase is almost 
completely resistant to digestion by the protease [239]. Since Hsp90 also interacts with 
GRK2 [240], one explanation for the preserved eNOS protein levels in GRK2+/- mice upon 
an Ang II challenge would be that in GRK2-hemizygous mice more Hsp90 protein could 
be available to bind eNOS, thus preventing eNOS from being degraded by calpain. Also, 
GIT1, a bona ?ide activator of NOS whose expression decreases during portal hypertension 
[241], is a GRK2-interacting protein. Therefore, in GRK2+/- endothelial cells, there might 
be increased activity of eNOS by increased binding to GIT, and also a better re-coupling 
of eNOS by a improved recruitment of activated Akt to the eNOS-Hsp90 complex [242]. 
Altogether, these effects would promote a partial preservation of eNOS levels, increased 
eNOS activation and enhanced NO bioavailability which could at least in part explain the 
protection against Ang II-induced vascular remodeling and hypertension observed in 
GRK2 hemizygous mice. 
It is worth noting that, in addition to the regulation that we describe in article #1, it 
was recently reported that GRK2 and eNOS inhibit each other in murine hearts. Whereas 
enhanced GRK2 levels downmodulated the Akt/eNOS axis promoting a decrease in 
NO production, eNOS could in turn contribute to inhibit GRK2 via S-nitrosylation 
[205]. We cannot exclude the possibility that this regulatory loop is taking place in our 
experimental setting and contributing to the observed phenotype. Although we have not 
explored the nitrosylation state of GRK2 in our model, it is tempting to suggest that in our 
system increased levels of GRK2, such as those detected in Ang-II-infused vessels, could 
be favoring a dysregulation of this GRK2-eNOS functional interaction (increased GRK2 
activity and/or decreased eNOS activity) decreasing NO bioavailability and fueling the 
progression of hypertension, whereas the partial deϐiciency of GRK2 would prevent such 
effects.
1.3. GRK2 IN VSMCs VERSUS ENDOTHELIUM
One of the clues for the protective role exerted by the partial deϐiciency of GRK2 
in the CVS is that hemizygosity somehow prevents the increase in GRK2 levels above a 
certain threshold that is observed after a pathological insult, in this case chronic Ang 
II infusion. In our study, the quantiϐication of GRK2 levels was performed in total cell 
lysates from aortic tissue, so we cannot elucidate if the marked increase of GRK2 levels 
observed in WT aortas (article #1), takes place in VSMCs, in endothelial cells or in both 
after Ang II infusion. It has been reported that GRK2 protein increases both in VSMCs 
[224, 225, 243] and in endothelial cells [204] during hypertension, so we would expect 
that the upregulation of GRK2 observed in our system occurs in both cell types, either 
simultaneously or as a sequential process. Thus, this pathological increase in GRK2 could 
affect different molecular mechanisms that should work together in the various cellular 
settings of the vascular system to keep blood pressure under control. In VSMCs increased 
levels of GRK2 would be altering GPCR signaling, preferentially downmodulating 
vasodilatory signals over constrictory ones [225, 232, 233](article #1). On the other hand, 
in endothelial cells increased GRK2 would affect not only GPCR signaling but also inhibit 
the Akt/eNOS axis, reducing NO bioavailability [204](article #1) required to depress 
agonist-induced vasoconstriction [244]. Such deleterious effects would be kept at bay 
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in GRK2 hemizygous animals. In addition, GRK2 has been described to modulate renal 
sodium transport through GPCR-dependent [245] and -independent mechanisms [246]. 
So GRK2 can act at different stages in the integrated system that regulates blood pressure 
and may exert its cardiovascular regulatory actions controlling different important 
signaling pathways in different cell types (Figure D1).
1.4. GRK2, ENDOTHELIAL DYSFUNCTION AND INSULIN RESISTANCE
Endothelial dysfunction is one manifestation of the many changes induced in the 
arterial wall by the metabolic abnormalities accompanying diabetes and insulin resistance 
Figure D1: Role of GRK2 in endothelial and VSMCs and impact in vascular function. Independently of the role 
of GRK2 in GPCR desensitization, GRK2 levels could modulate the Akt/eNOS axis at several levels including direct 
interactions with Hsp90 or Akt. Increased endothelial GRK2 levels upon Ang II infusion or other regulatory inputs 
would contribute as well to lower levels of eNOS, overall decreasing NO bioavailability. Higher GRK2 dosage would 
also promote insulin resistance and decreased signaling by the IRS1/PI3K/Akt axis. Upon chronic Ang II infusion, 
this fact could be aggravated by AT1R mediated tyrosine kinase receptor (TKR) transmodulation and enhanced 
ROS formation via NADPH oxidase, further unbalancing NO and ET-1 production and contributing to endothelial 
dysfunction. In VSMCs, decreased NO bioavailability, enhanced Ang II and ET-1 binding to their receptors, and 
impaired insulin sensitivity, would favor increased contraction, hypertension and vascular remodeling. These effects 
would be prevented in animals with lower levels of GRK2 (see text for detailed discussion).
 Cav, caveolin; CaM, calmodulin; MLC, myosin light chain; MLCP, MLC phosphatase; MLCK, MLC kinase. cGMP, 
guanylate cyclase. Red thick arrows reϐlect consequences of increased levels of GRK2.
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(IR). Under IR conditions, endothelium-dependent vasodilator function is compromised 
because of altered production of both vasodilator and vasoconstrictor substances, in 
particular decreased bioavailability of NO, decreased production of prostacyclin as well as 
increased production of thromboxane, other cyclooxygenase-dependent vasoconstrictors 
and endothelin [247]. 
Adult 9 month-old WT mice were described to exhibit higher blood glucose and 
insulin levels at baseline and also decreased systemic glucose and insulin tolerance 
than their GRK2+/- littermates [170]. This pre-diabetic state correlates with impaired 
insulin cascade activation in several tissues such as adipose tissue, liver, muscle [170] 
and heart (article #3). So it is tempting to assume that, in the adult WT mice used in 
our study, a certain degree of vascular IR exists that may contribute/predispose to the 
development of endothelial dysfunction. Endothelial IR selectively affects the PI3K/
Akt/eNOS axis downstream the insulin receptor [248] thus reducing the production 
of NO in favor of ET-1 and enhancing vasoconstriction. Therefore, GRK2+/- mice could 
be protected from hypertension, at least in part, because their increased sensitivity to 
insulin. Moreover, insulin can activate and upregulate eNOS gene expression [249] what 
correlates with the tendency of eNOS levels to be higher in GRK2+/- than in WT adult 
mice in the absence of Ang II (article #1). In addition, this mechanism could contribute to 
the increased preservation of eNOS levels in GRK2+/- aortas after Ang II infusion (article 
#1). In conclusion, GRK2 may exert its cardio-regulatory actions as a nodal point linking 
different signaling pathways that connect cardiovascular physiology and metabolism, 
with insulin signaling regulation playing a central role (Figure D1).
2.   GRK2 AND CARDIAC INSULIN SIGNALING
Cardiac IR is a metabolic and functional disorder with clear detrimental effects for 
the heart´s physiology. Major factors contributing to the development of cardiac IR are 
oxidative stress, hyperglycemia, hyperlipidemia, dysregulated secretion of adipokines/
cytokines and inappropriate activation of renin-angiotensin II-aldosterone system (RAAS) 
and the sympathetic nervous system [250]. Some of these features are representative of 
aging and overnutrition, situations where we have described that lower levels of GRK2 
prevent the development cardiac IR (article #3). 
2.1. GRK2 AS A NEGATIVE MODULATOR OF CARDIAC INSULIN SIGNALING
A relevant contribution of our work is that GRK2, previously reported to negatively 
regulate the insulin receptor cascade in different tissues such as liver, adipose and muscle 
(reviewed in article #2) is also an important modulator of insulin-mediated signaling in 
cardiac tissue (article #3). 
2.1.1. AGE-INDUCED INSULIN RESISTANCE
Insulin signaling in the heart is essential for growth and development, and for 
normal homeostasis of glucose, fat, and protein metabolism, so it is tightly regulated by 
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a complex network of phosphorylation/dephosphorylation mechanisms, and by negative 
feedback loops [251]. In other tissues [170], there is a certain impairment in the insulin 
cascade activation in adult WT animals, while insulin signaling is completely preserved 
in GRK2+/- mice. In article #3 we report signiϐicant differences upon acute insulin 
stimulation in adult 9 month-old mice GRK2+/- hearts compared to their WT littermates. 
The rapid insulin cascade activation is enhanced in adult GRK2+/- mice and also quickly 
shuts down as can be observed when comparing 3 and 5 minutes of stimulation (article 
#3). Interestingly, an effective downmodulation of insulin signaling after the activation of 
the cascade is critical to preserve the cardioprotective role of insulin. Indeed, excessive 
insulin signaling due to alterations in its regulatory mechanisms of control, as happens 
during hyperinsulinemia, is detrimental for the cardiac tissue. The chronic activation of 
the cascade can promote, among other effects, a pathological hypertrophic response and 
systolic dysfunction [252]. So, the lack of a basal chronic activation of the insulin cascade 
in GRK2 hemizygous animals, together with an enhanced acute signaling and normal 
shutdown, could serve to preserve the beneϐicial effects of insulin signaling in the absence 
of the detrimental cardiac consequences of sustained insulin cascade activation.
Notably, the increased sensitivity to insulin observed in cardiac tissue of GRK2+/- 
mice selectively affects the PI3K/Akt axis, since no changes in the activation of the MAPK 
axis were observed in the heart compared to WT mice (article #3). This correlates with 
what was described in vessels [248], so we predict that GRK2 modulation could have 
as a consequence a “biased” insulin resistance in several important tissues of the CVS. 
This “biased IR” imposed by altered GRK2 levels  would be characterized by an speciϐic 
downregulation of the IRS1/PI3K/Akt branch downstream the insulin pathway upon 
enhanced GRK2 expression in pathological settings, whereas it would be key to explain 
the cardioprotective role exerted by a partial deϐiciency of GRK2 (Figure D2, see below).
2.1.2. DIET-INDUCED INSULIN RESISTANCE. THE ROLE OF GRK2-IRS1 COMPLEXES
Not only age-induced IR but also diet-induced IR is avoided in GRK2+/- cardiac 
tissue. We observed that 12 weeks of HFD are enough to promote cardiac IR in young WT 
4 month-old mice, while insulin signaling sensitivity was completely preserved in GRK2 
hemizygous mice (article #3). Most interestingly, we found increased GRK2 levels in the 
hearts of mice fed with HFD and in adult ob/ob cardiac tissue in both animal models of IR. 
Our study has been the ϐirst to unveil the role of GRK2 in diet-induced IR in cardiac tissue.
We ϐind that in these models, increased levels of GRK2 correlate with higher amounts 
of IRS co-immunoprecipitated with GRK2 (article #3), as so happens in other cell types 
(discussed in articles #2 and #3). This is consistent with GRK2 being an important 
negative modulator of insulin signaling that could serve to link cardiac metabolism 
and functionality. Nevertheless, there are some aspects of the molecular mechanisms 
underlying the formation of GRK2-IRS1 complexes and their functional consequences 
that are still unsolved.
It has been described that GRK2-IRS1 complex formation promotes IRS1 
phosphorylation in Serine 307 by GRK2 ([253]; article #2 and references herein). Such 
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phosphorylation event has been reported to disrupt IRS1 binding to the insulin receptor 
and to promote IRS1 proteasomal degradation [254] under different IR conditions. 
However, we were unable to detect neither IRS1 phosphorylation in Ser307 nor changes 
in the total levels of IRS1 in our animal model. So, we postulate that IRS1 sequestration 
by GRK2 would be sufϐicient to impair signaling by hindering PI3K/Akt axis activation. 
However, it is important to highlight that, although the negative modulation of insulin 
signaling by GRK2 seems to be a general event that takes place in several cell types, the 
molecular mechanisms participating in each speciϐic tissue (IRS1 phosphorylation in 
Serine 307; formation of the GRK2/IRS1 complex) may vary depending on the cellular 
context. 
Figure D2: Effects of modulating GRK2 levels in age and long-term HFD feeding-related cardiac phenotypes. 
Adult WT mice display cardiac insulin resistance what may promote, together with other age-related alterations, 
changes in the gene expression proϐile related to pathological remodeling and diabetes, whereas a partial deϐiciency 
of GRK2 (GRK2+/- mice) protects from age-related alterations such as insulin resistance. The cardioprotective role 
of lowering GRK2 translates into the upregulation of genes more related to physiological hypertrophy and response 
to exercise, and, at a macromolecular level, into mild cardiac hypertrophy that seems to be physiological. On the 
other hand, a HFD-induced increase in GRK2 levels aggravates insulin resistance by the formation of GRK2-IRS1 
complexes and may alter mitochondrial function leading to increased ROS production, decreased ATP production 
and accumulation of intracellular fat from the diet. Altogether these features of lipotoxicity would promote cardiac 
dysfunction and pathological hypertrophy. In GRK2+/- hearts, GRK2 levels do not increase above the pathological 
threshold, so they are protected against the deleterious effects of HFD in cardiomyocytes (see text for detailed 
discussion). 
InsR, Insulin receptor; FFA, free fatty acids. Black arrows reϐlect activated pathways whereas grey arrows mean 
downmodulated pathways. Dotted arrows reϐlect impaired process and red lines, inhibition. 
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2.2. GRK2 DOWNMODULATION, AGING AND GENE REPROGRAMMING
Apart from the evident preservation of insulin sensitivity observed in GRK2 
hemizygous mice hearts, these animals also show increased induction of genes that 
exert cardioprotective actions while the expression of genes related to pathological 
heart hypertrophy were constitutively repressed (article #3). Notably, such differences 
were only observed in adult GRK2+/- mice, and not in younger animals (4 months old) 
suggesting that the effects of GRK2 dosage on cardiac gene expression become apparent 
only in the face of age-related changes. In fact, there are several examples of genes typically 
upregulated with age such as Timp4 [255] or Nppa [256] that are downregulated in adult 
GRK2 hemizygous mice.
Several signaling pathways have been shown to be involved in cardiac aging such 
as the insulin/IGF/PI3K and the renin-angiotensin II systems [257]. As described in 
article #3, the preserved cardiac insulin sensitivity in GRK2+/- mice could explain the 
upregulation of several genes reportedly modulated by insulin observed in this genotype 
(Nr4a1, Tcϐl2, Rrad, Aqp7, Cebpb, Ppargc1b, Egr1). On the other hand, genes found to be 
downregulated in GRK2+/- mice are upregulated in cardiac tissue by prorenin (Ptgds) or 
Ang II (Nppa and Zbtb16) [258, 259]. 
It is also worth mentioning here that the age-induced changes in gene expression 
controlled by the insulin and the angiotensin pathways are further related to cardiac 
remodeling and hypertrophy of a pathological kind [257]. On the contrary, the gene 
expression proϐile of GRK2 hemizygous is of a cardioprotective nature, what could be 
due, at least in part, to the preserved insulin sensitivity (article #3) and the increased NO 
bioavailability (article #1), both well-established cardioprotective systems (Figure D2).
3. GRK2 AND OBESITY?INDUCED CARDIAC REMODELING
To deepen on the cardioprotective role of GRK2, we performed a study to evaluate 
if lower levels of GRK2 could protect the heart against HFD-induced maladaptive 
remodeling of the cardiac tissue (article #4). This approach allows us to determine if 
the mild hypertrophy observed with age in adult GRK2+/- mice (article #3) predisposes 
the heart to maladaptive remodeling upon a pathological insult such as HFD, or, on the 
contrary, if it can help prevent or decrease pathological cardiac remodeling.
3.1. GRK2, OBESITY AND LIPOTOXICITY
One of the clues to discuss the results of article #4 is to determine the inϐluence of 
GRK2 in the modulation of systemic processes vs the control of cardiac-speciϐic ones. 
GRK2+/- mice seem to be protected against diet-induced obesity as shown by the 
ameliorated diet-induced body weight gain and the preserved systemic insulin tolerance 
(article #4). However, we observed that although the weight of epididymal white adipose 
tissue (WAT) increases in both genotypes after a long term HFD, there are no differences 
in WAT weight between WT and GRK2+/- mice (data not shown) as opposed to what 
we ϐind after a short-term HFD feeding. One plausible explanation for the differences 
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in body weight and insulin sensitivity we observe between genotypes could be that fat 
accumulation and lipotoxicity are taking place ectopically in WT mice, thus contributing 
to the increase in overall body weight and to peripheral IR independently of changes in 
adipose tissue. In this case, GRK2+/- mice may, by some mechanism, be accumulating less 
ectopic fat thus resulting in a protection against these pathological events. In line with 
this hypothesis, we observe an increased amount of intracellular lipid droplets in cardiac 
tissue (article #4) and increased liver weight in WT HFD-fed mice that could be due to 
liver steatosis (data not shown). Fat accumulation in heart and liver weight after a HFD 
was less pronounced in GRK2+/- mice. Although there are no reports to our knowledge 
describing a role for GRK2 in ectopic fat accumulation, we believe our results suggest 
there is a direct or indirect implication of GRK2 in this process. For instance, the decreased 
amount of intracellular lipid droplets observed in GRK2+/- cardiomyocytes, either after 
HFD or SD, could indicate that FFAs are not entering the cell in excess or are being more 
efϐiciently metabolized. It will be thus interesting to study the levels and dynamics of 
CD36, the main fatty acid transporter, and of lipoprotein lipase, required for the uptake 
of FFAs from lipoprotein triglycerides [260] in such conditions. However, if the uptake of 
FFA from the blood ϐlow is limited in GRK2+/- mice, the excess FFA from the HFD must 
be undergoing a different fate. As discussed in article #4, one possible explanation would 
be that the excess FFA are being oxidized in the brown adipose tissue by means of the 
better thermogenic capacity found in adult GRK2 hemizygous mice [169]. Interestingly, 
the possibility exists that this relationship between the improved oxidative phenotype 
and lower levels of GRK2 described for adipose tissue could be extrapolated to peripheral 
tissues such as muscle, liver, or heart. If this is the case, lowering GRK2 could result 
beneϐicial to avoid ectopic fat accumulation and lipotoxicity. This possibility is currently 
being investigated in our laboratory.
3.2. GRK2 AND MITOCHONDRIA
A key determinant of metabolic efϐiciency is an improved mitochondrial function. 
As mentioned above, several data suggest that GRK2 dosage could be playing a role on 
the control of mitochondrial fatty acid oxidation (FAO) either in an indirect or in a direct 
manner. As an example of the former, the increased NO bioavailability described in article 
#1 for GRK2+/- adult mice could be linked to increased mitochondrial biogenesis and 
enhanced coupled respiration and ATP production [261] (see below). 
In addition, a direct effect of GRK2 on mitochondrial function could also be envisaged. 
The mitochondrial localization of a population of GRK2 has been described [151, 152] 
that suggests a potential role for GRK2 in the regulation of energy metabolism. However, 
to date there are only a few and apparently contradictory reports on the role of GRK2 in 
mitochondria. It seems clear that GRK2 can be found inside the mitochondria in resting 
conditions [151, 152] and that GRK2 increases its mitochondrial localization upon 
stressful stimuli such as inϐlammation or ischemia/reperfusion [152, 262, 263] in different 
cell types. Nevertheless, the role that GRK2 exerts in mitochondria is more controversial. 
While some authors described that GRK2 enhances mitochondrial biogenesis thus 
leading to an increase in cellular ATP content [151], others suggest that increased GRK2 
promotes mitochondrial-based apoptosis [152]. Further study is required to determine if 
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in our model (upon the stress of a fatty diet) GRK2 is detrimental or advantageous, and 
the precise role that GRK2 could play on the regulation of metabolic plasticity and, in 
particular, on the control of mitochondrial fatty acid oxidation (FAO).
The most plausible hypothesis in our model would be that cardiac IR (article #3) in the 
face of hyperinsulinemic conditions (characteristic of overt T2DM) would be promoting 
an increased ERK activation that would lead to GRK2 phosphorylation on Ser670 in WT 
mice. Phosphorylated GRK2 would then interact with Hsp90 and together translocate 
into the mitochondria where GRK2 would promote an increased Ca2+-induced opening of 
the mitochondrial permeability transition pore [264]. This would in turn result in proton 
‘‘leak’’ and dissipation of the membrane potential. Such dysfunctional mitochondria 
would not be able to sustain enough levels of FAO to consume the excess FFA incoming 
from the diet hence precipitating the accumulation of FFA in intracellular lipid droplets. 
Hemizygous mice, on the contrary, do not present hyperinsulinemia, and GRK2 would 
neither be phosphorylated by ERK nor translocated inside mitochondria. Mitochondrial 
function would be preserved and FAO would be active enough to burn the excess fat thus 
preventing FFA accumulation in lipid droplets.
However, the hypothesis of a positive role of GRK2 on mitochondrial biogenesis and 
function would also ϐit with our results since, as part of an adaptive mechanism, GRK2 
could translocate to the mitochondria to promote an enhanced FAO, in an attempt to 
accommodate the excess of incoming fat. Similar to other adaptive mechanisms, the 
effect could be helpful at the very beginning, but, eventually, become detrimental for 
the physiology of the cell when the stimulus that promoted it becomes chronic. An 
exacerbated increase in the rate of FAO could eventually lead to its own downregulation 
due the increase in myocardial oxygen consumption, the uncoupling of the mitochondria 
and/or an enhanced production of ROS [31]. 
In sum, decreased levels of GRK2 may protect from lipotoxicity and preserve an 
insulin-sensitive state that prevents both the metabolic-induced perturbations and the 
pathological hypertrophy caused in cardiac tissue by a high fat diet feeding (article #4 
and Figure D2).
3.3 . ANTIOBESOGENIC ROLE OF NO
In animals, energy metabolism is regulated both at a cellular and a systemic level 
involving inter-organ cooperation. This is particularly important for the function of 
physiological levels of NO that stimulate blood ϐlow, thereby increasing the supply of fatty 
acids, glucose, and oxygen to tissues and, therefore, the mitochondrial oxidation of these 
substrates [265]. 
It is estimated that physiological levels of NO stimulate glucose uptake and 
oxidation by 25–40%, as well as fatty acid uptake and oxidation by 30–40% in insulin-
sensitive tissues (muscle, heart, liver, and adipose tissue) [266, 267]. The underlying 
mechanisms may involve multiple cGMP-dependent pathways in insulin target tissues 
[265]. First, NO stimulates the phosphorylation of AMPK [268] what results in increased 
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transport of glucose, better import of long-chain fatty acid transport from the cytosol 
into the mitochondrion and decreased expression of genes related to lipogenesis 
and gluconeogenesis [269]. Second, NO increases the phosphorylation of hormone-
sensitive lipase (HSL) and perilipins via activation of cGMP-dependent protein kinase 
(PKG). When both HSL and perilipins are phosphorylated, HSL interacts with perilipins 
and this association triggers the translocation of HSL from the cytosolic compartment 
to the surface of lipid droplets. This initiates lipolysis thus precluding cardiac steatosis 
[270-272]. Third, NO activates expression of PGC-1α, which is a key regulator of 
oxidative phosphorylation in mitochondria [273]. Long-term effects of physiological NO 
levels include beneϐicial increases in mitochondrial biogenesis (de novo formation of 
metabolically active mitochondria) [274].
All these mechanisms may help explain the phenotype observed in GRK2+/- mice 
after a HFD. Given that GRK2+/- exhibit higher NO bioavailability either under basal 
or after pathological conditions (Ang II infusion-induced hypertension, article #1), it is 
plausible that NO actions on cardiac mitochondrial metabolism can participate in the 
protection against diet-induced obesity observed in GRK2 hemizygous mice.
4. PATHOLOGICAL CHANGES IN GRK2 LEVELS: FUNCTIONAL IMPACT 
AND MECHANISMS INVOLVED
Emerging evidence indicate than an increase in the levels of catecholamines [275] and/
or angiotensin (article #1) and/or dietary fat (article #3 and #4), results in upregulated 
GRK2 levels what may help fuel additional maladaptive mechanisms. Our data suggest 
that cardiac or vascular GRK2 levels could act as an integrative sensor of a variety of 
pathological inputs in the CVS and serve as a point of convergence of different noxious 
stimuli such as a deregulated GPCR or insulin cascades. If the levels of GRK2 increase 
in the heart, and this increase is persistent in time, the sustained β-AR desensitization 
would fuel a detrimental cycle where the adrenal glands will try to compensate the lower 
β-adrenergic output by increasing catecholamine secretion. This in turn will further 
upregulate GRK2 levels in the cardiac tissue [276], thus triggering an impairment of 
cardiac insulin signaling and causing a metabolic shift towards fatty acid uptake and 
oxidation (discussed in article #3) further hampering insulin signaling. Together, these 
events would eventually bring about maladaptive changes in global gene expression 
patterns. Thus, altered GRK2 levels may trigger a “downhill from here” event as it fuels 
several detrimental cycles that inexorably lead to maladaptive cardiac remodeling and 
heart failure. In this context, the alteration of GRK2 levels induced by dietary fat would be 
part of the metabolic remodeling of the heart, an early event that initially may be adaptive, 
but that, when it becomes chronic, irreversibly unbalances the homeostasis of the cardiac 
system. Overall, our data put forward GRK2 as a new molecular link among aging, insulin 
resistance/obesity and cardiovascular co-morbidities.
An important question that remains unsolved is what is/are the molecular 
mechanism(s) that promote(s) the increase in GRK2 levels observed in our animal models 
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of hypertension and obesity, and also whether this increase is a cause or a consequence of 
the pathology.
Although not analyzed in the Ang II model of hypertension, no changes in GRK2 
transcription after HFD were detected in the diet-induced obesity model (article #4) 
suggesting that, as so happens in other animal models of pathology (reviewed in [199]) 
alterations in GRK2 levels are governed by post-transcriptional mechanisms. One such 
mechanism may implicate Hsp90. Hsp90 was described to protect GRK2 from degradation 
thus promoting its accumulation [240]. However the precise events triggering GRK2/
Hsp90 interaction are unknown. In addition, Hsp90 stabilization is complex including 
post-translational controls [277]. Moreover, to our knowledge, there are no evidences 
of alterations in Hsp90 levels under pathological conditions such as hypertension and 
obesity, and an upregulation of Hsp90 has been described in the hearts of type I diabetic 
rats [278, 279]. Therefore, the implication of the Hsp90 chaperone in GRK2 upregulation 
upon pathological insults remains a subject for future investigation. 
Other possible explanation of increased GRK2 levels is an impaired degradation 
by a decreased interaction with Mdm2. Mdm2 is an E3 ubiquitin ligase implicated in 
protein degradation by the proteasome. It has been described that, in a tumoral context, 
Akt activation downstream IGF-I receptor blocks Mdm2-dependent GRK2 degradation 
through the phosphorylation of Mdm2 [190]. However, we believe this mechanism 
is not taking place in our models for two reasons: i) Akt activation is decreased by the 
establishment of an insulin-resistant state, and ii) active Akt would correlate with 
lower levels, and not with an upregulation, of GRK2. In any case, we cannot discard the 
possibility that alterations of the Mdm2/GRK2 interaction could be playing a role in the 
ϐinal steady-state levels of GRK2 observed under diseased conditions. 
On the other hand, GRK2 downmodulation also occurs in several pathological 
and, mostly, physiological conditions. Several studies have demonstrated that chronic 
exercise promotes a decrease of GRK2 levels/activity in the CVS [280] that could exert 
a protective role against CVD. Moreover, exercise improves vascular insulin sensitivity 
in spontaneously hypertensive rats via downregulation of vascular GRK2, what may 
help limit the progression of hypertension [281], suggesting that at least part of the 
cardioprotection achieved through exercise could be related to GRK2 downregulation. A 
similar effect was described in a left ventricular assisted device study in humans where 
the decrease in GRK2 paralleled the amelioration of heart failure [282]. Interestingly, 
irisin, a myokine secreted by the muscle upon exercise, partially prevents obesity and 
T2D, an effect that mirrors that of reduced GRK2 levels [283]. It would be thus of interest 
to explore whether irisin or other myokines released from the muscle upon exercise could 
somehow regulate GRK2 levels what remains a subject for future research.
In sum, it appears that GRK2 levels are increased or reduced in response to the 
worsening or amelioration of different pathologies, and therefore they can potentially 
act as an intracellular sensor of the adaptive or maladaptive responses of the cell to 
various detrimental insults. However it is hard to determine if higher GRK2 levels are 
the cause or the consequence of a pathological insult. Changes in the levels of GRK2 over 
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a physiological threshold appear to fuel detrimental loops where pathology worsens in 
parallel to GRK2 upregulation. So, the possibility exists that GRK2 increases could be at 
the same time one of the causes and also one of the consequences of a given pathology 
depending on the degree of development and the stage of the disease.
5. PHYSIOLOGICAL IMPLICATIONS OF LOWERING GRK2 LEVELS AND 
THERAPEUTIC OPPORTUNITIES
GRK2 is an important modulator of cellular signaling in different cell types and under 
various cellular contexts. Our studies have contributed to build a new concept about 
the role of GRK2 in the cell: that of a “stress-sensing” protein acutely upregulated or 
mobilized by pathological insults such as chronic Ang II infusion (article #1) or excessive 
fat from the diet (article #3 and #4). We have also shown that GRK2 dosage promotes 
gene reprogramming with age that may have consequences at a tissue level (article #3). 
GRK2 is very important for physiology, and, indeed, gene ablation of GRK2 is 
embryonic lethal [159]. As mentioned above, its levels decrease with exercise [280], and 
this seems to be beneϐicial, but if they are completely deleted in the CVS, a GRK2 reduction 
becomes deleterious for the vessels [224, 226], although this is not the case for cardiac 
tissue [166]. In fact, when cardiomyocyte GRK2 expression was ablated after myocardial 
infarction, cardiac remodeling and function is partially preserved although the unharmed 
phenotype is not completely rescued [166]. Of note, this study was performed in young 
animals, but the effects of deleting GRK2 in adult animals where pathways such as 
β-AR, Ang II or even insulin are already altered may have effects in the heart that have 
not been explored. On the other hand, an increase in GRK2 levels also results damaging 
for the CVS as has been extensively demonstrated ([284]; article #1, #3 and #4). So, a 
physiological window may exist for GRK2 levels where an upregulation over basal may 
result pathological but where controlled downregulations inside a physiological range 
may be beneϐicial. Thus, there might be a pathological threshold beyond which a further 
elevation in GRK2 levels could initiate its contribution to disease development or to the 
aggravation of the pathology.
For all these reasons, the therapeutic opportunities of decreasing GRK2 activity/
levels can become certainly appealing. Several groups are trying to develop inhibitors 
of GRK2 kinase activity, as described in the Introduction, and although to date there are 
no selective small molecule inhibitors with proper pharmacological properties, it seems 
that the development of a good pharmacological inhibitor of GRK2 kinase activity is 
closer every day. However, GRK2 also elicits kinase-independent actions as a scaffold or 
as a signaling hub that would be very difϐicult to abrogate or control by small molecule-
based approaches. In those pathologies where GRK2 functions are more related to its 
scaffolding abilities or to its interacting partners, strategies aimed at decreasing GRK2 
levels by different means such as exercise, increased degradation or downregulation via 
neuro-hormonal approaches could constitute a better alternative.
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Other aspect that is important from a therapeutic point of view is whether lowering 
GRK2 activity and/or levels would rescue an individual from an already established 
pathological phenotype. As mentioned in the Introduction, the CVDC starts as a 
remodeling processes of the myocardium and vasculature in response to a range of 
potentially noxious stimuli but, when these changes persist, it progresses to structural 
alterations that become self-perpetuating and pathological [8]. It may appear that, as 
derived from inducible models of GRK2 deletion after myocardial infarction [166], a 
treatment to downmodulate GRK2 once the pathological situation is overt would not 
fully rescue the initial condition, but it can nevertheless partially improve the phenotype. 
Unpublished results from our laboratory using tamoxifen-inducible GRK2 KO mice also 
indicate that a deletion in GRK2 after HFD-induced systemic IR is already established can 
help ameliorate this condition ([285], submitted).  Finally, the use of beta blockers for 
the treatment of heart failure has additional beneϐits to the use of βARKct transgenesis 
alone [147, 286]. Thus, GRK2 could have a role not only in the prevention but also in the 
treatment of certain pathologies, and a potential for the combination of GRK2 inhibitors 
with other therapeutic strategies represents a ϐield of promising new research.
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1.-Los ratones adultos (9-10 meses de edad) con menores niveles de GRK2 (GRK2+/-) 
muestran una mayor sensibilidad ante algunas señales vasoconstrictoras, mientras que 
son más sensibles a la mayoría de estímulos vasodilatadores, en parte gracias a un au-
mento de la biodisponibilidad de óxido nítrico.
 2.- Tras una estimulación crónica con angiotensina II (Ang II), los ratones GRK2+/-
adultos conservan la activación de la cascada de Akt, mayores niveles de la enzima eNOS 
y la biodisponibilidad de óxido nítrico preservada en comparación con sus hermanos de 
camada de genotipo silvestre. Los ratones GRK2+/- muestran también una estructura 
vascular y un comportamiento mecánico de los vasos menos deteriorado después del 
tratamiento con Ang II. Estas características protegen a los animales hemicigotos para 
GRK2 del desarrollo de hipertensión severa y remodelado vascular patológico inducido 
por Ang II.
3.- La reducción de GRK2 en los ratones GRK2+/- adultos promueve una mayor 
sensibilidad a la insulina en corazón, lo que se correlaciona con un perϐil de expresión 
génica cardioprotector y una hipertroϐia ϐisiológica leve. Por el contrario, los niveles de 
GRK2 aumentan en el tejido cardiaco de modelos animales de resistencia sistémica a la 
insulina, tales como animales alimentados con dieta alta en grasa o ratones ob/ob. Estos 
mayores niveles cardiacos de GRK2 parecen desencadenar la alteración en la sensibilidad 
a la insulina cardiaca por mecanismos que implican una mayor formación de complejos 
GRK2/IRS1.
4.- Los ratones GRK2+/- adultos muestran un fenotipo más delgado y están protegidos 
contra la hipertroϐia cardíaca patológica y la acumulación ectópica de grasa que tiene 
lugar en los corazones de los animales de tipo silvestre después de un largo periodo (33 
semanas) de alimentación con una dieta alta en grasa.
CONCLUSIÓN GENERAL:
Nuestros resultados presentan a GRK2 como un sensor integrador de estímulos 
patológicos de diferente etiología. Unos niveles elevados de catecolaminas/angiotensina 
en estados hipertensivos, o situaciones asociadas a resistencia sistémica a insulina 
(obesidad/alto contenido de grasa en la dieta) convergen en promover un aumento 
en los niveles de GRK2 en tejido cardiaco y/o vascular. Teniendo en cuenta el papel de 
esta proteína como nodo central de las cascadas de señalización de GPCRs y de insulina, 
estos mayores niveles/funcionalidad de GRK2 favorecerían la progresión hacia procesos 
de maladaptación patológica, remodelación cardíaca/vascular y disfunción. Por el 
contrario, el mantenimiento de los niveles de GRK2 por debajo de un cierto umbral sería 
beneϐicioso para el metabolismo y la función cardíaca, así como para mantener el tono 
vascular y la sensibilidad a la insulina sistémica. Por lo tanto GRK2 emerge como una 
diana terapéutica potencialmente relevante en la insuϐiciencia cardíaca, en particular 
cuando comorbilidades tales como resistencia a la insulina, diabetes y la obesidad están 
presentes.
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1.-Adult mice (9 months old) with lower levels of GRK2 (GRK2+/-) show increased 
sensitivity to certain vasoconstrictor signals, whereas GRK2+/− arteries are more 
sensitive to most vasodilator stimuli in part by means of an increased bioavailability of 
nitric oxide.
 2.- Upon chronic Angiotensin II (Ang II) challenge, adult GRK2+/- mice display 
a preserved activation of the Akt cascade, higher levels of the eNOS enzyme, and 
preserved nitric oxide bioavailability compared to wild type littermates. GRK2+/- 
mice also show a less deteriorated vascular structure and mechanics after an Ang II 
treatment. These features protect GRK2 hemizygous animals from developing severe 
Ang II-induced hypertension and pathological vascular remodeling.
3.-  The lower GRK2 dosage in GRK2+/- mice promotes enhanced insulin sensitivity 
in adult hearts what correlates with a cardioprotective gene expression proϐile and 
mild physiological hypertrophy. Conversely, GRK2 levels increase in cardiac tissue in 
animal models of systemic insulin resistance, such as high fat diet-fed animals or ob/
ob mice. Such increased cardiac GRK2 levels appear to trigger impaired cardiac insulin 
sensitivity by mechanisms involving enhanced formation of GRK2/IRS1 complexes.
4.- Adult GRK2 +/- mice display a leaner phenotype and are protected against 
the pathological cardiac hypertrophy and against the ectopic lipid accumulation that 
occurs in the hearts of wild type littermates after a long term (33 weeks) high-fat diet 
feeding.
OVERALL CONCLUSION:
Our results put forward GRK2 as an integrative sensor of pathological inputs of 
different etiology. Increased levels of catecholamines/angiotensin in hypertensive 
conditions, or systemic insulin-resistance-associated situations (obesity/high dietary 
fat) would converge on promoting enhanced GRK2 expression in cardiac and/or 
vascular tissues. Given the role of this protein as a central node of both GPCRs and insulin 
signaling cascades, such increased GRK2 levels/functionality would play a key role in 
allowing progression to pathological maladaptation, cardiac and vascular remodeling 
and dysfunction. On the contrary, maintaining GRK2 levels below a certain threshold 
would be beneϐicial for cardiac metabolism and function, and also for maintaining 
vascular tone and systemic insulin sensitivity, thus emerging as a potentially relevant 
therapeutic target in heart failure, particularly when co-morbidities such as insulin 
resistance, diabetes and obesity are present.
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